{
  "responseHeader":{
    "status":0,
    "QTime":13,
    "params":{
      "q":"(Background: \"lung cancer\"^4 OR \"lung carcinoma\" OR \"small-cell lung carcinoma\" OR \"SCLC\" OR \"non-small-cell lung carcinoma\" OR \"NSCLC\" OR Doc_title: \"lung cancer\"^4 OR \"lung carcinoma\" OR \"small-cell lung carcinoma\" OR \"SCLC\" OR \"non-small-cell lung carcinoma\" OR \"NSCLC\") AND (Background: FGFR1 OR \"CEK\" OR \"FLG\" OR \"HH2\" OR \"OGD\" OR \"ECCL\" OR \"FLT2\" OR \"KAL2\" OR \"BFGFR\" OR \"CD331\" OR \"FGFBR\" OR \"FLT-2\" OR \"HBGFR\" OR \"N-SAM\" OR \"FGFR-1\" OR \"HRTFDS\" OR \"bFGF-R-1\" OR Doc_title: FGFR1 OR \"CEK\" OR \"FLG\" OR \"HH2\" OR \"OGD\" OR \"ECCL\" OR \"FLT2\" OR \"KAL2\" OR \"BFGFR\" OR \"CD331\" OR \"FGFBR\" OR \"FLT-2\" OR \"HBGFR\" OR \"N-SAM\" OR \"FGFR-1\" OR \"HRTFDS\" OR \"bFGF-R-1\")"}},
  "response":{"numFound":104,"start":0,"docs":[
      {
        "Meeting_name":" Correlations of FGFR1 with ligand signaling in small-cell lung cancer",
        "Background":"['Introduction', ' Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and has been under-studied relative to novel therapies. Signaling through fibroblast growth factors (FGF2, FGF9) and their high-affinity receptor (FGFR1) has recently emerged as a contributing factor in the pathogenesis and progression of non-small cell lung cancer (NSCLC). However, knowledge of FGFR1 and ligand expression in SCLC is limited.Methods', \" FGFR1 gene copy number, mRNA levels and protein expression were determined by silver in situ hybridization (SISH), mRNA ISH and immunohistochemistry (IHC) in primary tumors from 78 SCLC patients. Expression of the ligands FGF2 and FGF9 mRNA and protein were determined by mRNA ISH and IHC, respectively. Spearman's correlations were conducted using SAS 9.4.Results\", ' FGFR1 protein expression by IHC demonstrated a significant correlation with FGFR1 gene copy number (p = 0.03) and FGFR1 mRNA levels (p<0.0001). The positivity of FGFR1 mRNA in the SCLC cohort was 21%. FGFR1 mRNA expression correlated with both FGF2 (p = 0.0001) and FGF9 (p = 0.0018) mRNA levels, as well as with FGF2 (0.0105) and FGF9 (0.0012) protein levels. There was no significant association between FGFR1 and ligands with clinical characteristics or prognosis.Conclusions', ' FGFR1 amplification and mRNA levels correlate with FGFR1 protein expression. The SCLC cohort has a substantially higher proportion of FGFR1 mRNA positive cases (21%) compared to FGFR1 gene copy number positive cases (7.8%). Combined analysis of FGFR1 and ligand expression may be valuable to determine which SCLC patients may respond to FGFR1 inhibitor therapy.Key Words', ' small cell lung cancer; FGFR1; FGF2; FGF9']",
        "Doc_id":"AACR_2015-558",
        "Doc_title":" Correlations of FGFR1 with ligand signaling in small-cell lung cancer",
        "_version_":1606189007398502400},
      {
        "Meeting_name":" Molecular and genomic characterization of SCLC",
        "Background":"['Introduction', ' Small cell lung cancer (SCLC), strongly tobacco-associated, has been described to have a heavy mutation burden, harboring high rates of TP53 and RB1 alterations. While initially responsive to radiation and chemotherapy, SCLC is characterized by eventual progression and resistance to traditional therapy. We retrospectively analyzed a molecular profiling (MP) database to identify potentially actionable alterations using a multi-platform approach which includes massively parallel sequencing. Experimental Procedures', ' SCLC patient samples were referred to a central CLIA laboratory (Caris Life Sciences, AZ) for MP (immunohistochemistry [IHC] and next generation sequencing [NGS]). Expression of PD1 (MRQ-22, 1+) on tumor infiltrating lymphocytes (TILs) and PDL1 (130021, SP142, 2+5%) in tumor cells was performed by IHC. Additional IHC (ERCC1, TOPO1) and NGS on 591 genes was performed on FFPE samples using the Illumina NextSeq platform in a subset of patient samples. All variants were detected with > 99% confidence. Variants are described as follows', ' pathogenic, presumed pathogenic, variants of unknown significance and unclassified variants (excluding SNPs). Results', ' 203 SCLC samples were identified, 48% were females (97) and 52% were males (106). Median age was 65 [range', ' 29-88]. Cancer cells expressed PDL1 in 2.5% of cases (5/203) and PD1+ TILs were detected in 38% (75/197). For comparison, internal PDL1+ in non-small cell lung carcinomas (NSCLC) was 31% (339/1098). Notable findings from IHC included ERCC1 negative status in 93% (14/15) and TOPO1 + in 70% (14/20). CNV and mutational analysis (NGS) was available for 10 and 22 patients, respectively. Amplifications were found in the following genes', ' CCND3, CRKL, FGF4, FGFR1 and NFKB1A (n = 1, respectively), and CCND1, CCNE1, CDKN2A and FGF3 (n = 2, respectively). As previously reported, the most frequently altered genes were TP53 (73%) and RB1 (68%). Clinically relevant pathogenic or presumed pathogenic variants included', ' EGFR (exon 19 deletion), BRAF (G469A), APC (T1556fs), NF1 (A1610fs, D699fs), NOTCH1 (E473fs, C332Y, G546X) and PTCH1 (N1351fs). It was thought the patient with EGFR mutation is a case of NSCLC transformation to SCLC. Variants with unknown significance or unclassified variants detected in genes with clinical relevance and of potential interest for targeted therapy in SCLC include', ' DDR2, cMET, RET, FGFR1/3, BRCA2, IGF1R, RICTOR and NTRK1. Conclusion', ' Genomic and molecular characterization of SCLC samples reveals a heterogeneous population. Several potentially actionable targets are identified by NGS. Early reported trial data suggests susceptibility of SCLC to immune checkpoint inhibitors. We observed higher levels of PD1+ TILs, however differences in antibody clones, thresholds or staining localization (tumor cells vs. stromal lymphocytes), may account for the observed overall low PD-L1 expression. Further efforts are needed to identify and validate new therapeutic targets in SCLC.']",
        "Doc_id":"AACR_2016-2266",
        "Doc_title":" Molecular and genomic characterization of SCLC",
        "_version_":1606189038921842688},
      {
        "Meeting_name":" FGFR1 gene amplification in small cell lung cancer",
        "Background":"['Background', ' Fibroblast growth factor receptor 1 (FGFR1) received special attention from many clinicians according to finding that FGFR1 played a critical role in many human cancers. Some clinical trials using FGFR1 targeting agents are in progress especially in breast cancer and squamous non-small cell lung cancer. Recently, FGFR1 amplifications were also found in about 5.6-6% of small cell lung cancer (SCLC) by gene copy number analysis and FISH.Methods', ' Tumor tissues from 113 patients diagnosed with SCLC from October 2009 to February 2013 in YUHS, Korea were collected. FGFR1 FISH assay was performed on the tissue microarray using FISH probe that hybridized to the band 8p12-8p11.23 (FISH probes were provided by Abbott Molecular, Abbott Park, IL).Results', ' Thirty-two patients with limited-stage disease (LD) and eighty-one patients with extensive-stage disease (ED) were enrolled. Fourteen patients were female. Among 113 tumor samples, 5 samples (4.4%) showed FGFR1 amplification. All 5 samples were obtained from the patients with ED. The patients with FGFR1 amplification more frequently had pleural metastasis at the time of diagnosis (80% vs. 26%, P=0.022). In ED, the patients with FGFR1 amplification represented shorter disease free survival from first line chemotherapy (Hazard ratio [HR], 4.469; 95% confidence interval [CI], 1.600-12.483; P=0.004) and second line chemotherapy (HR, 6.533; 95% CI, 1.700-25.108; P=0.006) than the patients without FGFR1 amplification in multivariate analysis. Median overall survival time was 8.2 months in the patients with FGFR1 amplification and 10.2 months in the patients without FGFR1 amplifications (P=0.296).Conclusion', ' FGFR1 amplification is a poor potential predictive biomarker of standard chemotherapy, necessitating further research in a large cohort of SCLC. The validity of targeting FGFR1 in SCLC should be confirmed in a clinical trial.']",
        "Doc_id":"AACR_2014-4728",
        "Doc_title":" FGFR1 gene amplification in small cell lung cancer",
        "_version_":1606189038713176064},
      {
        "Meeting_name":" Xenograft models for development of new drugs targeting fibroblast growth factor receptor (FGFR)",
        "Background":"['The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells. There are 4 different fibroblast growth factor receptors (FGFR) in the cell', ' FGFR1, FGFR2, FGFR3, and FGFR4. The activation of FGFR pathway plays an important role in tumor angiogenesis, tumor growth, survival, as well as migration. Mutation or amplification/overexpresion of FGFR has been found in several types of tumors, including breast cancer, bladder cancer, gastric cancer, prostate cancer, colon cancer, multiple myeloma, and non-small cell lung carcinoma. Therefore, targeting FGFRs represents an attractive strategy for development of new cancer therapeutics. However, the lack of suitable models hinders the progress of research on FGFR inhibitors. Here we successfully validated subcutaneous models in several cancer types, in which FGFR is mutant or amplified/overexpressed, such as breast cancer MDA-MB-134 (FGFR1 amplification), gastric cancer SNU-16 (FGFR2 amplification), endometrial cancer AN3CA (FGFR2 N549K/K310R mutation), bladder cancer RT-4 (FGFR3 overexpression) and RT-112 (FGFR3 overexpression), lung cancer NCI-H1581 (FGFR1 amplification), as well as human derived gastric cancer GA114 (FGFR2 amplification). In conclusion, the validated cell line derived (CDX) and patient derived xenograft models (PDX) in several cancer types provide valuable platforms for the development of new compounds targeting FGFRs.']",
        "Doc_id":"AACR_2014-3124",
        "Doc_title":" Xenograft models for development of new drugs targeting fibroblast growth factor receptor (FGFR)",
        "_version_":1606189027014213632},
      {
        "Meeting_name":" FGFR1 protein overexpression as a prognosis marker for operated small cell lung cancer patients.",
        "Background":"['Background', ' This study was conducted to investigate whether mRNA or protein overexpression can predict the prognosis of patients with Small cell lung cancer (SCLC) after surgical resection. Methods', ' The expression of FGR1 was examined in 33 SCLC tissue samples by real-time quantitative PCR in mRNA level and immune-chemistry in protein level respectly. The association of the FGFR1 overexpression with overall survival (OS) and refractor-free survival (RFS) was analyzed. Results', ' FGFR1 was frequently overexpression in both mRNA level (17/33, 21.2%) and (15/33, 45.5%) in protein level. Interesting, negative correction was observed between mRNA and protein expression. Kappan-Melar analysis indicated that the FGFR1 protein overexpression was a significant negative prognostic factors for SCLC patient (HR = 2.76, 95%CI 1.09-18.2, p < 0.05). Patients with FGFR1 protein overexpression had both poor OS (63.0 vs. 22.0 months, p < 0.05) and RFS (48.0 vs. 9.0months, p < 0.05) compared to patients with normal expression of FGFR1. Conclusions', ' Our results suggest that elevated serum FGFR1 protein overexpression is a prognostic biomarker for poorer survival in small cell lung cancer patients.']",
        "Doc_id":"ASCO_171243-176",
        "Doc_title":" FGFR1 protein overexpression as a prognosis marker for operated small cell lung cancer patients.",
        "_version_":1606189014017114112},
      {
        "Meeting_name":" Mouse models of lung cancer mediated by lentiviral gene delivery",
        "Background":"['Lung cancer, the leading cause of cancer deaths, is responsible for 1.4 million lives lost worldwide every year. Good animal models that can faithfully recapitulate the human disease are in great need for pre-clinical studies. Based on the different responses to treatment, lung cancer is divided into two major classes', ' small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Adenocarcinoma (AdC) and squamous cell lung cancer (SqCC) are two major sub-types of NSCLC. We have successfully developed a novel lentiviral gene delivery system to study the initiation and development of all these lung cancers. We used CA2Cre-shp53 lentiviral vector to initiate lung adenocarcinoma in LSL-KrasG12D mice and proved the importance of NF-B/IKK2 pathway in tumor cell proliferation. To search for novel tumor suppressors in lung cancer, we incorporated an shRNA library targeting 5000 cell signal genes into our CA2Cre lentivector and did the screening in the mice. We have identified several dozens of candidates and are validating these genes back in animals. SCLC is the most malignant form of lung cancer with a five-year survival less than 6%. A mouse model with p53/Rb deletions activated by Adeno-Cre has been established in Berns lab. To improve the model and study other genes that are frequently mutated in human SCLC, we designed a single lentiviral vector to deliver oncogenes (L-myc etc.) and shRNAs against tumor suppressors (p53, Rb etc) and successfully initiated SCLC in wild-type mice. Furthermore, we included luciferase or fluorescence protein genes in the same vector to follow tumor growth and metastasis in the live animal. Using this new model, we are now studying the crosstalk of multiple mutations in the SCLC development. SqCC has not been well modeled by genetic approaches. Interestingly, when we gave KrasG12D-shp53 lentiviral vector after lung tissue damage induced by naphthalene, the mice quickly developed squamous tumors in the big bronchi other than adenocarcinomas in the peripheral lung. Kras mutations are actually not common in human SqCC patients, so we are now optimizing the model and see if more relevant genetic changes such FGFR1 amplification can also induce this type of lung cancer in mice. We hope that our unique lentiviral tool can simplify and accelerate the lung cancer study to understand the big signal pathway complex leading to tumorigenesis and metastasis in the lung and search for new therapies for this deadly human disease.']",
        "Doc_id":"AACR_2014-2973",
        "Doc_title":" Mouse models of lung cancer mediated by lentiviral gene delivery",
        "_version_":1606189011115704320},
      {
        "Meeting_name":" Both amplification and protein expression are required to predict FGFR tyrosine kinase inhibitor sensitivity in lung cancer",
        "Background":"['FGFR1 amplification has been suggested to be a driver oncogene in squamous and small cell lung carcinoma. However, early clinical trials show that response rate of FGFR tyrosine kinase inhibitors (FGFR-TKIs) is 20-30% in patients with FGFR1 amplified lung cancer. To elucidate the reason for de novo resistance to FGFR-TKI, six FGFR1 amplified lung cancer cell lines (NCI-H1581, DMS-114, NCI-H520, NCI-H1703, HCC95, and Calu-3) were analyzed. These cells were confirmed to have FGFR1 amplification by FISH analysis. Cell viability assay showed only 2 of six cell lines, NCI-H1581 and DMS-114, are sensitive to a FGFR-TKI, BGJ-398. Among BGJ-398 insensitive cells, NCI-H1703, HCC95, and Calu-3 cells express low mRNA and protein level of FGFR1 even in the presence of FGFR1 amplification. In addition, while BGJ-398 downregulates ERK phosphorylation in FGFR1 protein expressing cells, the drug had no effect on ERK signaling in BGJ-398 resistant cells with low FGFR1 protein expression. Importantly, other driver oncogenes were found in these BGJ-398 insensitive cell lines. PDGFRa amplification in H1703 cells and HER2 amplification in Calu-3 cells were reported previously. In this study, we have also found ERBB3 ligand NRG1 was overexpressed in HCC95 cells. Knockdown of NRG1 suppressed cell growth and combination of lapatinib with BGJ-398 led to cell death. To further determine whether FGFR1 protein expression is enough for the sensitivity to FGFR-TKIs, lung cancer cell lines were screened to FGFR-TKIs, BGJ-398 and PD-173034. This screen identified that all FGFR-TKI sensitive cell lines harbor FGFR1 amplification with high protein expression. These results suggest FGFR-TKIs should be used to patients harboring both FGFR1 amplification and protein expression. In case tumors with FGFR1 amplification, but expressing low FGFR1 protein, another driver oncogene may coexist and targeting both FGFR1 and these coexisting driver oncogenes are required to treat these tumors.']",
        "Doc_id":"AACR_2015-749",
        "Doc_title":" Both amplification and protein expression are required to predict FGFR tyrosine kinase inhibitor sensitivity in lung cancer",
        "_version_":1606189031261995009},
      {
        "Meeting_name":" Nelfinavir inhibits the growth of small cell lung cancer cells and patient-derived xenograft tumors",
        "Background":"['Small cell lung cancer (SCLC) is an aggressive lung cancer with a poor prognosis that is characterized by frequent metastasis at the time of diagnosis. Although SCLC is more responsive to chemotherapy and radiation therapy compared to other types of lung cancer, cure is difficult because of frequent recurrence. Molecular alterations in SCLC include inactivation of TP53 and RB1, high copy number of Myc family, and amplifications of FGFR1 and SOX2. Additionally, achaete-scute homolog 1 (ASCL1), a transcription factor for development of pulmonary neuroendocrine cells, is a lineage-dependent oncogene for SCLC. New drugs and molecular targets need to be identified. Previously, we reported nelfinavir (NFV), a HIV protease inhibitor, inhibited proliferation of non-small cell lung cancer (NSCLC) cells in vitro and human NSCLC xenograft tumors through induction of the unfolded protein response (UPR). Here we demonstrate that the effect of NFV in SCLC cells and preclinical treatment studies using SCLC patient-derived xenograft (PDX) mouse models. NFV inhibited SCLC cell proliferation and induced cell death in vitro. Activating transcription factor 4 (ATF4), a marker of the UPR, was rapidly increased, whereas Myc was decreased after 4 hr treatment with NFV. AMP-activated protein kinase (AMPK), which plays a role in cellular energy homeostasis, was activated in the early phase of NFV treatment, whereas the mammalian target of rapamycin (mTOR) that is a serine/threonine kinase that regulates cell growth, was inactivated. NFV inhibited the expression of SOX2, ASCL1 and Aurora B in a cell line- and time-dependent manner. Taken together, NFV had pleiotropic effects against multiple targets during the inhibition of SCLC cell proliferation. In vivo, NFV inhibited growth of SCLC PDX tumors, which correlated with induction of the UPR and decreased expression of ASCL1 and Aurora B. Collectively, these findings show that NFV is highly effective in SCLC in vitro and in vivo, suggesting possible value of incorporating NFV into clinical trials for patients with SCLC.']",
        "Doc_id":"AACR_2015-684",
        "Doc_title":" Nelfinavir inhibits the growth of small cell lung cancer cells and patient-derived xenograft tumors",
        "_version_":1606188996790059008},
      {
        "Meeting_name":" Fibroblast growth factor receptor 1 (FGFR1) protein expression and gene copy number in small cell lung cancer",
        "Background":"['PURPOSE', 'Small cell lung cancer (SCLC) comprises approximately 15% of all lung cancers, corresponding to >30,000 new cases per year in the United States. No major therapeutic progress has been achieved in SCLC in the past 30 years. Identification of new therapies in SCLC is urgently needed. Fibroblast growth factor receptor 1 (FGFR1) is a tyrosine kinase receptor implicated in the pathogenesis of several cancer types and is potentially an attractive target for cancer treatment. FGFR1 amplification and overexpression are known as a frequent event in lung squamous cell carcinoma. However, very little is known about FGFR1 protein expression and gene copy number in SCLC. One difficulty with research on SCLC is the limited availability of tumor specimens sufficient for molecular studies.METHODS', 'We investigated FGFR1 protein expression and gene copy number in a tissue microarray of resected SCLC tumors from 90 patients (67 men and 23 women) from Poland with limited stage. FGFR1 protein expression was assessed by immunohistochemistry (IHC) with H scores ranging from 0 (no expression) to 300 (strong expression in all tumor cells) using a FGFR1 antibody (clone EPR806Y, Origene) . FGFR1 gene copy number was evaluated by dual-color ISH assay using a cocktail of FGFR1 DNP probe (FGFR1 locus on 8p12) and chromosome 8 DIG probe (centromere 8), ultraView SISH DNP detection kit and ultraView Red ISH DIG detection kit (Tucson, AZ, US). Positive FGFR1 protein expression was defined as having an H-score 11. FGFR1 gene amplification was defined as FGFR1/CEN8 ratio 2.2, or average FGFR1 signals 4 per nucleus.RESULTS', 'FGFR1 protein expression was evaluable in 83 of the 90 patients and gene copy number was evaluable in 77 patients. FGFR1 protein expression was positive in 6 cases (7.2%) (mean H score=129, median 70, range', ' 40-285). FGFR1 gene amplification was observed in 6 cases (7.8 %) of evaluable SCLCs. There were 30%-90% tumor cells containing clusters in the amplified cases. Four of the 6 cases were positive for both FGFR1 protein expression and FGFR1 gene amplification. FGFR1 protein and gene copy number were not associated with patient age, sex, tumor size or overall survival (all p-values >0.15).FGFR1 gene copy number was significantly associated with protein expression (p=0.03, based on a t-test).CONCLUSIONS', ' A small subset of patients with SCLC is characterized by tumors with FGFR1 gene amplification and/or FGFR1 protein expression. Further studies are needed to determine whether or not this subset of patients would benefit from FGFR1-directed targeted therapy.']",
        "Doc_id":"AACR_2014-921",
        "Doc_title":" Fibroblast growth factor receptor 1 (FGFR1) protein expression and gene copy number in small cell lung cancer",
        "_version_":1606189041401724928},
      {
        "Meeting_name":" SOX2 and FGFR1 gene copy number in surgically resected non-small cell lung cancer (NSCLC).",
        "Background":"['Background', '  SOX2 is a member of the SRY-related HMG-box family of transcription factors and has been shown to be frequently amplified and overexpressed in squamous cell lung cancer, with conflicting results regarding its prognostic relevance. Similarly, FGFR1, a transmembrane tyrosine kinase receptor belonging to the fibroblast growth factor receptor family, has been recently reported to be amplified in squamous cell lung carcinomas, suggesting a potential role for FGFR1 as a therapeutic target in NSCLC. Aim of the present study is to evaluate SOX2 and FGFR1 gene copy number in surgically resected NSCLCs, to investigate their prognostic relevance and their association with clinico-pathological characteristics.  Methods', '  SOX2 and FGFR1 gene copy number was assessed by fluorescence in situ hybridization (FISH) in tissue microarray cores from 447 surgically resected NSCLCs. Each patient was given a  score ranging from 1 to 6 according to increasing mean copy number per cell of each gene, with 6 indicating true gene amplification.   Results', '  SOX2 and FGFR1 FISH was successfully performed in 445 patients (pts), which were grouped as + (score 5-6) and - (score 1-4). Using this scoring system 105 (23.6%) pts tested SOX2+, while 74 (16.6%) pts resulted FGFR1+. True gene amplification for SOX2 and FGFR1 was observed in 19 (4.3%) and 37 (8.3%) cases, respectively. SOX2+ and FGFR1+ status was significantly associated with squamous histology (p<.001). Additionally, SOX2+ pts had a significantly higher chance of being former/current smokers, male and FGFR1+. FGFR1 gene status had no prognostic impact in the whole population and in the squamous cell carcinoma subgroup. Conversely, SOX2+ pts had significantly longer overall survival compared with SOX2- pts (HR 0.68, p=.020). When restricting survival analysis to squamous cell histology, stage I-II SOX2+ pts had a significant survival advantage compared with SOX2- group (HR 0.38, p=.006), while no difference was observed in stage III-IV pts.  Conclusions', '  Increased SOX2 and FGFR1 gene copy number is a common event in lung cancer pts with squamous cell histology. SOX2 gene gain is a favorable prognostic factor in surgically resected pts, particularly in early stage squamous cell cancers.']",
        "Doc_id":"ASCO_100448-114",
        "Doc_title":" SOX2 and FGFR1 gene copy number in surgically resected non-small cell lung cancer (NSCLC).",
        "_version_":1606188978154766337},
      {
        "Meeting_name":" Acquired nintedanib resistance in FGFR1-driven small cell but not non-small cell lung cancer is mediated by ABCB1",
        "Background":"['Lung cancer accounts for the highest number of cancer-related deaths worldwide. Patient outcome is dismal and approval of targeted compounds is yet restricted to non-small cell lung cancer (NSCLC) histology. In defined subgroups of NSCLC, but also of small cell lung cancer (SCLC), genetically amplified fibroblast growth factor receptor 1 (FGFR1) is an oncogenic driver and inhibition of the FGFR1 signaling axis exerts potent antitumor effects. The FGFR/PDGFR/VEGFR inhibitor (TKI) nintedanib has recently been approved for second-line treatment of lung adenocarcinoma (AC) and is also being investigated in clinical trials for the treatment of SCLC. Despite initial treatment success, tumor recurrence due to acquired drug resistance is anticipated. We therefore aimed at characterizing the molecular mechanisms underlying resistance development of FGFR1-driven lung cancer against nintedanib.One SCLC line (DMS114) and two NSCLC squamous cell carcinoma (SCC) lines (NCI-H1703, NCI-H520) driven by FGFR1 based on gene amplification were selected for nintedanib resistance in vitro. Cytotoxicity was evaluated by MTT and FACS. Intracellular responses to drug exposure were analyzed by qPCR and Western Blot. To compare transcription levels of parental cells with their selected sublines, whole-genome gene expression array was performed. Cross-cytotoxicity profiles were determined by a large-scale anticancer compound screen. ATP-binding cassette (ABC) transporter activity was analyzed by calcein AM efflux- and ATPase assay, intracellular Nintedanib levels were determined by liquid chromatograpy-mass spectrometry (LC-MS).Chronic exposure to the FGFR/PDGFR/VEGFR inhibitor nintedanib led to expression of the ABCB1 multidrug-resistance (MDR) efflux pump in the SCLC cell line DMS114 but not in the NSCLC SCC cell lines NCI-H1703 and NCI-H520. In the nintedanib-selected subline of DMS114 (DMS114/NIN), the FGFR1 signaling axis remained active. Insensitivity of DMS1114/NIN towards Nintedanib was mediated by efflux via ABCB1, revealing Nintedanib as a substrate for this efflux pump. Ponatinib, another non-ABCB1-substrate FGFR inhibitor, retained strong cytotoxic activity. Additionally, DMS114/NIN cells exerted profound and ABCB1-dependent collateral sensitivity against the MDR-selective lanthanum compound KP772.ABCB1 needs to be considered as a factor underlying intrinsic and acquired nintedanib resistance. On one hand, in second-line therapy, chemotherapy-induced MDR might render tumors resistant to Nintedanib. On the other hand, in first-line treatment, high ABCB1 expression in cancer cells or the microvasculature e.g. in clear-cell renal carcinoma or CNS tumors might account for intrinsic Nintedanib resistance. Switching to MDR-selective anticancer compounds or to non-ABCB1-substrate small molecule TKIs in FGFR/PDGFR/VEGFR-driven tumors might be an option to circumvent nintedanib resistance.']",
        "Doc_id":"AACR_2016-2119",
        "Doc_title":" Acquired nintedanib resistance in FGFR1-driven small cell but not non-small cell lung cancer is mediated by ABCB1",
        "_version_":1606189021882482688},
      {
        "Meeting_name":" Oncogenic potential of FGF9 in lung cancer",
        "Background":"['Rationale', ' Recently, the importance of fibroblast growth factor (FGF) and its receptor (FGFR) signals has been emphasized in various types of cancer, including lung cancer. FGFs and FGFRs are reported to be related to drug resistance, cell proliferation, differentiation and motility. Among various FGFs, FGF9 is a developmentally important FGF associated with epithelial airway branching, and its expression is repressed in normal adult lungs. We have previously shown that FGF9 is highly expressed in NSCLC cells, and FGF9 expression was associated with poor prognosis of NSCLC patients. Furthermore, we reported that induction of FGF9 in adult lung results in the rapid formation of adenocarcinoma in specific gene engineered mouse model. However, the exact roles of FGF9 in lung epithelial cells remain elusive.Objectives', ' The objective of this study is to clarify the roles of FGF9 in lung epithelial cells.Methods', ' For in vitro experiments, a stable cell line with constitutive expression of FGF9 in MLE12 (a mouse lung alveolar type II cell line transformed by SV40 large T antigen) was established by retroviral infection. The effect of FGF9 on proliferation, colony formation capacity and downstream signaling was evaluated by MTS assay, softagar colony formation assay and Western blotting, respectively. For in vivo experiments, the cells were transplanted into immunodeficient mice subcutaneously, and the size of tumor was measured. To evaluate the efficacy of FGFR inhibitors for FGF9-driven lung cancers, AZD4547, selective FGFR inhibitor, was orally administered. For pathological characterization of the tumors, immunohistochemical staining was performed.Fifteen surgically-resected SCLC samples were obtained and the expression of FGF9 was evaluated by immunohistochemistry.Results', ' FGF9 has oncogenic ability in vitro and its effect may be exerted by the activation of MAPK pathway through FGFR1 and FGFR3 in MLE12 cells. Unexpectedly, pathological analysis revealed FGF9-driven tumors exhibited SCLC histology. Selective FGFR inhibitor, AZD4547 suppressed tumor growth of FGF9-driven MLE12 tumors. FGF9 is highly expressed in human SCLC samples (67%).Conclusions', ' These results suggest that FGF9 has roles of tumor initiation and progression in lung cancer, especially in SCLC.SCLC which highly expresses FGF9 may be a target of FGFR inhibitors.']",
        "Doc_id":"AACR_2015-3916",
        "Doc_title":" Oncogenic potential of FGF9 in lung cancer",
        "_version_":1606188986126041088},
      {
        "Meeting_name":" The role of fibroblast growth factor receptor 1 (FGFR1) in small cell lung cancer (SCLC).",
        "Background":"['Background', ' Although molecularly-targeted treatment options for solid tumors have advanced in recent years, there remains a significant therapeutic need for SCLC, which constitutes 12% of all lung cancers and carries a poor prognosis. FGFR1, a transmembrane tyrosine kinase receptor encoded by the FGFR1 gene in chromosome 8p12 is involved in cell cycle, differentiation, survival, apoptosis, and angiogenesis. In SCLC, FGF/FGFR pathway is known to induce proliferation, disrupt apoptosis and mediate chemo-resistance. Pharmacologic FGFR inhibition in SCLC reduces proliferation and increases apoptosis both in vitro and in vivo. We and others have reported high copy number gains (CNG) in cytogenetic bands encoding FGFR1 in SCLC suggesting that FGFR1 may be driver mutation and a potential therapeutic target in SCLC. In this study we further characterize FGFR1 as a therapeutic target in SCLC.Methods', ' Thirteen SCLC cell lines, 16 SCLC patient samples, and 14 SCLC tumors from commercially available tissue microarray (TMA) were screened for copy number alterations using array comparative genomic hybridization (aCGH) and focal FGFR1 amplifications using fluorescence in situ hybridization (FISH). In the cell lines, FGFR1 exons were sequenced from genomic DNA, mRNA expression evaluated using real-time polymerase chain reaction and protein expression determined semi-quantitatively using western blot. Growth inhibition assays were performed using PD173074, a selective FGFR inhibitor and standard cytotoxic agents (cisplatin and etoposide) to determine the correlation between FGFR1 expression and drug sensitivity.Results', ' CNG was detected in 10/16 (63%) patient samples and in 5/14 (36%) of tumors from TMA (range 4-9 copies per cell). 5/13 (38%) of cell lines demonstrated CNG, but we found no FGFR1 mutations or focal amplifications in SCLC cell lines. FGFR1 mRNA expression did not correlate with CNG and the FGFR1 protein expression was unrelated to the mRNA expression. FGFR1 CNG predicted sensitivity to PD173074 with cell lines carrying higher copy numbers being more sensitive. No such correlation was detected between FGFR1 mRNA expression and PD173074 sensitivity. Higher FGFR1 mRNA expression was associated with etoposide resistance.Conclusion', ' FGFR1 protein expression in SCLC cell lines is unrelated to copy number alterations and mRNA expression. CNG of 8p12 region which encodes FGFR1 predicts sensitivity to PD173074, a selective FGFR inhibitor.']",
        "Doc_id":"AACR_2013-5466",
        "Doc_title":" The role of fibroblast growth factor receptor 1 (FGFR1) in small cell lung cancer (SCLC).",
        "_version_":1606188977101996032},
      {
        "Meeting_name":" Preclinical efficacy of fibroblast growth factor ligand trap HGS1036 in lung carcinoma models with genomic amplification of FGFR1",
        "Background":"['Lung cancer is the most common cause of cancer-related death in industrialized countries. In 2010, it is estimated that cancer of the lung and bronchus will be responsible for 157,300 deaths in the US (Jermal et al. 2010). A number of recent publications have reported the genomic amplification of the fibroblast growth factor receptor 1 gene (FGFR1) in lung cancer (Weiss et al. 2010; Voortman et al. 2010). Subtype analysis indicates that approximately 22% of squamous non-small cell lung cell carcinomas (NSCLC) and 27-33% of small cell lung cancer (SCLC) have amplification of the FGFR1 gene. Amplification of the FGFR1 gene in lung cancer cell lines is associated with over-expression of the FGFR1 receptor protein and increased signaling through the FGFR1 pathway resulting in increased cell proliferation and tumorigenesis. HGS1036 (formerly FP-1039) is a soluble fusion protein consisting of the extracellular domain of human FGFR1 isoform -IIIc linked to the Fc region of human immunoglobulin G1 (IgG1). HGS1036 acts as a ligand trap that sequesters multiple fibroblast growth factor (FGF) family ligands, blocking their ability to bind to and activate multiple FGF receptors. We investigated the preclinical efficacy of HGS1036 in preclinical lung cancer models with genomic FGFR1 amplification as a novel therapeutic strategy. A panel of lung cancer cell lines (n=5) were identified that displayed genomic FGFR1 amplification on chromosome 8. Two of the cell lines, DMS53 and DMS114, were derived from the tumors of patients with SCLC. The other three cell lines, NCI-H1581, NCI-H520 and NCI-H1703, were derived from the tumors of patients with NSCLC. Examination of in vitro drug sensitivity indicated that all 5 cell lines were sensitive to HGS1036. Treatment of NCI-H1581, NCI-H520, NCI-H1703, DMS53 and DMS114 cells with HGS1036 in vitro resulted in a 52%, 71%, 46%, 47% and 82% reduction in cell proliferation, respectively, as determined by CellTiterGlo. Sensitivity to HGS1036 in vitro generally correlated with FGFR1 copy number and total FGFR1 protein expression. HGS1036 treatment of mice bearing FGFR1 amplified lung cancer xenografts resulted in tumor growth inhibition in all five FGFR1-amplified models examined (p=<0.01). The degree of tumor growth inhibition, as assessed by area-under-the-curve analysis, varied from 31-84% depending on the FGFR1 amplified lung model examined. These experiments demonstrate that lung tumor cell lines with genomic FGFR1 amplification can be sensitive to FGF-ligand blockade by HGS1036 and provide preclinical rationale for the clinical study of HGS1036 in the treatment of lung cancer.']",
        "Doc_id":"AACR_2012-1876",
        "Doc_title":" Preclinical efficacy of fibroblast growth factor ligand trap HGS1036 in lung carcinoma models with genomic amplification of FGFR1",
        "_version_":1606189024336150528},
      {
        "Meeting_name":" Molecular profiling of small cell lung cancers in Japanese patients.",
        "Background":"['Background', '  Molecular abnormalities discovered in the last decade have led to a paradigm shift in the diagnosis and treatment of lung adenocarcinoma. But there have been few reports about molecular profiling of small cell lung cancers (SCLC). We conducted the Shizuoka Lung Cancer Mutation Study to analyze driver mutations in patients with thoracic SCLC malignancies.  Methods', '  We collected molecular profiling data of SCLC from the biobanking system in conjunction with the clinic, including the pathology lab, where 23 mutations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications, and EML4-ALK translocations were assessed using pyrosequensing plus capillary electrophoresis, qRT-PCR, and RT-PCR, respectively. To evaluate mutation status for SCLC patients, we collected patient characteristics data from medical records. Results', '  Between July 2011 and July 2012, fifty small cell lung cancer patients were assessed in our biobanking system. Patient characteristics were as follows', ' median age (range) 70 (43 - 82) years; male 82%; smoker 96%; limited disease/extended disease 56/44%; small cell carcinoma/combined small cell carcinoma with adenocarcinoma 94/6%; surgically resected snap-frozen samples 8, formalin-fixed paraffin-embedded samples 40 and pleural effusion 7. We detected driver mutations in 8 cases (16%). Mutations found', ' EGFR 1 (2%), KRAS 1 (2%), PIK3CA 2 (4%), AKT1 1 (2%), MET amplification 1 (2%), PIK3CA amplification 6 (12%). EGFR and KRAS mutation were found in combined small cell carcinoma with adenocarcinoma. No significant differences in age, sex, disease extent at diagnosis or smoking status were found between patients with mutations and those without mutations. But serum neuron-specific enolase (NSE) levels were significantly higher in patients without mutations (p=0.03).  Conclusions', '  In our analysis, driver mutations were found in 16% of SCLC patients and PIK3CA amplification seemed to be relatively frequent in SCLC. Our results suggest that PIK3CA might become a target of treatment for SCLC patients.']",
        "Doc_id":"ASCO_116449-132",
        "Doc_title":" Molecular profiling of small cell lung cancers in Japanese patients.",
        "_version_":1606188985148768256},
      {
        "Meeting_name":" Comprehensive genome and transcriptome analyses on small cell lung cancer",
        "Background":"['Small cell lung cancer (SCLC) is a malignant neuroendocrine tumor of the lung accounting for 15% of all lung cancer cases. SCLC is a highly aggressive disease characterized by early metastasis and a high mortality rate of 95%. The standard of care is chemotherapy, which remains largely ineffective due to quick relapse of chemo-resistant tumors. To date, targeted therapies have not been identified for the treatment of SCLC.In order to comprehensively characterize the genomic alterations in this cancer type, we sought for a worldwide collaboration to collect rare surgical specimen of SCLC patients. Thus, we were able to study copy number alterations in 130 cases, and performed whole genome sequencing on over 78 tumor-normal pairs and transcriptome sequencing of at least 62 primary tumors and 16 SCLC cell lines. In a complementary approach we analyzed tumors derived from a murine SCLC model that was established by the conditional inactivation of Rb1 and Trp53 in lung epithelial cells (Meuwissen et al., 2003). We collected copy number alteration data for 20 mouse SCLC cases and performed exome and genome sequencing of at least 8 tumors derived from SCLC mice which additionally harbored a conditional knockout of Rbl2 (Schaffer et al., 2010).Human SCLC tumors comprise large areas of copy number alterations, revealing focal amplifications of MYC transcription factors. In line with this finding recurrent MYCL1 amplifications were also detected in murine SCLC. Human primary tumors were additionally found to harbor focal homozygous deletions of the CDKN2A locus. Furthermore, low frequent amplifications of oncogenes were identified among which therapeutic tractable FGFR1 amplifications were observed in approximately 6% of the cases.The genomic data allowed for the comprehensive characterization of the TP53 and RB1 locus at higher resolution, aiding in the identification of mutations, hemizygous and homozygous deletions, and larger genomic rearrangements. Consequently, lesions of TP53 and RB1 were found to affect both alleles in almost 100% of the cases analyzed. Other TP53 and RB1 family members were also altered in human tumor specimen thus supporting the mouse models for SCLC. In line with previous findings PTEN inactivation was found in 14% of the cases. Furthermore, recurrent mutations were detected in neuroendocrine specific genes and in chromatin and histone modifiers, among which the inactivation of the histone-acyl-transferases CREBBP and EP300 occurred at a frequency of 24%.In summary, as a continuation of our initial pilot study on 29 SCLC exomes (Peifer et al., 2012) this comprehensive large scale genomic analysis provides further insight into the complex genomic architecture of SCLC tumors and substantially improves the resolution to detect genomic alterations. This larger SCLC tumor cohort allows for the identification of low frequent alterations that might play a decisive role in the development and progression of this disease.']",
        "Doc_id":"AACR_2014-1542",
        "Doc_title":" Comprehensive genome and transcriptome analyses on small cell lung cancer",
        "_version_":1606189025568227328},
      {
        "Meeting_name":" FGFR1 amplification and EGFR mutation in Chinese squamous cell lung cancer.",
        "Background":"['Background', '    Squamous cell lung cancer (SCC) lacks for effective targeted therapies. FGFR1 amplification has emerged as a potential biomarker. This study aimed to explore clinicopathologic characteristics of FGFR1 amplification in Chinese SCC patients and further explore the correlation between FGFR1 amplification and EGFR mutations.  Methods', '    One hundred seventy-seven SCC patients were included in this retrospective study. Gene copy number of FGFR1 and EGFR mutations were detected by fluorescence in situ hybridization (FISH) and denaturing high-performance liquid chromatography (DHPLC), respectively.  Results', '    FGFR1 amplifications were detected in 24.9% (44/177) Chinese SCC patients. FGFR1 amplification in SCC was more common in male (28.0%, 40/143) and smokers (28.7%, 39/136) than female (11.8%, 4/34, p=0.049) and nonsmokers (12.2%, 5/41, p=0.032). FGFR1 amplification and EGFR mutations were mutually exclusive (p=0.006), fourty-one of 139(29.4%) patients with wild-type EGFR had FGFR1 amplification, while 3 of 38 (7.9%) patients with EGFR mutation had FGFR1 amplification.  Conclusions', '    FGFR1 amplification was common in Chinese squamous cell lung cancer, and mutually exclusive with EGFR mutations.']",
        "Doc_id":"ASCO_95499-114",
        "Doc_title":" FGFR1 amplification and EGFR mutation in Chinese squamous cell lung cancer.",
        "_version_":1606189000133967873},
      {
        "Meeting_name":" FGFR and FGF ligand overexpression in lung cancer",
        "Background":"['Background', '  Fibroblast growth factor receptors (FGFR) have been shown to be frequently dysregulated in non-small cell lung cell carcinoma (NSCLC). To determine the impact of dysregulation of FGFR pathway in NSCLC, we profiled 100 samples using a sensitive gene expression assay for FGFR and its ligands.  Methods', '  FGFR and FGF gene expression in formalin fixed paraffin embedded (FFPE) samples was performed using a sensitive quantitative nuclease protection assay. This gene expression panel includes all four FGFRs, all 22 FGF ligands and known FGF interacting proteins KLOTHO and KLOTHO beta. Using this array we profiled 100 NSCLC samples (45 squamous, 55 non-squamous).  Results', '  Gene expression analysis of the FGFR family in lung cancer showed overexpression by 3X over median levels of FGFR2 and FGFR3 predominantly in squamous subtype (28% and 19% respectively), FGFR4 overexpresion mainly in non-squamous subtype (25%) and FGFR1 overexpression evenly distributed between squamous and non-squamous subtypes (9 %). There were rare instances of joint overexpression of more than one FGFR, FGFR 1 and 2  together (6%), FGFR 1 and 3 together (2%) and FGFR 3 and 4 together (2%). Overexpression of FGFs was seen in ~35% of all NSCLC samples with FGF19 overexpression being the most common, with increases seen in 20 % of all NSCLC samples.  Conclusions', '   We report for the first time a sensitive and comprehensive FGF and FGFR gene expression analysis of 100 lung cancers. Our expression profiling did not confirm frequent overexpression of FGFR1 in squamous NSCLC in contradiction to frequent gene amplification at this locus suggesting that DNA amplification may not result in transcriptional alteration in many cases. Additionally, we detected frequent overexpression of FGFR2 and 3 in squamous NSCLC and FGFR4 overexpression in adenocarcinoma subtype of NSCLC. The receptor overexpression is frequently associated with overexpression of FGF ligands suggesting a paracrine effect. Expression profiling data support frequent FGFR pathway dysregulation in lung cancer and highlight that gene expression profiling is an important modality for identifying potential responders to novel anti-FGFR therapies.']",
        "Doc_id":"ASCO_135272-144",
        "Doc_title":" FGFR and FGF ligand overexpression in lung cancer",
        "_version_":1606188998474072064},
      {
        "Meeting_name":" FGFR1 gene amplification predicts the antitumor response of FGFR inhibitor LY2874455 in human lung cancer cells",
        "Background":"['Lung cancer is the leading cause of cancer-related death for both men and women in the world. FGFR receptor tyrosine kinase signaling pathway has been implicated in tumor cell growth, survival, angiogenesis, and metastasis. Activation of the FGFR pathway via FGFR over-expression, and chromosomal amplification and translocation as well as genetic mutation contributes to the tumor progression and the resistance to anti-EGFR and -VEGF treatment in lung cancer. Targeting FGFR pathway is therefore an attractive therapeutic strategy for lung cancer. We have discovered and developed a novel, ATP competitive and orally active small molecule inhibitor of FGFR, LY2874455, currently in clinic development. LY2874455 is a potent inhibitor against four FGFRs, and demonstrates a broad-spectrum of anti-tumor activity in a number of tumor xenograft models. In the current study, we evaluated the anti-tumor activity of LY2874455 in lung tumor cells with or without FGFR1 gene amplification. FGFR1 is known to be amplified in human lung cancer cells NCI-H1581, NCI-H520 and DMS-114, but not in NCI-H460, A549 and NCI-H1299. The mRNA expression levels of FGFR1 are shown to be higher in the FGFR1 amplified cells than those in the FGFR1 non-amplified cells. Consistent with this, the FGFR1 amplified cells exhibited the much more robust b-FGF-induced phosphorylation of FRS2 and ERK, which are also more sensitive to the inhibition by LY2874455 than that in the FGFR1 non-amplified cells. Furthermore, the FGFR1 amplified cells exhibit the better responses to the growth inhibition and apoptosis induction by LY2874455 than those in the FGFR1 non-amplified cells. Therefore, these findings suggest that FGFR1 plays an important role in lung cancer cell growth and survival, and that LY2874455 may provide a promising treatment option for some lung cancer patients whose tumor harbors FGFR1 gene amplification. The in vivo anti-tumor response of LY2874455 is being further investigated in the tumor xenograft models derived from these FGFR1 amplified or non-amplified human lung cancer cells.']",
        "Doc_id":"AACR_2012-1716",
        "Doc_title":" FGFR1 gene amplification predicts the antitumor response of FGFR inhibitor LY2874455 in human lung cancer cells",
        "_version_":1606189035287478272},
      {
        "Meeting_name":" Estrogen modulation of fibroblast growth factor signaling in non-small cell lung cancer",
        "Background":"['The estrogen signaling pathway induces proliferation in non-small cell lung cancer (NSCLC) and represents a novel therapeutic target for lung cancer. Estrogen receptor  (ER) is the predominant ER isoform in lung cancer and we have previously shown that high cytoplasmic ER combined with low progesterone receptor (PR) expression is a poor prognostic marker for NSCLC patients. To further elucidate the biological differences between ER high/PR low versus ER low/PR high expressing lung tumors, a mRNA microarray analysis using the Illumina HT-12 V4 Bead Chip platform was performed using RNA extracted from 64 cases. 165 genes were differentially expressed between these two groups at P<001. Fibroblast growth factor receptor 1 (FGFR1) was a highly over-expressed gene associated with ER high tumors (2.1-fold, P<0.004), while the decoy receptor for FGFR ligands, fibroblast growth factor receptor like-1 (FGFR5), was down-regulated (0.54-fold, P<0.0001). Ingenuity Pathway analysis revealed a network among the 165 differentially expressed genes that linked FGFR1 and FGFR5 to the ER. To analyze cross-talk between the FGF and E2 pathways, we determined the FGF/FGFR profile in a panel of three FGFR1 amplified and five non-amplified NSCLC cell lines. FGF2, 3, 10, and 19 were the most highly secreted FGFs in the cell line panel. FGFR1 amplified cells secreted statistically more FGF3, 6 and 10 compared to non-amplified cells. -estradiol (E2) induced secretion of FGF2 in a cell line without FGFR1 amplification. FGFR3 and 5 were ubiquitously expressed across all cell lines while FGFR1, 2 and 4 expression was higher in amplified cell lines. There was no relationship between ER protein expression and FGFR1 amplification status or FGFR1-5 protein expression. Because FGF signaling has been shown to increase stem cell-like phenotypes in breast cancer, we determined basal and E2-stimulated expression of the stem cell markers, SOX2 and OCT4. Basal SOX2 and OCT4 were more highly expressed in FGFR1 amplified cells compared to non-amplified cells. SOX2 and OCT4 protein expression were increased by E2 treatment in FGFR1 non-amplified cells, with lesser effects in FGFR1 amplified H520 cells. SOX2 expression was also down-regulated in lung sections from mice treated with a combination of the anti-estrogen fulvestrant and the aromatase inhibitor anastrozole. Finally, we have shown that in FGFR1 non-amplified cells, the anti-proliferative effect of a pan-FGFR inhibitor, AZD4547, can be enhanced in the presence of the anti-estrogen fulvestrant. These results suggest that there is an interaction between the estrogen and FGF signaling pathways in lung cancer and provides a rationale for combination treatment of NSCLC tumors. Further characterization of the molecular types of NSCLC that will benefit from joint therapy is warranted. This work was supported by P50 CA090440.']",
        "Doc_id":"AACR_2015-1861",
        "Doc_title":" Estrogen modulation of fibroblast growth factor signaling in non-small cell lung cancer",
        "_version_":1606188982557736960},
      {
        "Meeting_name":" Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis program at Memorial Sloan-Kettering Cancer Center (MSKCC).",
        "Background":"['Background', '  Oncogenic events in adenocarcinoma and squamous cell cancers of the lung are well described. In contrast, the repertoire of possible molecular targets in SCLC is still unclear. Recent studies using next generation sequencing on rare resected SCLC specimens have provided insights into the molecular heterogeneity of this disease. Comprehensive, prospective molecular profiling of patients with SCLC using the small biopsy specimens available in clinical practice has not been performed.    Methods', '  Utilizing an IRB-approved protocol to prospectively test SCLC tumors (Small Cell Lung Cancer Mutation Analysis Program, SC-MAP), these biopsies are evaluated by', ' FISH for FGFR1 and MET amplification; immunohistochemistry for MGMT and PTEN loss; point mutation genotyping with Sequenom for PIK3CA (and others); and next-generation sequencing with our MSK-IMPACT assay (Integrated Mutation Profiling of Actionable Cancer Targets). MSK-IMPACT uses exon capture followed by massively parallel sequencing to profile all protein-coding exons and select introns of 279 cancer-associated genes, enabling the identification of mutations, indels, and copy number alterations of these genes. We tested the feasibility of this approach in a series of patients with SCLC. We performed next generation sequencing with MSK-IMPACT, with findings confirmed by FISH.  Results', '  We identified 11 patients with SCLC with FFPE samples available from both matched normal tissue and small tumor biopsies, including 3 core biopsies and 8 fine needle aspirations. 9/11 patients had adequate tissue for MSK-IMPACT, which revealed recurrent mutations in Rb1 (N=7) and p53 (N=7), FGFR1 amplification (N=2), and MET amplification (N=1), using as little as 15 nanograms of DNA. FGFR1 and MET amplification were confirmed by FISH testing. We have initiated this prospective SC-MAP program for our patients with SCLC.  Conclusions', '  Comprehensive molecular evaluation of SCLC is feasible on clinically available, small samples. Such analyses will allow us to characterize the molecular diversity of this disease and identify patients who will be candidates for targeted therapies.']",
        "Doc_id":"ASCO_116782-132",
        "Doc_title":" Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis program at Memorial Sloan-Kettering Cancer Center (MSKCC).",
        "_version_":1606189019919548416},
      {
        "Meeting_name":" Prospective genomic characterization of small cell lung cancer by targeted next generation sequencing",
        "Background":"['INTRODUCTION', ' Recent studies using next generation sequencing (NGS) technologies have provided insights into the molecular landscape of small cell lung cancer (SCLC), including frequent inactivation of TP53 and RB1. However, molecular profiling of SCLC has been impeded by lack of tissue. We performed prospective genomic profiling of patients with advanced SCLC, demonstrating the ability to test small biopsy specimens, and we report trends associated with clinical characteristics.METHODS', ' Formalin fixed paraffin embedded surgical resections, core biopsies, and fine needle aspirates from 50 patients with SCLC were subjected to FGFR1 FISH testing, PTEN immunohistochemistry (IHC), and deep-coverage targeted NGS (median 420x) to identify single nucleotide variants, indels, and copy number alterations in a common set of 222 cancer-associated genes. Demographic and clinical data were collected. Genotyping data were stratified by smoking status, stage, and response to therapy.RESULTS', ' Of the 50 patients with SCLC, 58% had extensive stage disease, and 30% were resistant to first line therapy. We observed diverse genetic profiles in SCLC, with alterations occurring in 202 of 222 targeted genes. The median number of non-synonymous somatic mutations was 7. Of 526 total non-synonymous mutations, 5% were hotspot COSMIC mutations, 25% were loss-of-function, and 47% were G-to-T transversions indicative of tobacco-induced carcinogenesis. Recurrent loss-of-function mutations in RB1 (96%) and TP53 (92%) were observed. Other frequent genomic events included alterations in SOX2 (26%), EPHA5 (22%), CDKN2C (20%), MYCL1 (20%), and PIK3CA (18%). Actionable point mutations in PIK3CA, amplifications of FGFR1, amplifications of MYC, and loss of PTEN were confirmed by independent clinically validated assays. The genotyping data showed differences based on disease stage, response to therapy, and smoking status. Patients with limited disease had a higher median number of mutations detected (9 mut/tumor) than patients with extensive disease (5 mut/tumor). Tumors refractory to chemotherapy were more likely to harbor homozygous deletions including on chromosome 3p, while tumors sensitive to chemotherapy had more diversified amplifications, deletions, and mutations. The median number of mutations detected for never smokers (0 pack years), moderate smokers (<20 pack years), and heavy smokers (20+ pack years) were 3, 4.5, and 8 mut/tumor, respectively (P<0.05). None of the mutations detected in tumors from never smokers were G-to-T transversions.CONCLUSION', ' Comprehensive molecular profiling is feasible on clinical SCLC specimens. Our study illustrates the molecular diversity and mutational patterns in SCLC. We confirmed previously reported recurring events, and further identified associations between genomic profiles and clinical features including stage, response, and smoking status.']",
        "Doc_id":"AACR_2015-610",
        "Doc_title":" Prospective genomic characterization of small cell lung cancer by targeted next generation sequencing",
        "_version_":1606189015416963072},
      {
        "Meeting_name":" A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan).",
        "Background":"['Background', ' Recent genomic studies of small-cell lung cancer (SCLC) have identified promising therapeutic strategies for this highly lethal form of cancer. Thus, we established a nationwide lung cancer genomic screening project in Japan (LC-SCRUM-Japan) to identify SCLC patients harboring targetable genomic alterations for the development of novel targeted therapies. Methods', ' The samples were subjected to a next-generation sequencing (NGS) system, Oncomine Comprehensive Assay, enabling the simultaneous analysis of 143 cancer-related genes. Results', ' As of December 2016, 133 institutions were participating and 295 patients had been enrolled. The median age was 69 years (range, 14-90 years). Two hundred seventeen (74%) were male and most patients (93%) were smokers. Among 268 samples completed analysis, we identified high prevalence of inactivating TP53/RB1 mutations in 198 (74%) /82 (31) of cases, respectively. MYC/MYCL1/MYCN amplifications were detected in 10 (4%) /13 (5) /4 (1) of cases, respectively. The NGS analysis also showed that 62 (23%) of cases had at least one targetable genomic alterations, including 7 EGFR activating mutations (3%), 6 KRAS activating mutations (2%), and 8 FGFR1 copy number gains (3%). No case was positive for ALK or ROS1 fusions. Never-smokers (71% vs. 5%, p<0.001) were significantly frequent in the EGFR type compared to the others. The KRAS type showed significantly poor progression free survival (PFS) of the first-line chemotherapy compared to the others (median PFS 1.2 vs. 6.1 months, respectively; p<0.001). Mutations in the PI3K/AKT/mTOR pathway were detected in 22 (8%) of the tumors', ' 10 PIK3CA mutations (4%), 9 PTEN inactivating mutations (3%) and 3 TSC2 inactivating mutations (1%). Among them, a case with PTEN mutation was enrolled in the investigator initiated phase II study of gedatolisib named EAGLE-PAT (UMIN 000020585). Conclusions', ' We identified a series of targetable genomic alterations in SCLC. This nationwide screening system is helpful for identifying targetable genomic alterations and their clinical features, contributing to the development of novel targeted therapies for this disease. Updated screening results will be presented at the 2017 ASCO Annual Meeting.']",
        "Doc_id":"ASCO_189081-199",
        "Doc_title":" A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan).",
        "_version_":1606188999100071936},
      {
        "Meeting_name":" Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of primary lung explant models",
        "Background":"['Lung cancer remains one of the most lethal and prevalent cancer types within developed nations. Despite recent advances in molecularly-targeted treatment options (epidermal growth factor and anaplastic lymphoma kinase inhibitors for EGFR mutations and EML4-ALK fusions respectively), there still remains significant therapeutic need, particularly for squamous cell lung cancer. Indeed, further molecular segmentation has been suggested recently through the discovery of frequent genetic amplification of the fibroblast growth factor receptor 1 gene (FGFR1) in squamous cell lung clinical samples. Preclinical validation of the tumour cells dependence on FGFR1 signaling in FGFR1-amplified lung cell lines has subsequently been confirmed, both in vitro and in vivo(1). AZD4547 is an orally bioavailable, highly selective and potent small molecule inhibitor which competes with ATP for binding to FGF receptors 1, 2 and 3, thereby inhibiting autophosphorylation and downstream signalling(2). This agent is currently in Phase I clinical studies. Cell line derived xenografts have proven utility as models for pharmacological studies (PK/PD) and as efficacy models in cases of oncogene addiction. However, the utility of cell line xenografts is limited by the lack of molecular and cellular heterogeneity. Primary explants offer the promise of better disease models through increased diversity of molecular lesions and the presence of significant stromal cell components. Characterisation of 127 Chinese NSCLC clinical samples using FGFR1 fluorescent in-situ hybridisation (FISH) analysis revealed an FGFR1 amplification rate of 13% (6/48) within squamous cell carcinoma. A bank of 26 primary lung explant tumour models were established and characterised - 4 of these harboured genetically amplified FGFR1 and corresponding high level protein expression. In vivo efficacy studies demonstrated rapid, potent and durable tumour regression in these models in response to oral daily dosing of AZD4547 (94-199% tumour growth inhibition after 2-3 weeks dosing of 12 or 25mg/kg AZD4547, all models p=<0.0001), correlating with pharmacodynamic modulation of FGFR signalling. Conversely, more modest anti-tumour efficacy was observed in FGFR1 non-amplified models (normal copy number and low copy gain) - (18% and 45% tumour growth inhibition after 3 weeks daily dosing of 25mg/kg AZD4547, p=0.25 and p=0.02 respectively). These data highlight the potential clinical utility of AZD4547 as a selective agent for the therapeutic treatment of squamous cell lung carcinoma harboring genetic amplification of FGFR1. 1 Weiss et al. 2010 Sci Transl Med. Dec 15;2(62)', '62ra93. 2 Gavine et al. 2011 AACR Annual Meeting. Abstract 3568.']",
        "Doc_id":"AACR_2012-1917",
        "Doc_title":" Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of primary lung explant models",
        "_version_":1606189035737317377},
      {
        "Meeting_name":" Circulating cell-free tumor DNA (cfDNA) testing in small cell lung cancer.",
        "Background":"['Background', ' The diagnosis of small cell lung cancer (SCLC) is often made using fine needle aspiration or small biopsy specimens, which may be insufficient for next generation sequencing (NGS). Guardant360 (G360), a blood-based liquid biopsy that analyzes circulating tumor DNA, may allow the detection of targetable gene abnormalities without the need for repeated biopsies. Methods', ' Peripheral blood samples from patients with SCLC were collected in two 10 mL tubes and cell-free DNA was analyzed by digital sequencing for the detection of single nucleotide variants (SNVs), copy number amplifications (CNAs), indels, and fusions. The Tumor Alterations Relevant for Genomics Driven Therapy (TARGET) curated database (http', '//www.broadinstitute.org/cancer/cga/target) was queried for potentially actionable mutations. Results', ' 143 consecutive samples from 134 de-identified patients were collected between June 2014 and December 2015. 6 patients had more than one sample. During the accrual time, the number of genes evaluated increased from 54 (6 tests) to 68 (98 tests) and finally to 70 (43 tests). The median time from collection to report was 15 days (range 9-27 days). Alterations in at least one gene were found in 132 (92.3%) of samples and 124 (92.5%) of patients. Inactivating mutations in TP53 and RB1 were seen in 70% and 32% of patients with detectable alterations respectively. Potentially targetable alterations were observed in 66 patients (49%). Amplifications in CCNE1 (12.0%) and FGFR1 (8.6%), and PIK3CAmutation (6.7%) were the most common potentially targetable alterations. Conclusions', ' G360 is non-invasive and rapid sequencing method, which may be particularly useful in patients with advanced stage SCLC where archival tissue samples may be suboptimal for NGS or no longer reflective of an evolving genomic profile. Due to the limited treatment options in this patient population, G360 may provide valuable information to guide treatment decisions.']",
        "Doc_id":"ASCO_166261-176",
        "Doc_title":" Circulating cell-free tumor DNA (cfDNA) testing in small cell lung cancer.",
        "_version_":1606189035905089536},
      {
        "Meeting_name":" FGFR1 amplification in squamous cell lung cancers.",
        "Background":"['Background', '  Squamous cell carcinoma of the lung (SqCCL) is the second most common type of lung cancer.  There are currently no established targeted therapies that take advantage of SqCCL-specific genetic abnormalities.  Amplification of the fibroblast growth factor receptor type 1 gene (FGFR1) has been identified as a driver event in breast cancers and in SqCCL. The demographic characteristics and prognosis of patients with these tumors remains to be defined.  Methods', '  DNA from 123 surgically resected, fresh frozen, and clinically annotated SqCCLs was extracted using a resin-based or phenol-based  methodology.  DNA quantity and quality was assessed using the Quantifiler kit (ABI).  Specimen histology was validated, and the proportion of tumor cells was >60%.  Copy number variation (CNV) analysis was performed using quantitative PCR with primers specific for exons 12 and 16 of FGFR1 and data analysis using CopyCaller (ABI).  Samples with a predicted CNV of at 2 or greater in at least one exon were scored as amplified.   Chi-squared tests were used to examine clinical and demographic differences between patients with and without amplification of FGFR1.  Survival differences were examined by Kaplan Meier and Cox regression models.   Results', '  Men comprised the majority of the population (n=91, 74%) and most cases were pathological stage I (n=75, 61%) or stage II (n=32, 26%).  Thirty (24.4%) tumors showed amplification of FGFR1.  There was no association between amplification and sex (p=0.18) or stage (p=0.37).  The majority of the patients were white (n=114, 92.7%), but the proportion of tumors that were amplified was higher among non-whites (5/9, 55.5%) than whites (25/114, 21.9%, p=0.02).  Overall, median survival was 32.2 months.  In univariate survival analysis, amplification was associated with an increased hazard of death (HR=1.55, Wilcoxon p=0.03).  Tumor stage at diagnosis was also associated with increased risk of death (HR=1.67, p=0.0009).  Only stage remained a significant predictor of death in the multivariate survival models (HR=1.65, p=0.004).  Conclusions', '  Somatic amplification of FGFR1 is a relatively common event in SqCCL and may be associated with race and overall survival.']",
        "Doc_id":"ASCO_100227-114",
        "Doc_title":" FGFR1 amplification in squamous cell lung cancers.",
        "_version_":1606189023637798912},
      {
        "Meeting_name":" FGFR1 can act as an oncogene or a tumor suppressor depending on the molecular context",
        "Background":"['FGFR family of proteins has been extensively related to oncogenic properties in several types of tumors, including lung cancer. Among its members, FGFR1 has been related to squamous cell lung carcinoma, where FGFR1 amplification is present in 20% of patients. However, its role in lung cancer has not yet been thoroughly described.Several lung cancer cell lines with different genetic backgrounds were transfected with plasmids to either overexpress or silence FGFR1. Then several tumorigenic abilities were tested in vitro and in vivo. mRNA from Paraffin-embedded tissue of a cohort of lung cancer patients was extracted and FGFR1 expression levels were measured and related to clinical characteristics.FGFR1 increases oncogenic properties in SCC cell lines, but exerts anti-oncogenic effects in several lung ADC cell lines, suggesting a tumor suppressor role under certain circumstances. This is a consequence of differentially expressed genes among these two histologies. According to this, analysis of FGFR1 mRNA expression of a cohort of lung cancer patients revealed that high FGFR1 mRNA expression was associated to a shorter overall survival (OS) and progression free survival (PFS) in lung SCC patients. However, a trend for longer OS was observed for the ADC patients with higher FGFR1 mRNA expression.FGFR1 has the potential to be either a tumor suppressor or an oncogene and the molecular context is a determining factor to define its final role in tumorigenesis.']",
        "Doc_id":"AACR_2016-1122",
        "Doc_title":" FGFR1 can act as an oncogene or a tumor suppressor depending on the molecular context",
        "_version_":1606189029870534657},
      {
        "Meeting_name":" Multiplexed molecular profiling of Japanese squamous cell lung cancers.",
        "Background":"['Background', ' Little advancement has been achieved in the development of efficacious molecular targeted therapies for squamous cell lung cancer, though great progress has been made in the treatment of lung adenocarcinoma in the past decade. However, results of comprehensive genome-wide characterization of squamous cell lung cancer have recently been reported and candidates for druggable targets were revealed. Thus it is becoming increasingly important to genotype squamous cell lung cancer as in the case of lung adenocarcinoma in which molecular profiles are incorporated into the lung cancer clinic. We conducted the Shizuoka lung cancer mutation study to analyze driver mutations in patients with thoracic malignancies and here we report the results of squamous cell lung cancer.Methods', ' Based on the biobanking system in conjunction with the clinic including the pathology lab, we have developed a multiplexed mutational panel designed to assess 23 mutations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications, and EML4-ALK translocations using pyrosequensing plus capillary electrophoresis, qRT-PCR, and RT-PCR, respectively. These results are communicated to clinicians for assigning patients to appropriate therapy and/or clinical trials. A written informed consent was obtained upfront from all patients enrolled into this study.Results', ' Between July 2011 and July 2012, sixty-eight squamous cell lung cancer patients were included in this study. Patients characteristics were as follows', ' median age (range) 72 (38-92) years; male 85%; smoker 97%; stage I/II/III/IV 18/35/26/21 %; well/moderate/poor/undetermined differentiated 6/34/40/20 %; surgically resected snap-frozen samples 46% and formalin-fixed paraffin-embedded (FFPE) samples 54%. We detected driver mutations in 47% of all cases. Mutations found', ' EGFR 2 (3%), KRAS 3 (4%), PIK3CA 9 (13%), NRAS 1 (1%), EGFR amplification 2 (3%), PIK3CA amplification 5 (7%), FGFR1 amplification 3 (4%). The frequency of FGFR1 amplification was much lower in our study than that in previous reports in Caucasian population. Seven patients harbored simultaneous driver mutations (EGFR + other 5 (7%), PIK3CA amplification + other 2 (3%)). Driver mutations were more frequently detected in surgically resected snap-frozen samples than in FFPE samples (65% v.s. 32%). Tumor differentiation was not significantly correlated with the presence or absence of driver mutations.Conclusions', ' Driver mutations were detected in 47% of squamous cell lung cancer patients in this study. PIK3CA mutation seemed to be relatively frequent in squamous cell lung cancer as reported in other studies, while FGFR1 amplification seemed less frequent. This multiplexed mutational profiling should be incorporated into lung cancer clinic to facilitate personalized cancer medicine in patients with squamous cell lung cancer.']",
        "Doc_id":"AACR_2013-1194",
        "Doc_title":" Multiplexed molecular profiling of Japanese squamous cell lung cancers.",
        "_version_":1606189010114314240},
      {
        "Meeting_name":" FGFR1/MAPK pathway regulates transcription factor brachyury-driven epithelial-mesenchymal transition in lung cancer",
        "Background":"['Lung cancer is the leading cause of cancer-related death worldwide. Failure of treatment is attributed to recurrence, metastasis, and chemotherapeutic resistance. Previous studies have demonstrated that the transcription factor brachyury is a potential regulator of epithelial-mesenchymal transition (EMT) and plays a role in tumor resistance to conventional antitumor therapies. However, the mechanisms underlining brachyury-induced EMT are unknown. Recent studies have revealed that fibroblast growth factor (FGF)/ fibroblast growth factor receptor (FGFR) signaling is activated in lung cancer, and suppression of FGFR results in cell growth inhibition and apoptosis. Here we investigated the role of FGFR signaling, a critical component of mesoderm induction during normal embryogenesis and a regulator of normal brachyury expression, in brachyury-driven lung cancer. Quantitative RT-PCR and Western Blot analysis showed that the chemotherapy-insensitive/metastatic lung cancer cell line H460 and adenocarcinoma tissues in patients had significantly high expressions of brachyury and FGFR1, 3 and 4 compared to the chemotherapy-sensitive/non-metastatic lung cancer cell line H440 and normal tissues adjacent to tumor. To further explore the association between FGFR and brachyury expression and its function, we specifically silenced FGFR using siRNAs for FGFR1, 2, 3 and 4 in H460 cells or overexpressed FGFR1, 3 and 4 in H441 cells. We found that only FGFR1 inhibition led to suppression of brachyury, whereas overexpression of FGFR1 induced brachyury expression, suggesting that brachyury is a potential target of FGFR1. Immunofluorescence staining and RT-PCR showed that silencing of FGFR1 led to inhibitions of brachyury and EMT (an increased epithelial marker E-cadherin expression and decreased mesenchymal biomarker Snail expression) in H460 cells. Overexpression of FGFR1 promoted EMT in H441 cells, but this effect was suppressed by concomitant knockdown of brachyury. In addition, the mitogen-activated protein kinases (MAPK)/extracellular signal-related kinase (ERK) inhibitor, PD184352, suppressed FGF1-upregulated brachyury and Snail expressions and invasion in H460 cells. PD184352 also inhibited FGFR1 overexpression-induced brachyury expression, EMT and invasion in H440 cells, indicating an important regulatory role of FGFR1 in brachyury-driven EMT through MAPK/ERK. These findings provide novel insights into the molecular mechanism of brachyury-driven EMT and highlight the FGFR1/MAPK/ERK pathway as a new therapeutic target for brachyury-driven lung cancer.']",
        "Doc_id":"AACR_2015-2079",
        "Doc_title":" FGFR1/MAPK pathway regulates transcription factor brachyury-driven epithelial-mesenchymal transition in lung cancer",
        "_version_":1606189032705884160},
      {
        "Meeting_name":" Clinical characteristics and molecular profile in patients with non-small cell lung cancer harboring CRKL amplification.",
        "Background":"['Background', '  It has been reported that CRKL amplification, associated with overexpression, has induced cell transformation as well as resistance to EGFR inhibitors. We analyzed CRKLamplification in archived genomic DNA samples from the Shizuoka Lung Cancer Mutation Study.  Methods', '  To identify CRKL amplification, we performed copy number analysis using the real-time PCR system. The standard curve was generated by PCR of serially diluted plasmid clones of CRKL and a reference gene. Triplicate reactions were performed using 2 ng of genomic DNA extracted from surgically resected tissues and tumor biopsies from non-small cell lung cancer (NSCLC) patients. Biopsy samples were obtained from NSCLC patients with EGFR mutations. In surgically resected tissues, TruSeq amplicon cancer panel was used for the detection of somatic mutations in 48 cancer related genes followed by ultra-deep sequencing (Illumina) at an average coverage of approximately 3,400x. ALK, ROS1 and RET translocations and EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications were also detected by multiplex RT-PCR and quantitative PCR, respectively.  Results', '  Between July 2011 and March 2013, 268 NSCLC patients treated with surgical resection, and 40 NSCLC patients with EGFR mutations, were enrolled in this study. Patient characteristics (treated with surgical resection) were as follows', ' median age (range) 69 (38-92) years; female 35%; never-smoker 27%; histology adenocarcinoma/squamous cell carcinoma/others 74/23/3 %; and differentiation well/moderate/poor 21/53/23 %. We detected CRKL amplification in 7.5% of 268 NSCLC patients treated with surgical resection. Frequencies of CRKL amplification in patients with gene alterations were as follows', ' 7.5 % of 93 EGFR; none of 38 KRAS, 8.7% of 23 PIK3CA; 8.8% of 91 TP53, none of 4 EML4-ALK, and 50% of 4 KIF5B-RET. 18% of 40 patients with EGFR mutations  showed CRKL amplification before EGFR-TKI treatment.  Conclusions', '  CRKL amplification was identified in 7.5% of NSCLC patients. These results suggest that CRKL amplification may be mutually exclusive with mutations in KRAS, and frequently observed in those with KIF5B-RET.']",
        "Doc_id":"ASCO_133258-144",
        "Doc_title":" Clinical characteristics and molecular profile in patients with non-small cell lung cancer harboring CRKL amplification.",
        "_version_":1606189018308935680},
      {
        "Meeting_name":" Activation of FGF2-FGFR1 pathway in EGFR-mutant lung cancer cell line with long-term gefitinib exposure.",
        "Background":"['Many of the patients with non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR)-mutation who initially responded well to EGFR-tyrosine kinase inhibitors (TKIs) eventually relapse. In spite of many studies over the last few years to elucidate this mechanism of acquired resistance to EGFR-TKIs, approximately 30% of the mechanisms of acquired resistance are still unknown. Recently autocrine signaling of fibroblast growth factors (FGFs) and their receptors (FGFRs) has been demonstrated in NSCLC cell lines. And several studies suggest that the FGF-FGFR autocrine growth pathway could be an important mechanism for intrinsic resistance to EGFR-TKIs in NSCLC cell lines with wild-type EGFR. But until now, no report has clarified the role of FGF-FGFR pathway in acquired resistance to EGFR-TKIs in NSCLC cell lines with sensitive EGFR mutations. We have established a gefitinib-resistant cell line (PC9 GR), by serial exposure of gefitinib to PC9, an originally gefitinib-sensitive lung cancer cell line (PC9 na). We confirmed that these cell lines did not harbor two well-known EGFR-TKI resistance mechanisms, the second mutation in the EGFR gene itself, EGFR T790 and the amplification of the MET oncogene. We collected total RNA from both PC9 na and PC9 GR and examined mRNA expression profile, by using cDNA microarray analysis. We found the expressions of FGFR1 and FGF2 were increased in PC9 GR compared to in PC9 na. The growth of PC9 GR cells was inhibited either by PD173074 (inhibitors of FGFRs) or knocking down of FGFR1 or FGF2 by siRNA in combination with gefitinib. FACS analysis revealed that the combination treatment with PD173074 and gefitinib induced apoptosis more efficiently in PC9 GR cells compared to gefitinib alone. PC9 na cells and PC9 GR cells did not show any change in the proportion of apoptotic cells after treatment with PD173074 alone. To further investigate how FGF2-FGFR1 pathway affects resistance to gefitinib in these cell lines, the downstream targets of EGFR signaling including the MEK-ERK and PI3K-AKT pathways were examined. In PC9 na cells, the phosphorylation of EGFR, ERK, and AKT was efficiently inhibited by gefitinib alone. On the other hand, in PC9 GR cells, the phosphorylation of ERK and AKT was not efficiently inhibited by gefitinib alone. However, the inhibition of phosphorylation of ERK was completely and AKT was less efficiently rescued by gefitinib and PD173074 combination therapy. In conclusion, these data suggest the activation of FGF2-FGFR1 signaling pathway contributes to the gefitinib resistance in PC9 GR. FGF2-FGFR1 pathway will be a therapeutic target for a subset of NSCLC that acquires EGFR-TKI resistance.']",
        "Doc_id":"AACR_2013-5652",
        "Doc_title":" Activation of FGF2-FGFR1 pathway in EGFR-mutant lung cancer cell line with long-term gefitinib exposure.",
        "_version_":1606188990165155840},
      {
        "Meeting_name":" Association of PIK3CA mutations and age with the occurence of second primary lung cancer (SPLC).",
        "Background":"['Background', \"    The incidence of SPLC in Germany was reported to be 1.2 per 100,000 inhabitants in 2007 and the prevalence of second primary cancers reported by the US International Cancer Institute's Surveillance, Epidemiology and End Results Program has more than doubled over the last 25 years. Recently there has been tremendous progress in the ability to detect driver mutations in lung cancer and large studies presented the frequencies of driver mutations in unselected patient populations. We conducted an association study of known genetic driver events and clinical characteristics with the occurence of SPLC.  Methods\", '  Within the Network Genomic Medicine Lung Cancer, a local molecular screening network encompassing hospitals and office-based oncologists in the catchment area of the Center for Integrated Oncology Kln Bonn, we retrospectively reviewed the medical records of 375 molecularly annotated NSCLC patients for their SPLC status and clinical characteristics (age at diagnosis, histology, sex, smoking status). Molecular analysis for lung adenocarcinoma included the EGFR, ALK, BRAF, KRAS and PIK3CA status and for squamous cell lung cancer the FGFR1 and PIK3CA status.  Results', '  84 of 375 (22,4%) patients were SPLCs. The median age of SPLC diagnosis was 70 yrs. (Range 53 - 85 yrs.) and differed significantly from the rest of the population with a median age of 65 yrs. (Range 28 - 86 yrs.). The frequency of SPLCs was not significantly different between males and females (p = 0,259). In univariate logistic regression analysis active and former smoking, positive PIK3CA mutation and FGFR1 amplification status as well as age were significantly associated with the occurrence of SPLC. In a multivariate logistic regression analysis including the variables mentioned above only PIK3CA mutations (OR 9,48 95% CI 1,83 - 49,1) (p = 0,007) and age (OR 1,06 95% CI 1,03 - 1,1) (p = 0,015) could be confirmed to be independent prognosticators for the occurrence of SPLCs.  Conclusions', '  The occurrence of SPLC was associated with age and PIK3CA mutations in our study population. Further comprehensive investigations on this topic are needed to confirm our findings and to further understand the association between mutation status and SPLCs.']",
        "Doc_id":"ASCO_114545-132",
        "Doc_title":" Association of PIK3CA mutations and age with the occurence of second primary lung cancer (SPLC).",
        "_version_":1606189027585687552},
      {
        "Meeting_name":" Prognostic value of a 12-gene signature in platinum-based chemotherapy treated SCLC.",
        "Background":"['Background', ' Small cell lung cancer (SCLC), which accounts for 15-20% of lung cancer, is a highly aggressive neoplasm. Different from non-small cell lung cancer, SCLC is characterized by a high proliferation rate and early metastasis. Only about 25% of patients with limited stage disease will be cured after first-line standard treatment and majority of the patients will relapse after initial sensitivity to the chemotherapy and radiotherapy. The highly complex genetic landscape of SCLC may be the reason for its resistance to conventional therapy but the details are still unclear. Methods', ' Nine patients with SCLC received platinum-based chemotherapy and/or radiotherapy were included in this study. According to the prognosis, patients were classified into two groups', ' poor prognosis group (PP group, PFS < 6 months, n = 5) and better prognosis group (BP group, PFS > 24 months, n = 4). Tumor DNA was isolated from pre-treatment paraffin-embedded tumor tissue and subjected to enrichment for a 1.15M size panel cover exon regions from 1,086 genes. Followed by next generation sequencing on an Illumina X10 platform, the captured sequencing data was further processed using bioinformatics analysis to identify somatic mutations, including single nucleotide variants (SNV), short insertions/deletions (indels) and copy number variation (CNV). Changes in tumor DNA were compared with clinical efficiency. Results', ' We show that the tumor mutation burden in PP group is higher than the BP group (p = 0.06). Using the mutation burden of 12 genes (PTEN, TP53, JAK2, BCL2, CCNE1, EGFR, ROS1, NTRK3, MYC, FGFR1, RANBP2, and CREBBP) as a factor, the PP group can be distinguished from BP group. In addition, TP53 loss is more frequently appeared in the PP group. Conclusions', ' Our results suggest that high mutation burden status of 12 genes (PTEN, TP53, JAK2, BCL2, CCNE1, EGFR, ROS1, NTRK3, MYC, FGFR1, RANBP2, and CREBBP) might correlate with poor prognosis of small cell lung cancer.']",
        "Doc_id":"ASCO_188733-199",
        "Doc_title":" Prognostic value of a 12-gene signature in platinum-based chemotherapy treated SCLC.",
        "_version_":1606189020674523136},
      {
        "Meeting_name":" FGFR",
        "Background":"['Background', '   Genetic modifications of the FGFR family of transmembrane tyrosine kinase growth factor receptors are described in a range of cancers.  Amplification of FGFR2 is detected in up to 10% of oesophagogastric cancers where it is associated with poor prognosis.   FGFR1 amplification has also been demonstrated in 10% of breast cancers, is more common in luminal B ER positive tumors, and is also associated with inferior survival outcomes.  Finally, FGFR1 amplification has been described in up to 22% of squamous cell lung cancers.  AZD4547 is a potent and selective inhibitor of FGFR-1, 2 and 3 receptor tyrosine kinases.   Preclinically,  AZD4547 potently inhibits growth in FGFR amplified gastric and lung cancer cell lines and induces dose dependent  tumor growth inhibition and regression in FGFR amplified tumour xenograft and patient derived explant models.    Methods', '   This is an open label, phase II non-randomised multi-centre study to assess the efficacy of AZD4547 monotherapy and resulting molecular changes in serial biopsies in pts with previously treated FGFR1 amplified advanced breast cancer, FGFR2 amplified advanced oesophagogastric cancer, or FGFR1 amplified advanced squamous lung cancer.  Eligibility include centrally verified FGFR amplified tumour (ratio >2.2), PS=0-2, ability to comply with the collection of tumor biopsies (mandatory at baseline and on days 10-14), calcium and phosphate within normal limits, measurable disease (RECIST 1.1), and no history of significant eye disease. Pts may be prescreened for FGFR amplification on archival tissue while undergoing first line or adjuvant chemotherapy.   Sixteen pts will be enrolled per cohort.  All pts will receive AZD4547 80mg bd on a two week on, one week off schedule.  The primary endpoint  is correlation between change in pERK in pretreatment and day 10-14 biopsy and change in tumour diameter on week 8 CT.  Secondary endpoints include ORR, DCR and PFS.  Multiple exploratory translational endpoints are also planned.    The study is currently open at the Royal Marsden Hospital and will open at 15 selected UK cancer centres.  This study is sponsored by the Royal Marsden Hospital, funded by AstraZeneca and has been adopted to the UK National Cancer Research Network (NCRN) portfolio. Clinical trial information', ' 2011-003718-18.']",
        "Doc_id":"ASCO_111826-132",
        "Doc_title":" FGFR",
        "_version_":1606189021342466048},
      {
        "Meeting_name":" Prospective mutational characterization of Japanese patients with non-small cell lung cancer by next-generation sequencing",
        "Background":"['Background', ' Detection of tumor genetic alterations is critically needed for lung cancer clinic as well as for the development of molecular targeted therapeutics. Here we report the results of a broad spectrum of genetic alterations identified in Japanese patients with non-small cell lung cancer (NSCLC) by ultra-deep targeted sequencing.Material and Methods', ' Highly multiplexed amplicon sequencing was performed using genomic DNA extracted from snap-frozen tumor specimens. TruSeq amplicon cancer panel was used for the detection of somatic mutations in 48 cancer related genes followed by ultra-deep sequencing (Illumina) at an average coverage of approximately 3,400x. ALK, ROS1 and RET translocations and EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications were also detected by multiplex RT-PCR and quantitative PCR, respectively.Results', ' Between July 2011 and March 2013, 279 consecutive patients were enrolled in this prospective study at Shizuoka Cancer Center', ' median age 69 years (range', ' 38-92); male 66%; never smoker 25.8%; histology', ' adenocarcinoma 70.6%, squamous cell carcinoma (SQ) 25.1%, others 4.3%; pathological stage', ' I 58.1%, II 22.6%, III 15.4%, IV 3.9%. TP53 mutation was most frequently detected (35.9%) in all patients, particularly in SQ (59.2%). Mutations in genes such as CTNNB1 (4.0%), SMAD4 (1.5%), GNAS (1.0%), STK11 (1.0%), HRAS (0.5%) and PTPN11 (0.5%) were also detected in addition to major mutations in genes such as EGFR (44.8%), KRAS (18.4%) and PIK3CA (4.5%) in adenocarcinoma. PIK3CA (19.7%), HRAS (2.8%), APC (1.4%), FGFR2 (1.4%), FGFR3 (1.4%) and SMAD4 (1.4%) mutations were identified in SQ and notably, 40.9% of SQ patients harbored concurrent gene mutations, suggesting the genetic complexity of this histological subset. In EGFR mutation, deletion in exon 19 (42.6%) and L858R point mutation in exon 21 (41.5%) were frequently observed. As for PIK3CA mutation, the majority (92.8% of all PIK3CA mutant SQ cases) was detected in exon 9 (residues E542 and E545) in SQ but in contrast, mutations in exon 1 and 20 (residues G106 and H1047, respectively) were more frequently detected (33.3% combined of all PIK3CA mutant adenocarcinoma cases) in adenocarcinoma.Conclusions', ' We managed to detect a wide range of genetic alterations and to identify additional actionable mutations along with popular driver mutations in NSCLC by next-generation sequencing technology. These data should be incorporated into lung cancer clinic to implement personalized cancer medicine.']",
        "Doc_id":"AACR_2014-1537",
        "Doc_title":" Prospective mutational characterization of Japanese patients with non-small cell lung cancer by next-generation sequencing",
        "_version_":1606189028165550080},
      {
        "Meeting_name":" PD-L1 expression correlation with TP53 gene mutation status in lung cancer but not in colorectal cancer.",
        "Background":"['Background', ' Expression of PD-L1 is, in general, associated with response to immunotherapy. However, it is believed that additional intrinsic factors play a role in determining the potential of response to immunotherapy. Toward this goal we investigated the relationship between mutation profile and PD-L1 expression in lung and colorectal cancers. Methods', ' Molecular profiling using a panel of gene 24 genes was performed by next generation sequencing (NGS) on 158 non-small cell lung cancer (NSCLC) and 42 colorectal cancers. The genes studied included ERBB2, FGFR1, FGFR2, FGFR3, SRC, JAK3, ERBB4, ERBB2, and SMAD4. In addition, these tumors were studied for the expression of PD-L1 using immunohistochemistry (IHC). PD-L1 expression was performed using standard IHC approach using SP142 clone (Spring Biosciences). Results', ' The level of PD-L1 expression was significantly (P = 0.0005) lower in colorectal cancer as compared with NSCLC. The NSCLC cohort had significantly (P = < 0.0001) more cases with 3 or more genes mutated as compared with colorectal cancer. However, there was no significant difference in TP53 mutation frequency between the two tumor types. There was no correlation between PD-L1 expression and the presence or absence of 3 or more gene mutations in either NSCLC or colorectal cancer. However, PD-L1 expression was significantly (P = 0.01) higher in tumors with TP53 mutation in the NSCLC cohort, but not in the colorectal carcinoma cohort (P = 0.5). This was true whether PD-L1 level was used as a continuous variable or if it was dichotomized at 20% (P = 0.02) or 40% (P = 0.03) cutoffs. Conclusions', ' There is significant difference between NSCLC and colorectal cancers in PD-L1 expression levels. More importantly, TP53 mutation in NSCLC correlates with the expression of PD-L1 protein, but not in colorectal cancer despite similar rate of mutation of the TP53 between the two tumor types. This suggests a possible difference in the mechanism of regulating PD-L1 expression between the two tumor types.']",
        "Doc_id":"ASCO_166917-176",
        "Doc_title":" PD-L1 expression correlation with TP53 gene mutation status in lung cancer but not in colorectal cancer.",
        "_version_":1606189038580006912},
      {
        "Meeting_name":" Identification of actionable mutations in surgically resected tumor specimens from Japanese patients with non-small cell lung cancer by ultra-deep targeted sequencing.",
        "Background":"['Background', '  Detection of tumor genetic alterations is critically needed for lung cancer clinic as well as for the development of molecular targeted therapeutics. Here we report the results of a broad spectrum of genetic alterations identified in Japanese non-small cell lung cancer (NSCLC) patients by ultra-deep targeted sequencing.  Methods', '  Highly multiplexed amplicon sequencing was performed using genomic DNA extracted from snap-frozen tumor specimens. TruSeq amplicon cancer panel was used for the detection of somatic mutations in 48 cancer related genes followed by ultra-deep sequencing (Illumina) at an average coverage of approximately 2800x. ALK, ROS1 and RET traslocations and EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications were also detected by multiplex RT-PCR and quantitative PCR, respectively.  Results', '  The demographics of 204 consecutive patients enrolled in this prospective study at Shizuoka Cancer Center between July 2011 and November 2012', ' median age 69 years (range', ' 38-92); male 66%; never smoker 25.5%; histology', ' adenocarcinoma 68.6%, squamous cell carcinoma (SQ) 27.0%, others 4.4%; tumor stage', ' I 53.9%, II 28.4%, III 12.7%, IV 4.9%. TP53 mutation was most frequently detected (44.4%) in all patients, particularly in SQ (67.9%). Mutations in genes such as MLH1 (4.9%), STK11 (6.3%), CTNNB1 (5.6%), SMAD4 (1.4%), VHL1 (1.4%), PTPN11 (0.7%) and GNAS (0.7%) were detected besides major mutations in genes such as EGFR (43.0%), KRAS (17.6%) and PIK3CA (14.1%) in adenocarcinoma. PIK3CA (21.4%), MLH1 (5.4%), APC (3.6%), STK11 (3.6%), FGFR2 (1.8%) and VHL (1.8%) mutations were identified in SQ and notably, 48.2% of SQ patients harbored simultaneous gene mutations, suggesting the genetic complexity of this histology. FGFR1 amplification was found in 8.9 % of SQ, suggesting lower frequency in Asian population than in Caucasian population.  Conclusions', '  We managed to detect a wide range of genetic alterations and identified additional actionable mutations besides popular driver mutations. This approach may facilitate elucidation of detailed molecular characteristics of NSCLC, thereby implementing personalized cancer medicine.']",
        "Doc_id":"ASCO_117390-132",
        "Doc_title":" Identification of actionable mutations in surgically resected tumor specimens from Japanese patients with non-small cell lung cancer by ultra-deep targeted sequencing.",
        "_version_":1606188975214559232},
      {
        "Meeting_name":" Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.",
        "Background":"['The estrogen receptor (ER) promotes cell proliferation in non-small cell lung cancer (NSCLC). Since fibroblast growth factors (FGFs) are known regulators of stem cell markers in ER positive breast cancer, we investigated whether a link between the estrogen pathway, FGFs, and stem cell markers could be demonstrated in NSCLC animal models, human cells lines and tumor tissue. In the lungs of female FVB/N mice exposed to the tobacco carcinogen 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone, NNK, treatment with the anti-estrogen fulvestrant and/or the aromatase inhibitor anastrozole blocked secretion of both FGF2 and FGF9, and reduced expression of the stem cell markers SOX2 and nanog. These effects were observed in the normal airway epilthelium as well as in both lung preneoplasias and lung adenomas. To investigate the effects of -estradiol (E2), male mice were administered E2 in the drinking water during exposure to NNK for 4 weeks. In this mouse model, the incidence of carcinogen-induced lung preneoplasias increased 1.8-fold (p<0.05) with E2 exposure accompanied by increased expression of FGF2, FGF9, SOX2, and nanog in airway preneoplasias demonstrating a relationship between activation of the FGF pathway in the lungs, expansion of cells with a stem cell phenotype, and promotion of pre-cancerous changes. In FGFR1 normal copy number NSCLC cell lines that express multiple FGFR family members and secrete several FGFs, E2 treatment caused a significant increase (up to 4-fold; p<0.05) in release of FGF2, an effect that was completely blocked by fulvestrant. Treatment with fulvestrant also resulted in a 30% reduction in phosphorylation of fibroblast growth factor receptor substrate 2, the FGFR docking protein. Upon co-inhibition of ER and FGFRs using fulvestrant and the pan-FGFR inhibitor AZD4547, significantly enhanced (p<0.01) anti-proliferative effects were observed in FGFR1 normal copy number NSCLC cells that show low sensitivity to FGFR inhibitors as single agents. In NSCLC xenografts, the combination of AZD4547 (daily 12.5 mg/kg) and fulvestrant (30 mg/kg twice weekly) resulted in a significantly greater inhibition (67-85% decrease; p<0.05) of tumor growth and decreased expression of Ki67 and stem cell markers compared to each single agent treatment. Furthermore, tumor histology appeared more differentiated and up to a 25% decrease in malignant cellularity was observed with combination treatment compared to each single agent treatment. In NSCLC patient tumors, high ER expression correlated with high FGFR1 expression (p<0.001). Taken together, these results suggest that interaction between the ER and FGFR pathways in NSCLC promotes a stem-like state. Combining an FGFR inhibitor with an ER pathway inhibitor could be exploited to increase the efficacy of FGFR inhibitors for NSCLC patients who lack FGFR genetic alterations. Supported by P50 CA090440 and the V-Foundation.']",
        "Doc_id":"AACR_2017-1005",
        "Doc_title":" Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.",
        "_version_":1606189026940813312},
      {
        "Meeting_name":" Inhibitor of differentiation-1 (Id1) expression deficiency in the tumor microenvironment impairs experimental hepatic metastasis of lung cancer",
        "Background":"['Background', \" Liver metastasis (LM) occurs in 30% of non-small cell lung cancer patients but the contribution of the patient's genetic background to the hepatic metastasis development is unclear. Previously, we reported that inflammation contributes to the prometastatic microenvironment of the liver. Upregulation of transcriptional regulator Id1 gene has been associated with inflammation while ablation of Id1 in mice reduced inflammation. In this study Id1 deficient mice were used to analyze the role of host Id1 in the hepatic colonization of an experimental lung cancer.Methods\", ' Lewis lung carcinoma cells were used for the experimental production of hepatic metastasis via intrasplenic injection of cancer cells in C57BL/6 wild-type and Id1-knockout (KO) mice. Animals were splenectomized to avoid flank tumor formation and weekly FDG-micro-positron emission tomographies (PET) were performed to monitor LM formation. Animals were sacrificed at the time of LM occurrence and total RNA was purified from LM. A microarray gene expression analysis (Affymetrix) with the support of Ingenuity Pathways Analysis (IPA) was performed to evaluate the potential impact of Id1 deficiency on the regulation of genes mediating cancer cell invasion and proliferation, angiogenesis and metastasis.Results', ' By week two after cancer cell injection, 70% wild-type and 10% Id1-KO mice had detectable hepatic metastasis by FDG-PET (p=0.02). Three weeks after injection, when 100% wild-type had LM, still just 20% Id1-KO mice had LM (p=0.015). Moreover, 50% Id1-KO mice remained LM-free >4 weeks after cancer cell injection. No other metastasis sites were detected at necropsy. A microarray gene expression analysis of LM from Id1-KO animals uncovered a remarkable downregulation (p<0.05) of specific genes involved in the activation of cancer cell proliferation (Myc, Cdc20, Smc2, Aurora kinase B, Cyclin B1, CDK1, TIMP1, Epiregulin), migration (Ccl7, Serpine1/PAI-1, VIM, Anxa2, S100A4, S100A6, Akt3, Adrenomedullin), angiogenesis (Hif1a, PGF, Nestin) and metastasis (FGFR1, Src, IL-18, MMP3, MMP12, MMP13, Amphiregulin, PDGFA, FoxM1, Hsp90AA1, MIF, Ccl2, RhoC).Conclusion', ' Our results demonstrate that Id1 expression deficiency impaired the metastatic process of lung cancer cells to the liver through the specific downregulation of key metastasis-associated genes and suggest that Id1-dependent mechanisms are new targets for hepatic metastasis therapeutic.This study has been partially funded by UTE project CIMA and an ISCIII-FIS grant 2011.']",
        "Doc_id":"AACR_2014-1996",
        "Doc_title":" Inhibitor of differentiation-1 (Id1) expression deficiency in the tumor microenvironment impairs experimental hepatic metastasis of lung cancer",
        "_version_":1606189024314130432},
      {
        "Meeting_name":" Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets",
        "Background":"['Lung neuroendocrine tumors (LNETs) comprise small-cell lung cancer (SCLC), large-cell neuroendocrine tumors (LCNEC), and pulmonary carcinoids (PCA), and account for 25% of all lung cancer cases. The low 5-year survival rate of the highly aggressive LNETs (SCLC and LCNEC) combined with the lack of an effective treatment, suggest that understanding how these tumors arise and identifying therapeutic targets are unmet needs. We performed genome/exome, and transcriptome sequencing of 29 SCLC (Ref.1), 60 LCNEC, and 45 PCA to better understand their molecular origin and identify altered genes that may offer therapeutic opportunities.In contrast to SCLC and LCNEC, we found that RB1 and TP53 mutations were rare events in PCA suggesting that PCA are not early progenitor lesions of SCLC or LCNEC, but arise through independent mechanisms. Moreover, GSEA analysis showed that genes of the RB1 pathway were downregulated in SCLC but not in PCA. Our data also show that inactivation of chromatin-remodeling genes, specifically genes involved in histone methylation and subunits of the SWI/SNF complex, is sufficient to drive transformation in PCA.In a preliminary analysis of 15 LCNEC (Ref.2) we observed a predominance of mutations typical of SCLC, such as RB1, TP53, and CREBBP/EP300. In this larger series, we additionally found samples with mutations frequent in adenocarcinoma (AD) or squamous (SQ) lung cancer. We could then distinguish two well-defined groups of LCNEC', ' a SCLC-like group, carrying MYCL1 amplifications and mutations in both RB1 and TP53 genes; and an AD/SQ-like group, harbouring CDKN2A deletions, TTF1 amplifications, and frequent mutations in KEAP1 and STK11. Interestingly, RB1, STK11, and KEAP1 mutations happened in an almost mutually exclusive way. These data suggest that LCNEC might represent an evolutionary trunk that can branch to SCLC or AD/SQ, and also that LNETs and non-LNETs are not completely different entities. This is already suggested by the fact that one of the resistance mechanisms of EGFR-mutant adenocarcinomas to tyrosine-kinase inhibitors is through trans-differentiation to SCLC (Ref.3).Finally, we also identified new targetable driver genes in SCLC and LCNEC', ' FGFR1 amplifications were observed in 6% and 18% of the cases respectively; PTEN mutations were identified in 10% of the SCLC cases; and interestingly, one of the LCNEC samples (belonging to the SCLC-like group) harboured an activating RFWD2-NTRK1 fusion gene suggesting that fusions affecting NTRK1 may not only be a targetable opportunity for AD (Ref.4) but also for LCNEC and, based on the molecular similarities, also SCLC.(1) Peifer and Fernandez-Cuesta et al. Nat Genetics 2012(2) The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) Sci Transl Med 2013(3) Sequist et al., Sci Transl Med 2011(4) Vaishnavi et al. Nat Medicine 2013']",
        "Doc_id":"AACR_2014-1531",
        "Doc_title":" Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets",
        "_version_":1606189010835734528},
      {
        "Meeting_name":" Exploring the in vitro and in vivo activity of lucitanib in FGFR1-amplified lung cancer models",
        "Background":"['Lucitanib (S80881, formerly E-3810) is a novel tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1-3 (VEGFR1-3) and fibroblast growth factor (FGF) receptor 1-2 (FGFR1-2). It exhibits a unique pharmacological profile and demonstrates potent antitumor activity in xenograft models derived from multiple oncology indications. The on-going phase I/II clinical study of lucitanib has demonstrated objective RECIST responses in breast cancer patients with FGF-aberrant (FGFR1 and/or FGF3/4/19 gene amplified) tumors and in oncology indications anticipated to benefit from antiangiogenic agents (e.g. renal cell and thyroid cancer patients).In an attempt to further elucidate the mechanism of action of lucitanib, we evaluated the in vitro and in vivo activity of lucitanib in lung cell lines with FGFR1 amplification. The FGFR1 gene is frequently amplified in lung cancer tumors and FGFR1 copy number may provide a patient selection marker for clinical trials of FGFR inhibitors. Lucitanib cytotoxic activity was evaluated and compared to other FGFR inhibitors (Dovitinib, AZD4547 and PD173074) in a panel of 11 lung cancer cell lines characterized for FGFR1/2 gene copy number and FGFR1, FGFR2 and FGF2 mRNA expression level. Lucitanib IC50 values ranged from 0.14 to 23 M; interestingly the two most sensitive cells lines (NCI-H1581 and DMS114) harbored FGFR1 amplification, while cell lines with lower FGFR1 gene copy number (2) displayed a higher drug IC50 value. In order to understand the involvement of FGFR1 inhibition in the antitumor activity of lucitanib, nude mice bearing FGFR1 amplified NCI-H1581 cell xenografts were treated with escalating doses of lucitanib (2.5, 5, 10 and 20mg/kg/day PO) continuously for 30 days. The antitumor activity of lucitanib at the dose of 2.5mg/kg was marginal (tumor volume of treated / control (T/C%) = 46), while at 5, 10 and 20mg/kg the drug was equally very active (T/C% = 24, 21 and 16, respectively). Pharmacodynamic and pharmacokinetic assessments were undertaken at the same drug doses employed for the xenograft efficacy experiments in NCI-H1581 tumor bearing mice treated for 12 continuous days. Tumor concentrations of lucitanib, measured by LC-MS/MS, were related to the administered dose and ranged from 0.31-3.68 M and from 0.26-2.52 M at 4 and 24hrs, respectively. Lucitanib drug concentrations were higher in the tumor than in the plasma, with tumor/plasma ratios at 4 and 24 hrs of 2.00.22 and 20.56, respectively. In conclusion, these preclinical data indicate that lucitanib demonstrates in vitro efficacy in lung cancer cell lines with FGFR1 gene amplification and has a favorable drug distribution profile in tumor models.']",
        "Doc_id":"AACR_2014-2670",
        "Doc_title":" Exploring the in vitro and in vivo activity of lucitanib in FGFR1-amplified lung cancer models",
        "_version_":1606189035235049472},
      {
        "Meeting_name":" A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers",
        "Background":"['Background', '  Squamous cell lung cancers (SQCLC) account for 25% of all NSCLCs.  Prognosis is poor with few treatment options. Amplified FGFR1 is one of the most common oncogenic events in SQCLCs and occurs in ~20% of cases. AZD4547 is a potent and selective FGFR1-3 inhibitor with activity in FGFR1 amplified SQCLC cell lines and patient-derived xenografts. Prior work identified a recommended dose of 80mg po bid.  Methods', '    This was a multicentre Phase 1 expansion of AZD4547 in patients with previously treated stage IV FGFR1 amplified SQCLCs (NCT00979134).  FGFR1 amplification (FGFR1', 'CEP8 2) was confirmed through central FISH (N=13) or review of local results (N=2). Primary endpoint was safety/tolerability.  Secondary endpoints were preliminary anti-tumor activity, PK, and PD. CT scans were performed at baseline and every 6 weeks.   Results', '  15 patients were treated. Median age=66 (48-72); female=46%; former/current smoker=100%; WHO restricted PS=69%. 8 patients had FISH ratios between 2-2.8 (low amplification).  7 patients had FISH ratios > 2.8 (high amplification).  Mean relative dose intensity= 97%.  The most common related AEs were GI and dermatologic. Grade  3 related AEs occurred in 3 patients (20%) (central serous retinopathy (CSR), hyponatremia, dehydration).  Related SAEs occurred in 3 patients (CSR,dehydration, asthenia and dyspnea). There were 3 discontinuations due to AEs and no deaths due to drug. 14 patients were evaluable for tumor response assessment.  There were', ' 1 PR, 4 SD, 9 PD (7 progressions and 2 deaths). The 1 PR was observed in a patient with high FGFR1amplification.  Preliminary analysis found an increase in serum phosphate following treatment with AZD4547.  Exon-sequencing of 283 cancer-related genes in 6 patient tumors, including 1 with a PR, showed no clear response modifiers.   Conclusions', '  AZD4547 was well-tolerated in patients with FGFR1 amplified SQCLC but did not meet its pre-specified efficacy endpoint in terms of overall response rate for continuation. The increase in serum phosphate concentration observed in this study provides evidence that AZD4547 at this dose and schedule causes pharmacologic target inhibition. Clinical trial information', ' NCT00979134.']",
        "Doc_id":"ASCO_128825-144",
        "Doc_title":" A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers",
        "_version_":1606189040098344960},
      {
        "Meeting_name":" Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.",
        "Background":"['Growth factor receptors (GFRs) are amenable to therapeutic intervention in cancer and it is important to select patients appropriately.One of the mechanisms for activation of GFRs is gene amplification (GA) but discrepancies arising from the difficulties associated with data interpretation and the lack of agreed parameters confound the comparison of results from different laboratories. Here, we attempt to establish appropriate conditions for standardization of the determination of GA in a panel of GFRs. A NSCLC tissue microarray panel containing 302 samples was screened for alterations at ALK,FGFR1, FGFR2, FGFR3, ERBB2, IGF1R, KIT, MET and PDGFRA by FISH, immunostaining and/or real-time quantitative RT-PCR. Strong amplification was found for FGFR1, ERBB2, KIT/PDFGRA and MET, with frequencies ranging from 1 to6%. Thresholds for overexpression and GA were established. Strong immunostaining was found in most tumors with ERBB2, MET and KIT amplification, although some tumors underwent strong immunostaining in the absence of GA. KIT and PDFGRA were always co-amplified, but only one tumor showed PDGFRA overexpression, indicating that KIT is the main target.Amplification of FGFR1 predominated in squamous cell carcinomas, although the association with overexpression was inconclusive. Interestingly, alterations at ALK,MET, EGFR, ERBB2 and KRAS correlated with augmented levels of phospho-S6 protein, suggesting activation of the mTOR pathway, which may prove useful to pre-select tumors for testing.Overall, here, we provide with parameters for the determination of GA at ERBB2, MET, KIT, and PDGFRA which could be implemented in the clinic to stratify lung cancer patients for specific treatments.']",
        "Doc_id":"AACR_2013-3034",
        "Doc_title":" Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.",
        "_version_":1606189042072813568},
      {
        "Meeting_name":" Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR.",
        "Background":"['Background', ' Aberrant activity of the MET, FGFR1 and AXL receptors has been associated with the development of resistance to first, second and third generation EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutated non-small cell lung cancer (NSCLC) patients.']",
        "Doc_id":"AACR_2017-3077",
        "Doc_title":" Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR.",
        "_version_":1606189005223755776},
      {
        "Meeting_name":" Distribution and pathogenicity of nsSNPs in receptor tyrosine kinases (RTKs) in non-small cell lung cancer (NSCLC) patients (pts).",
        "Background":"['Background', ' Non-synonymous SNPs (nsSNPs) in RTKs can alter kinase activity and are not exclusive to the tyrosine kinase domain (TKD). In NSCLC, EGFR lesions were previously identified using TKD-limited tests; however, next-generation sequencing (NGS) enables the entire protein sequence of many RTKs to be interrogated. Methods', ' We analyzed all nsSNPs in 28 RTKs in lung cancer pts who received tumor profiling with Caris NGS from 2013-2015. Mutations were classified by location including the TKD, extracellular domain (ECD), transmembrane domain (TM), juxtamembrane domain (JM), and carboxy-terminal (CT) regions. nsSNPs underwent in silico analysis using PolyPhen-2 (Harvard) to predict pathogenicity. Results', ' 167 pts (156 NSCLC, 11 SC) were identified with a median age 65 (range 26-85); 51% male; 65% white, 31% black; 77% 20 pack-years (py), 11% non-smokers; 52% samples tested were metastases. NSCLC pts were 63% adenocarcinoma, 22%, squamous, 8% large-cell; 81% stage IV, 14% III; 17 were EGFR+, 6 BRAF+, 3 HER2+, 3 ROS1 rearranged and 1 MET exon 14. A total 300 nsSNPs (286 NSCLC, 14 SC) were found in 28 RTKs, excluding EGFR. 123/156 NSCLC pts (79%) and 9/11 SC (82%) had 1 RTK lesion with median 2 (range 0-8); 143/300 (48%) nsSNPs were predicted-damaging (pnsSNP) by in silico and 89 pts (53%) had 1 pnsSNP (median 1; range 0-5). 28/28 RTKs had 3 mutations, with median 11 (range 3-23), and 26/28 contained 1 pnsSNP (median 5; range 0-14). RTKs in NSCLC with the most frequent nsSNPs were EPHA3 (14/23 variants were pnsSNP), EPHA5 (11/17), EPHB1 (10/11), RET (9/11), ERBB4 (8/12), ALK (7/16), NTRK3 (7/15), ROS1 (6/22) and FLT1 (6/15). 6/14 lesions in SC pts were pnsSNPs in ERBB3, ERBB4, FGFR1, FLT1, RET and ROS1. nsSNPs were found along RTKs', ' 57% were ECD (72/172 pnsSNP), 26% TKD (47/77), 10% CT (14/29), 6% JM (8/18) and 1% TM (2/4). 6/6 SC pnsSNPs were ECD. 67% BRAF+ and ROS1-rearranged, 59% EGFR+, 33% HER2+ and 0/1 MET exon 14 pts had 1 pnsSNP. Conclusions', ' Nearly 80% NSCLC and SC pts had 1 nsSNP in 28 RTKs, excluding EGFR, with 48% pnsSNPs by in silico analysis. As > 70% nsSNPs were extra-TKD lesions, further characterization is needed to identify kinase-effecting variants and their potential clinical significance.']",
        "Doc_id":"ASCO_185154-199",
        "Doc_title":" Distribution and pathogenicity of nsSNPs in receptor tyrosine kinases (RTKs) in non-small cell lung cancer (NSCLC) patients (pts).",
        "_version_":1606188975055175680},
      {
        "Meeting_name":" Signaling-associated complexes to define targetable vulnerabilities in lung cancer",
        "Background":"['Lung cancer is the leading cause of cancer related death in the U.S. Despite successes targeting tyrosine kinase drivers such as EGFR and EML4-ALK, identification of patients who will benefit from emerging targeted therapy regimens remains a challenge. This is exemplified by the disappointing results in the recent Phase III evaluation of ornatuzumab in combination with erlotinib in advanced non-small cell lung cancer (NCT01456324), targeting both MET and EGFR in biomarker-defined patient populations. We have previously shown that proximity ligation assay (PLA) technology can be harnessed to evaluate EGFR pathway activation by annotating the presence of EGFR in complex with its major signaling adaptor GRB2. Presence of these signaling-associated complexes correlates with EGFR activity, reveals erlotinib pharmacodynamics and associates with improved outcomes to EGFR-directed therapies. Here, we show that PLA technology can also be harnessed to assess MET signaling activity in lung cancer. We have found that MET is constitutively associated with GRB2 in MET-amplified lung cancer cell lines and this interaction is abrogated by the MET-specific tyrosine kinase inhibitor PHA665,752 (MET TKI) as measured by biochemical approaches and PLA. In parallel experiments, siRNA-mediated knockdown of GRB2 and 100nM MET TKI both lead to dramatic reductions in cell viability, indicating that this interaction is critical in MET-driven cells. Conversely, GRB2 knockdown has no effect in MET-amplified H1648 cells which are also completely resistant to MET TKI. In MET-amplified patient-derived xenograft models of lung cancer we observe MET', 'GRB2 complexes in regions that also stain strongly using pMET(Y1234/5) immunohistochemistry (IHC). However, only a subset of regions exhibiting strong staining for total MET by IHC had MET', 'GRB2 complexes or pMET. Surprisingly, we have observed a very low frequency (2%) of lung adenocarcinoma patients (N = 169) with MET', 'GRB2 signaling complexes, even among high MET-expressing tumors, defined by MET IHC. These data suggest that MET', 'GRB2 is critical in the amplified setting, but may be less important in stromal-induced MET signaling. Consistent with this, GRB2 knockdown in non-amplified A549 and H292 cells fails to impair HGF-induced increases in pAKT and pERK. We are currently conducting mass spectrometry experiments to decipher differences between MET complexes in the amplified vs. ligand-stimulating setting and updated results will be presented. We suggest that only a subset of high MET-expressing cells has evidence of MET in complex with GRB2, potentially explaining the relatively low response rates observed with MET-directed therapies in lung cancer. We believe our approach of combining biochemical, PLA and mass spectrometry-based techniques will also be applicable to the development of improved biomarker strategies for newly emerging targets such as FGFR1.']",
        "Doc_id":"AACR_2015-4999",
        "Doc_title":" Signaling-associated complexes to define targetable vulnerabilities in lung cancer",
        "_version_":1606189004709953536},
      {
        "Meeting_name":" Defining a FISH chromosomal aneusomy panel for predicting lung cancer in the setting of CT-detected lung nodules.",
        "Background":"['Background', ' Early detection of lung cancer by CT is supported by the National Lung Screening Trial; but while sensitivity of CT is high, specificity is low.  Biomarkers to predict the malignant nature of CT detected lung nodules would have great clinical utility. We previously found in a nested case-control study that a 4-target chromosomal aneusomy (CA) FISH panel exhibited sensitivity/specificity of 76%/88% in sputum samples of heavy smokers obtained within 18 months of lung cancer diagnosis. We hypothesized that CA-FISH may be an effective biomarker to assist with clinical decisions in the setting of CT detected lung nodules of indeterminate etiology and attempted to identify a more effective reagent.  Methods', '  Homebrew probes encompassing genomic sequences of EGFR, NXK2-1, PIK3CA, MYC, BRF2, SOX2, PPMID, FGFR1 and the commercial reagent LSI D5S721/D5S23 (Abbott Molecular) were combined in 2-4-target FISH assays to investigate tissue copy number in early stage lung squamous cell carcinoma (SCC, N=19) and adenocarcinoma (AC, N=20). Logistic regression models were used to estimate predictive discrimination [sensitivity, specificity, area under the ROC curve (AUC)].  Results', ' Copy number gain was largely detected for all markers (mean range 3.39 - PPMID to 4.67 - MYC). Mean copy number of PI3CA, BRF2, SOX2 and FGFR1 were significantly higher in SCC than AC, while NKX2 and MYC were marginally higher in AC than SCC. Gene amplification was detected for all 9 markers, most frequently for SOX2 and FGFR1 (6 and 5 cases) with significant overlap between FGFR1/BRF2 and SOX2/PIK3CA. Based on the AUC results and the existence of targeted inhibitors, the probe set EGFR/FGFR1/MYC/PIK3CA was selected as a candidate for further development as an adjunct to CT screening for early detection. For this selected set,the optimal cutoff based in the linear predictor from logistic regression yields a sensitivity and specificity of 0.85. Conclusions', ' A highly sensitive/specific CA-FISH probe set was identified which may well complement CT screening in the early diagnosis of lung cancer. This probe set will be tested in the setting of CT detected lung nodules. (Supported by LUNGevity and NCI-Lung Cancer SPORE grants).']",
        "Doc_id":"ASCO_95551-114",
        "Doc_title":" Defining a FISH chromosomal aneusomy panel for predicting lung cancer in the setting of CT-detected lung nodules.",
        "_version_":1606189026634629120},
      {
        "Meeting_name":" Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study",
        "Background":"['Background', ' Fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell non-small cell lung cancer (sqNSCLC) has been described as potential oncogenic and targetable driver in cell lines and murine models. However, a phase I study evaluating FGFR 1-3 inhibitor BGJ398 showed moderate response rate of 11% in FGFR1amplified sgNSCLC treated with dose  100mg. To identify underlying mechanisms of resistance, we analyzed tumor tissues of selected patients. Methods', ' Within the phase I BGJ398 study, patients (pts) with FGFR1amplified sqNSCLC were treated orally with escalating dose (5 to 150mg) of BGJ398 once daily (QD) or 50mg twice a day. In the expansion phase, pts received BGJ398 either continuously QD or on a 3-weeks on/1-week off schedule. CT scans for response were performed every 8 weeks. Available tumor tissue of pts treated with BGJ398 at our center was analyzed using hybrid capturebased massively parallel sequencing (CAGE). Results', ' Twenty-one pts with FGFR1 amplified sqNSCLC were treated with  100mg BGJ398 at our site. As best response, 3 pts showed partial response (PR), 7 pts stable disease (SD) and 7 pts progressive disease (PD). Two pts withdrew their consents and 2 pts died ahead of first CT scan', ' one due to infection and one due to sudden death. We performed CAGE covering 256 genes on 9 patients', ' on 3 pts with PR, 2 pts with SD, 2 pts with PD and 2 pts who died before first CT scan. All analyzed patients harbored mutations in TP53. Additionally, we detected two CDKN2A (one patient with PR and one patient who died before first CT) and three MLL2 stop codon and frame shift mutations (two patients with SD and one patient with PD). Of interest, we identified three patients with two canonical (one patient with SD and one patient who died before first CT) and one non-canonical mutations in PIK3CA(one patient with SD). Conclusions', ' In our analysis, MLL2 and PIK3CA mutations seem to have a negative impact on response in FGFR1 amplified pts treated with BGJ398. Further analysis with higher patient number is needed to identify the role of MLL2 and PIK3CA mutations in FGFR1 amplified sqNSCLC. Clinical trial information', ' NCT01004224']",
        "Doc_id":"ASCO_189173-199",
        "Doc_title":" Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study",
        "_version_":1606188991070076928},
      {
        "Meeting_name":" Clinical characteristics and natural history of patients with squamous cell lung carcinoma with FGFR1 amplification.",
        "Background":"['Background', '  FGFR1 amplifications have been described as a promising oncogenic target in squamous cell lung cancer. Here we aimed at describing the clinical characteristics and natural history of FGFR1amplified squamous cell lung cancer patients.  Methods', '    From 01/2011 to 01/2012 we screened 553 squamous cell lung cancer patients in our Network for Molecular Screening of Lung Cancer for the presence of FGFR1 amplifications by FISH analysis in accordance with the local ethics committee. FGFR1 was defined as amplified if the ratio of FGFR1 copies to centromeric copies was above 2 or if more than 50% of tumor cells showed 5 copies or if more than 15% of tumor cells demonstrated clusters of FGFR1. Clinical data were collected by extracting information from medical records, the local cancer registry and by questioning treating physicians and patients.   Results', '  FGFR1FISH analysis could be performed in 95% of the cases and was amplified in 16%. Of the amplified cases 75 % were male and 25% female without significant enrichment for male or female. The median age of the patients at diagnosis was 67 yrs (range 46 - 82). Stage at presentation was', ' 16% I; 17.3% II; 26.7% IIIa, 40% IIIb/IV. 97,3% of the patients were former or active smokers with a median of 40 pack years. The median progression free survival of patients with stage IIIb/IV disease was 11 months (95% CI 8-14; n=14). The median overall survival was not yet reached after a median follow-up time of 14 months (95% CI 11 - 17; n=24).  We further screened for co-existing genetic lesions such as mutations in EGFR, BRAF, KRAS, PIK3CA as well as translocations of ALK and amplifications of ERBB2. Two patients demonstrated co-occurring PIK3CA mutations and one a BRAFmutation.  Conclusions', '    Screening for FGFR1 is feasible under routine clinical conditions. By implementation of a regional molecular screening network the ability to screen for FGFR1 amplification was successfully expanded to non-academic centers and private practices. FGFR1 amplifications in squamous cell cancer of the lung are frequent (16%) and associated with smoking history. Screening for FGFR1 might pave the way for the application of new FGFR1 directed targeted drugs in squamous cell lung cancer.']",
        "Doc_id":"ASCO_96760-114",
        "Doc_title":" Clinical characteristics and natural history of patients with squamous cell lung carcinoma with FGFR1 amplification.",
        "_version_":1606188975557443584},
      {
        "Meeting_name":" Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung",
        "Background":"['Background', 'As the comprehensive genomic analysis of small cell lung cancer (SCLC) progresses, novel treatments for this disease need to be explored. With attention to the direct connection between the receptor tyrosine kinases (RTKs) of tumor cells and the pharmacological effects of specific inhibitors, we systematically assessed the RTK expressions of high-grade neuroendocrine carcinomas of the lung (HGNEC), including SCLC and large cell neuroendocrine carcinoma (LCNEC).Patients and Methods', 'Fifty-one LCNEC and 61 SCLC patients who underwent surgical resection were enrolled in this research. As a control group, 202 patients with adenocarcinomas (ADCs) and 122 patients with squamous cell carcinomas (SQCCs) were also analyzed. Using immunohistochemical staining (IHC), we stained all tumors with antibodies for 10 RTKs; c-Kit, EGFR, IGF1R, KDR, ERBB2, FGFR1, c-Met, ALK, RET and ROS1. We scored the expression of these RTKs for all enrolled tumors, and compared them according to the histological types.Results', 'The LCNEC and SCLC patients exhibited similar clinicopathological characteristics. The IHC scores for each RTK were almost equivalent between the LCNEC and SCLC groups, but they were significantly different from those of the ADC or SQCC groups. Especially, c-Kit was the only RTK that was remarkably expressed in both LCNECs and SCLCs. On the other hand, about 20% of the HGNEC tumors exhibited strongly positive RTK expression, and this rate was similar to those for the ADC and SQCC tumors. Intriguingly, strongly positive RTKs were almost mutually exclusive in individual tumors.Conclusions', 'Compared with ADC or SQCC, LCNEC and SCLC had similar expression profiles for the major RTKs. The exclusive c-Kit positivity observed among HGNECs suggested that c-Kit might be a distinctive RTK in HGNEC. These HGNECs which have strongly positive RTKs could be the targets of personalized therapies.']",
        "Doc_id":"AACR_2015-5004",
        "Doc_title":" Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung",
        "_version_":1606188999424081920},
      {
        "Meeting_name":" MAP-kinase pathway activation facilitates survival of persistent FGFR1-amplified lung cancer cells upon FGFR inhibition",
        "Background":"['One recurrent alteration of squamous cell lung cancer is the amplified region of the 8p12-p11 locus. The tyrosine kinase fibroblast growth factor receptor 1 (FGFR1) seems to be one of the most prominent targets of this amplification. Thus, small molecules inhibiting FGFRs have been employed to treat FGFR1-amplified squamous cell lung cancer. However, only about 16% of such FGFR1-amplified tumors respond to single agent inhibitor therapy. Several tumors exhibited insufficient tumor shrinkage, compatible with the existence of persistence of inhibitor-resistant tumor cells in the tumor. To investigate the mechanism of FGFR-inhibitor persistence we studied the lung cancer cell lines DMS114 and H1581. Both cell lines demonstrate GI50 values in the nanomolar range upon three different FGFR-inhibitors. However, both cell lines exhibit sustained cell viability within 0.5 to 5 M inhibitor treatment, indicating a subpopulation of persistent cells. We therefore isolated these persistent cells by treating with a high dose of FGFR inhibitors. After 8 to 12 weeks the cells were completely resistant against all FGFR inhibitors tested. Genetic identity with the original cell line was confirmed by fingerprinting. We found that while parental cell lines showed depleted pERK signals, persistent cells were marked by a constant pERK level upon treatment. In H1581 cells, reactivation of the mitogen-activated protein kinase (MAPK) pathway was demonstrated by an active RAS-pulldown assay. Whole exome sequencing (WES) revealed high and focal NRAS amplification and DUSP6 depletion, leading to MAPK-pathway reactivation. Furthermore, retroviral overexpression of wild type RAS-isoforms induced FGFR-inhibitor resistance in parental H1581 cells. In DMS114 we observed MET and IGF-1R activation as possible mechanisms of persistence. Furthermore, co-inhibition of FGFR and MEK was a highly effective combination therapy to treat FGFR-inhibitor persistent cells. This study associates the MAPK-pathway as a key pathway for FGFR-dependent cell lines. Furthermore, these results suggest a beneficial FGFR / MEK combination treatment to avoid the outgrowth of FGFR-inhibitor persistent cells.']",
        "Doc_id":"AACR_2016-2954",
        "Doc_title":" MAP-kinase pathway activation facilitates survival of persistent FGFR1-amplified lung cancer cells upon FGFR inhibition",
        "_version_":1606189002359046145},
      {
        "Meeting_name":" Concordance between formalin-fixed paraffin-embedded biopsy samples and surgically resected snap-frozen samples in multiplexed molecular profiling of lung cancers.",
        "Background":"['Background', '  The results of comprehensive genome-wide characterization of lung cancer have recently been reported. However, the concordance of driver mutations between formalin-fixed paraffin-embedded (FFPE) and surgically resected snap-frozen samples is unclear. We conducted the Shizuoka Lung Cancer Mutation Study to analyze driver mutations in patients with lung cancer.  Methods', '  Based on the biobanking system in conjunction with the clinic including the pathology lab, we developed a multiplexed mutational panel designed to assess 23 mutations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications, and EML4-ALK translocations, using pyrosequencing plus capillary electrophoresis, qRT-PCR, and RT-PCR, respectively.DNA concentration in FFPE samples was analyzed by measuring absorbance at 260 nm (A260) in a spectrophotometer.  Results', '  Between July 2011 and July 2012, sixty-five lung cancer patients with both FFPE and snap-frozen samples were included in this study. Patient characteristics were as follows', ' median age (range) 70 (38-92) years; female 68%; never-smoker 34%; histology adenocarcinoma/squamous cell carcinoma/small cell carcinoma/other 52/29/6/13 %. FFPE samples included 64 transbronchial biopsies and one pleural biopsy. We detected driver mutations in 58% of all cases. Mutations found', ' EGFR 28%, KRAS 12%, PIK3CA 6%, NRAS 2%, HER2 5%, EGFR amplification 5%, PIK3CA amplification 12%, FGFR1amplification 2%. Complete concordance of driver mutations between FFPE and snap-frozen samples was shown in 65%. Median DNA concentration in FFPE samples was 72.7 ng/ul (range; 2.4 - 472.4 ng/ul). Exploratory analyses using an ROC curve, done to evaluate the useful cutoff of DNA concentration in FFPE samples, showed low AUC (AUC; 0.5326).  Conclusions', '  These results suggest that the rate of complete concordance of driver mutations between FFPE and snap-frozen samples might be acceptable, and DNA concentration in FFPE samples might not be correlated with concordance.']",
        "Doc_id":"ASCO_116307-132",
        "Doc_title":" Concordance between formalin-fixed paraffin-embedded biopsy samples and surgically resected snap-frozen samples in multiplexed molecular profiling of lung cancers.",
        "_version_":1606189018811203584},
      {
        "Meeting_name":" Next-generation sequencing in metastatic lung cancer patients",
        "Background":"['Background', '  Several patients with lung cancer (LC) maintain good performance status even after disease progression following all standard therapies. More recently, targeted therapies have been improving prognosis of patients with advanced LC. We aim at exploring the role of a next-generation sequencing (NGS) assay in identifying therapeutic targets for refractory LC. Methods', '  Patients diagnosed with metastatic LC with available paraffin-embedded tissue evaluated by the method of NGS (Foundation Medicine, USA) were included. Hybridization capture of 3,769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to  50 ng of DNA extracted from 12 LC specimens and sequenced to high, uniform coverage. Genomic alterations (GA) were reported for each patient sample. Actionable GA were defined as those identifying anti-cancer targeted therapies available on the market or in registered clinical trials.  Results', '    Twenty-nine patients were included (86.2% adenocarcinoma, 6.9% squamous cell carcinoma). Median age was 59 years (range 30-80); 65.5% were male and 55.2% were smokers or previously smokers. A total of 40 GA were identified', ' 29 patients (72.4%) harbored    1 GA, and 16 patients harbored    1 actionable GA (55.2%). The most frequent actionable GA were detected in EGFR (24.1%), AKT2 (10.3%), STK11 (10.3%), MET (6.8%), HER2 (3.4%), ROS1 (3.4%), and FGFR1 (3.4%). Non-actionable GA were mostly detected in TP53 (48.3%), MCL1 (17.2%), and CDKN2A (13.8%). The use of trastuzumab in a patient with mutated HER-2 yielded a time to progression (TTP) of 8 months. Five patients previously identified as wild-type EGFR were found to actually have EGFR mutation, with a median TTP of 11 months (1-16m) with tyrosine kinase inhibitors. Conclusions', '  Comprehensive NGS may identify novel mutations in LC patients with potential clinical utility and serve as genetic biomarkers for personalized therapeutics.']",
        "Doc_id":"ASCO_152355-156",
        "Doc_title":" Next-generation sequencing in metastatic lung cancer patients",
        "_version_":1606188975860482048},
      {
        "Meeting_name":" Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network.",
        "Background":"['Background', ' PIK3CA mutations are a rare oncogenic event of potential therapeutic relevance in NSCLC. Here we report frequency and characteristics of patients with PIK3CA mutated lung tumors. Methods', ' Patients with NSCLC and PIK3CA mutations were identified within our regional Network for Molecular Screening in Lung Cancer. We further analyzed the presence of BRAF, KRAS, EGFR mutations as well as ALK translocation, ERBB2 and FGFR1 amplifications in PIK3CA mutated samples. Clinical data on age, sex, TNM classification and tumor stage, histological type, grading, overall survival, smoking status, comorbidity, BMI and secondary malignancies were retrieved from clinical charts in accordance with the local ethics committee. Results', ' PIK3CA mutations were detected with a frequency of 3.7% (24% exon 20,76% exon 9) in 1000 patients. Histologically 32% were defined as squamous cell carcinoma, 48% as adenocarcinoma and 18% other histological subtypes or NSCLC-NOS. Exon 9 mutations were present in the acinar and lepidic subtype, whereas exon 20 mutations were seen in the papillary and solid subtype. Cooccuring genetic lesions were observed in 16%  (mutations in KRAS=2, EGFR=1, BRAF=1; FGFR1 amplification=2). 14 were female, 23 male with a mean age of 69 years.  21 of these patients were further clinically annotated. 11 patients presented with stage IIIb/IV eligible for palliative treatment and 10 stage I  IIIa eligible for surgical therapy +/- adjuvant therapy. All but 1 patient were smokers with an average BMI of  26,2kg/m2 with a typical high load of comorbidity mainly of cardiovascular diseases, 8 of 21 patients showed prior malignancies in their medical history. The median overall survival within this population has not been reached yet. Conclusions', ' Screening for PIK3CA mutations is feasible. A high proportion (38%) of patients with PIK3CA mutated lung cancer have prior malignancies and show a high load of comorbidity. Furthermore PIK3CA mutations are not exclusive to KRAS, EGFR or BRAF mutations or FGFR1 amplifications. Successful identification of patients with oncogenic lesions in lung cancer in a screening network might allow future personalized treatment of these patients.']",
        "Doc_id":"ASCO_96154-114",
        "Doc_title":" Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network.",
        "_version_":1606189037508362240},
      {
        "Meeting_name":" Multiplex testing for driver mutations in squamous cell carcinomas of the lung.",
        "Background":"['Background', '    While the majority of lung adenocarcinomas (ADCL) harbor an identifiable driver mutation, targeted therapies for squamous cell lung carcinomas (SQCLC) have lagged in development due to a paucity of druggable oncogenic events.  Three targets, which together occur in up to 50% of SQCLC, have been recently identified (FGFR1 amplification, DDR2 mutations, PIK3CA mutations/PTEN loss).  Comprehensive molecular analysis of SQCLC tumors by The Cancer Genome Atlas is ongoing, with new therapeutic targets on the horizon.  Methods', '    We have instituted prospective, multiplex testing of SQCLC tumors (Squamous Cell Lung Cancer Mutation Analysis Program, SQ-MAP).  Tests include FISH for FGFR1 amplification (defined as FGFR1', 'CEP8  2 in >10% of cells), IHC for loss of PTEN expression, and Sequenom MassARRAY for PIK3CA mutations (and others, below).  We are also incorporating targeted exon sequencing (Agilent SureSelect/Ion Torrent) of a panel of over 80 lung cancer oncogenes and tumor suppressors in preparation for future studies.  All tests were performed on formalin-fixed paraffin-embedded samples and with Institutional Review Board/Biospecimen Utilization Committee approval.   Results', '    40 SQCLC patient specimens have been processed through SQ-MAP over 3 months.  8 samples were excluded (insufficient tissue in 4, reclassification to ADCL in 4).  Data are available for 28 patients.  PTEN IHC was performed on 15 samples to date.  Molecular results are summarized in the table.   Events were non-overlapping.  Results for the 80 gene sequencing component will be described.  Based on SQ-MAP, accrual to 2 approved clinical trials (FGFR1 inhibition; PI3K inhibition) has begun, with a third planned (DDR2 mutations).   Conclusions', '    Actionable defects were detected in 60% (95% CI', ' 37-75%) of SQCLC specimens.  Mutation data for 80 other oncogenes and tumor suppressors will be available shortly (including DDR2).  SQ-MAP serves as a platform supporting both personalized care and research.']",
        "Doc_id":"ASCO_99985-114",
        "Doc_title":" Multiplex testing for driver mutations in squamous cell carcinomas of the lung.",
        "_version_":1606189022327078912},
      {
        "Meeting_name":" MerTK promotes resistance to irreversible EGFR TKIs by activation of the PI3K-AKT pathway in NSCLCs expressing wild-type EGFR.",
        "Background":"['Lung cancer is the leading cause of cancer-related death with poor survival rates worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and 60% of these have overexpression of wild-type EGFR (wtEGFR), which portends a poor prognosis. In addition, in a recent clinical trial 6 of 12 lung cancer patients whose tumors acquired a resistance-conferring T790M EGFR mutation during treatment with an EGFR TKI reverted to wtEGFR after treatment with Rociletinib/CO-1686, an irreversible EGFR TKI that is selective for the T790M mutant. These data suggest that targeting wtEGFR may improve treatment outcomes; however, to date single agents that target wtEGFR have not been effective in large scale clinical trials and new ways to target wtEGFR in this context are needed. Our laboratory previously identified the MerTK receptor tyrosine kinase as a potential therapeutic target in NSCLC and developed MRX-2843 as a novel MerTK-selective small molecule tyrosine kinase inhibitor with favorable properties for clinical translation. Irrespective of driver oncogene status, treatment with a MerTK inhibitor yields potent anti-tumor effects in NSCLC cell culture models and blocks tumor growth in xenografts of the MerTK-dependent wtEGFR-expressing A549 cell line. In an attempt to more potently block A549 lung cancer cell proliferation, we screened a library of 378 kinase inhibitors that are in various stages of development and identified synergy between MRX-2843 and multiple irreversible EGFR TKIs, including CO-1686 and Osimertinib/AZD-9291. Further, we found that wtEGFR and MerTK were frequently co-expressed and co-immunoprecipitated with each other in NSCLC cancer cell lysates. Synergistic inhibition of cell expansion was observed in a spectrum of NSCLC cell lines with wtEGFR expression treated with the combination therapy, including H1299 (NRAS mutation), H157 (KRAS mutation), H3122 (ALK fusion), and Colo699 (FGFR1 overexpression). On a mechanistic level, combined treatment with 1M CO-1686 and 100 nM MRX-2843 dramatically inhibited phosphorylation of both MerTK and EGFR and downstream signaling through the PI3K-AKT and MAPK-ERK pathways, while treatment with equivalent doses of either single agent did not efficiently inhibit MerTK, EGFR or downstream signaling. Additionally, CO-1686 mediated synergistic inhibition of A549 expansion in combination with a PI3K or AKT inhibitor, suggesting a role for PI3K-AKT activation downstream of MerTK contributing to the resistance of wtEGFR NSCLCs to irreversible EGFR TKIs. Taken together, our data provide rationale for a novel strategy for treatment of NSCLC with wtEGFR overexpression by combining MRX-2843 and an irreversible EGFR inhibitor.']",
        "Doc_id":"AACR_2017-1082",
        "Doc_title":" MerTK promotes resistance to irreversible EGFR TKIs by activation of the PI3K-AKT pathway in NSCLCs expressing wild-type EGFR.",
        "_version_":1606188990484971520},
      {
        "Meeting_name":" High-throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathologic routine diagnostics for a regional health care provider network.",
        "Background":"['Background', '  Treatment paradigms for nonsmall-cell lung cancer have shifted from histology based towards incorporation of molecular subtypes involving particular genetic alterations such as mutations in EGFR or translocations of ALK. The list of  targetable lesions is rapidly increasing including mutations in genes such as EGFR, HER2, KRAS, ALK, BRAF, PIK3CA, AKT1, ROS1, NRAS, FGFR1 and MAP2K1. Analysis of these potential targets is becoming a challenge in terms of work load, tissue availability as well as cost.  Within the Network Genomic Medicine Lung Cancer (NGM), a regional molecular screening network of the Center for Integrated Oncology Kln Bonn, we aimed to improve the sequential analysis of a set of 9 target amplicons by Sanger sequencing using bench top ultra-deep parallel sequencing platforms. We aimed to reduce 1) the time requirement for comprehensive molecular diagnostics, 2) the minimal amount of formalin fixed paraffin embedded (FFPE) derived input DNA, 3) while at the same time increasing the number of target regions analysed.  Methods', '   We established a multiplex PCR to amplify up to 640 lung cancer relevant target regions from at least 20ng of FFPE derived tumor DNA. The amplicon libraries were ligated to adapters encompassing medical identifier sequences that allowed multiplexing of up to 48 patients. The resulting libraries were sequenced on a benchtop Illumina platform (MiSeq). Mutations identified by parallel sequencing were confirmed by Sanger sequencing.  Results', '  330 patients were analyzed by traditional Sanger sequencing of 9 amplicons and the newly established parallel sequencing protocol. The time needed to complete the mutation screening was significantly reduced to 7 working days from previously 21 days. A total of at least 300ng of DNA was needed to complete the analysis of 9 amplicons by Sanger sequencing compared to 20 to 100ng of DNA needed for up to 640 amplicons analyzed by parallel sequencing.  Conclusions', '  Newly multiplex PCR based parallel sequencing allows rapid comprehensive mutation testing in routine molecular pathological diagnostics even on small transbronchial biopsies.']",
        "Doc_id":"ASCO_115519-132",
        "Doc_title":" High-throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathologic routine diagnostics for a regional health care provider network.",
        "_version_":1606189023664013312},
      {
        "Meeting_name":" FGFR1 amplification as a druggable target in lung squamous cell carcinoma.",
        "Background":"['Background', ' Focal gene amplification is a potential target for diagnosis and therapy in cancer. Fibroblast growth factor receptor-type 1 (FGFR1) may play a role in the pathogenesis of lung squamous cell carcinoma (LSCC) and amplification of the FGFR1 gene is considered a candidate target for treatment of LSCC. The aim of this study was to simultaneously explore copy number changes of FGFR1 and 23 other genes by multiplex ligation-dependent probe amplification (MLPA), to compare the results with fluorescent in situ hybridization (FISH) data, and determine the clinicopathological significance of gene amplification.Methods', ' This study included 81 resected LSCC specimens obtained between 2008 and 2010, and 14 lung cancer cell lines. MLPA was performed using fresh tumor samples and cell lines and FISH was applied to formalin-fixed, paraffin-embedded tissues.Results', ' MLPA showed amplification/gain of MYC (48.1% of LSCCs), AURKA (44.4%), MET (29.6%), KIT (21.0%), and FGFR1 (14.8%). FISH showed FGFR1 amplification in 22 LSCCs (27.2%) using a cut-off value of 5. There was high concordance between FISH and MLPA (85.2%). No association between FGFR1 amplification and any clinicopathological variables was observed; however, associations were identified between EGFR and FGFR1 FISH-amplified tumors; PDGFRA and poor differentiation; KDR, ABL1, and MET and age; and SMO and CCND2 and pT stages.Conclusions', ' Our MLPA and FISH data showed that FGFR1 amplification is a common event, occurring in 15-27.2% of LSCCs. Other amplified genes may be also candidate targets for the treatment of LSCC.']",
        "Doc_id":"AACR_2013-1913",
        "Doc_title":" FGFR1 amplification as a druggable target in lung squamous cell carcinoma.",
        "_version_":1606189034427645952},
      {
        "Meeting_name":" Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.",
        "Background":"['Background', '    Personalized treatment of genetically stratified subgroups has the potential to substantially improve outcome in NSCLC. A major challenge now is to implement high-quality molecular diagnostics and personalized treatment strategies in routine clinical practice also outside of highly specialized academic centers.   Methods', '    We have established a molecular screening network in the catchment area of our comprehensive cancer center encompassing about 2.5 million inhabitants in March 2010 after review of the local ethics committee (10-242). Lung adenocarcinoma (AD) was screened centrally for ALK translocations, mutations in KRAS, EGFR, BRAF and PIK3CA and for amplification of ERBB2. Squamous cell carcinoma (SQ) was analyzed for FGFR1 amplifications.   Results', '    2032 NSCLC samples were acquired of which 1782 in the Cologne-Bonn area indicating a capture rate of 60-70% of all NSCLC samples in the area. Material was suitable for molecular analysis in 77%. Distribution of histological subtypes was as expected (AD 63.4%, SQ 26.7, large cell carcinoma 1.4%, adenosquamous cell carcinoma 1.8%, carcinoid 0.1%, NSCLC NOS 6.7%. In AD the following frequencies of genetic lesions were detected', ' KRAS (32%), EGFR (13%), ALK (3%), BRAF (2%), PIK3CA (2%), ERBB2 (2%). EGFR mutations were highly enriched in the lepidic and micropapillary subtype of AD (30-32%), whereas the solid subtype only harboured a very small amount of the tested oncogenic lesions. In SQ FGFR1 amplification was detected in 78/500. Overall 40% of all NSCLC samples harboured potentially tractable oncogenic lesions. All patients with ALK translocations received crizotinib when clinically indicated. 75% of the stage IIIB/IV patients with activating EGFR mutations received EGFR-TKI treatment. In addition, clinical trials have been initiated to provide personalized treatment options to all patients with tractable genetic lesions.   Conclusions', '    High-quality molecular diagnostics and identification of patients for personalized treatment approaches is feasible in daily clinical routine for the majority of diagnostic samples also in a non-academic setting.']",
        "Doc_id":"ASCO_96219-114",
        "Doc_title":" Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.",
        "_version_":1606189040627875840},
      {
        "Meeting_name":" FGFR2 gene amplification and overexpression frequently occur in squamous cell carcinomas of the lung",
        "Background":"['Introduction', ' To date, only a few genetic abnormalities have been reported to be involved in tumorigenesis of squamous cell carcinomas (SqCCs) of the lung. Recently, fibroblast growth factor receptor (FGFR) 1 gene amplification was identified as a potential target for treatment in approximately 20% of SqCCs. In order to identify the clinical significance of FGFR family (FGFR1, FGFR2, FGFR3, and FGFR4) in SqCC, we performed a clinical study on the FGFR family in patients with non-small cell lung cancers (NSCLCs). Methods', ' Consecutive 138 NSCLC patients were studied. Gene expressions of FGFR family were evaluated by quantitative real-time RT-PCR. Intratumoral protein expressions of FGFR1, FGFR2, and Ki-67 were evaluated by immunohistochemistry. Gene amplifications of FGFR1 and FGFR2 were investigated by FISH. In addition, mutations of EGFR (exon 19-22) and KRAS (exon 1) were also investigated using either PCR-SSCP or PCR-RFLP, confirmed by direct sequencing. Results', ' Among 138 NSCLCs, 91 tumors were adenocarcinoma, 37 tumors were SqCCs, and 10 tumors were other types. Regarding FGFR gene expressions in NSCLCs, The FGFR2 gene expression was significantly higher in NSCLCs with both wild-type EGFR and wild-type KRAS than in NSCLCs with either mutant EGFR or mutant KRAS (P = 0.0012). FGFR2 gene expression was significantly higher in SqCCs than in adenocarcinomas (P < 0.0001). Furthermore, the FGFR2 gene expression was the highest among the gene expressions of FGFR family in SqCC. In contrast, no significant difference was observed in FGFR1 gene expression in relation to tumor histology. Regarding FGFR protein expressions in NSCLCs, the intratumoral FGFR2 protein expression significantly correlated with the FGFR2 gene expression (P < 0.0001, r = 0.5492), and the intratumoral FGFR2 protein expression was also significantly higher in SqCCs than in adenocarcinomas (P = 0.0008). Furthermore, the FGFR2 protein expression significantly correlated with Ki-67 proliferation index (P < 0.0001, r = 0.4677). In FISH analysis, FGFR1 gene amplification was detected in 34.3% (12/35) of SqCCs, and FGFR2 gene amplification was detected in 22.9% (8/35) of SqCCs. Furthermore, the Ki-67 proliferation index was significantly higher in SqCCs with FGFR2 gene amplification than in SqCCs without FGFR2 gene amplification (P = 0.0069). Conclusions', ' FGFR2 gene amplification and overexpression frequently occur and correlate with the tumor proliferation in SqCCs of the lung. FGFR2 could be a potential molecular target for the treatment of SqCCs of the lung as well as FGFR1.']",
        "Doc_id":"AACR_2012-3662",
        "Doc_title":" FGFR2 gene amplification and overexpression frequently occur in squamous cell carcinomas of the lung",
        "_version_":1606189036837273600},
      {
        "Meeting_name":" Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.",
        "Background":"['Background', '  Enriching PhI trials with patients harboring alteration in the FGFR pathway is key to the successful development of FGFR pathway inhibitors. FGFR1 and 2 amplification (amp) are considered a driver event in many carcinomas.  Methods', '  ISO-accredited FGFR1 and 2 FISH assays were run in samples from candidates to enter a PhI clinical study. FGFR amp status was defined as a ratio gene/centromere 2.2. FGFRs status was correlated with available PTEN expression (IHC) and mutations data (AKT, KRAS, BRAF, PIK3CA, among others).  Results', '  From January 2012 we screened 272 samples for FGFR1 and 190 for FGFR2. Samples came from primary tumors in 196 cases (PT=71.8%), and 141 (PT=74.2%); and metastatic disease in 61 cases (MET=22.3%), and 41 (21.6%) for FGFR1 and FGFR2, respectively. Rest of cases was of unknown (UKN) origin. Overall, FGFR1 gene amp was observed in 11% and FGFR2 in 3% of cases with amplification rates similar between PT and MET. After subgrouping by tumor origin, FGFR1 ampl was most frequently observed in breast cancer (19%) followed by lung cancer (8%). FGFR2 was amplified in 5% of gastric and gynecological cancers, followed by breast cancer (2.5%).  No associations were observed with FGFR1 and 2 amplifications and PTEN loss. Mutation results were available in 141 and 122 samples with FGFR1 and 2 amp data, respectively. Only one point mutation in AKT and one in PIK3CA genes were observed in FGFR1 amplified samples, while none in FGFR2 amplified cases.  Conclusions', '  Incorporation of FGFRs gene amp status in a routine molecular prescreening is feasible and may provide clinicians with a tool to select patients to targeted therapies.']",
        "Doc_id":"ASCO_133725-144",
        "Doc_title":" Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.",
        "_version_":1606188991055396864},
      {
        "Meeting_name":" Co-amplification of FGF receptors and ligands in FGFR inhibitor-sensitive cell lines",
        "Background":"['The fibroblast growth factor receptors (FGFR) play a key role during development and in adult function. FGFRs belong to a family of receptor tyrosine kinases which are single-pass transmembrane receptors with extracellular ligand binding domains and an intracellular tyrosine kinase domain. Upon binding of the ligand the kinase domain activates intracellular signaling networks that coordinate cellular processes such as proliferation, growth, differentiation, migration and survival. Fibroblast growth factors (FGFs) are a family of 18 ligands which are able to bind and activate distinct FGFRs. Deregulated FGFR activity, through mutations or translocations, is often associated with oncogenic events. Overexpression of FGFR or FGF may lead to increased cell proliferation, growth, differentiation, migration or survival, thus making it an interesting target.In this study we optimized a TaqMan qRT-PCR-based approach to evaluate the copy number variation for several FGFRs (FGFR1, FGFR2, FGFR3 and FGFR4) and several FGF ligands (FGF1, FGF2, FGF3, FGF4, FGF10, FGF12, and FGF19) on a panel of 23 cell lines. The cell types covered a variety of diseases including bladder, breast, endometrial, gastric, kidney, liver, lymphoma, melanoma, sarcoma, small cell lung carcinoma and squamous cell carcinoma. These cell lines had been tested for sensitivity to the JNJ FGFR small molecule inhibitor JNJ42541707 which is a pan-FGFR inhibitor. We observed in the sensitive (IC50<100nm) and moderately sensitive (IC50 100 nM - 1000 nM) cell lines a co-amplification of FGF receptor and ligand. Two of the most sensitive cell lines to FGFR inhibitor treatments had the greatest amplification of FGFR2 with a copy number value greater than 100. This finding that co-amplification occurs in receptor and ligand offers a new potential biomarker for patients that may be sensitive to small molecule FGFR inhibitors.']",
        "Doc_id":"AACR_2015-4326",
        "Doc_title":" Co-amplification of FGF receptors and ligands in FGFR inhibitor-sensitive cell lines",
        "_version_":1606189018697957376},
      {
        "Meeting_name":" Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.",
        "Background":"['Background', '  FP1039/GSK3052230 (GSK230) is a soluble fusion protein that acts as a ligand trap by sequestering fibroblast growth factors (FGFs) involved in tumor growth. FGF ligand-dependent signaling plays an important role in cancer development and growth through autocrine production of FGFs from cancer cells, or paracrine production of FGFs from local stroma, or by tumor overexpression of FGF receptors (FGFRs) or amplification of FGFR genes. FGFR1 amplification has been identified in ~15-20% of squamous non-small cell lung cancers (NSCLC) and is associated with shorter disease-free and overall survival. Efficacy was observed with GSK230 + chemotherapy in FGFR1 amplified in NSCLC xenograft models and in xenograft models of malignant pleural mesothelioma (MPM) where FGF2 mRNA levels were overexpressed. In a phase I study, no maximum tolerated dose (MTD) was identified and 20 mg/kg weekly was the maximum feasible dose (MFD) achieving the desired target concentration. Toxicities associated with small-molecule FGFR inhibition, namely hyperphosphatemia and retinal, nail, and skin changes, were not observed.  Methods', '  This is a multi-arm, nonrandomized, open-label phase IB study designed to evaluate the safety and preliminary efficacy of GSK230 in combination with paclitaxel + carboplatin in previously untreated FGFR1 amplified metastatic squamous NSCLC (Arm A), in combination with docetaxel in FGFR1 amplified metastatic squamous NSCLC that has progressed after 1 line of chemotherapy (Arm B), or in combination with pemetrexed + cisplatin in patients with untreated and unresectable MPM (Arm C). Approximately 70 patients will be enrolled. Each arm involves a dose escalation phase utilizing the 3+3 design, followed by a cohort expansion phase of at least 12 patients treated at either MTD or MFD. GSK230 will be administered as a 30-minute intravenous infusion once a week in a 21-day cycle. The starting dose is 5 mg/kg and will be dose escalated until MTD or MFD in combination with chemotherapy is reached. Endpoints include the combination dose of GSK230 with chemotherapy, safety, response rates and their duration, and translational objectives (NCT01868022). Clinical trial information', ' NCT01868022.']",
        "Doc_id":"ASCO_132016-144",
        "Doc_title":" Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.",
        "_version_":1606189003020697600},
      {
        "Meeting_name":" Development of a nationwide genomic screening network for squamous cell lung cancer in Japan (LC-SCRUM-Japan).",
        "Background":"['Background', ' Potentially targetable genes have been identified in squamous cell lung cancer (SqLC), but effective molecular-targeted therapies against SqLC have not yet been established. To select appropriate patients for clinical trials of targeted therapies, we have analyzed advanced SqLCs for genetic alterations in our nationwide genomic screening system (LC-SCRUM-Japan). Methods', ' LC-SCRUM-Japan was established in February 2013, and a genomic screening of advanced SqLCs has been operated since March 2015. As of December 2015, 155 institutions across Japan were participating and 105 SqLCs patients had been enrolled in this study. Submitted tumor samples were analyzed for genetic alterations using a next-generation sequencing system, Oncomin Comprehensive Assay, enabling the simultaneous analysis of 143 cancer-related genes. Results', ' The median age of the 105 patients was 69 years (range, 27-84 years). Eighty-eight (84%) were male and most patients (95%) were smokers. Among 88 available samples, potentially targetable gene alterations were detected in 47 (53%), including 21 (24%) with PIK3CA alterations, 2 (2%) with AKT1 mutations and 2 (2%) with PTEN mutations as candidate targets for clinical trials of PI3K or AKT inhibitors. There were also 9 patients (10%) with FGFR1 copy number gains and 1 case (1%) with a FGFR3 fusion as candidates for clinical trials of FGFR inhibitors. Other genetic alterations were mutations of NFE2L2 (16 cases, 18%) and KRAS (12, 14%), and copy number gains of SOX2 (14, 16%), DCUN1D1 (13, 15%), MYC (6, 7%) and EGFR (3, 3%). An ALK fusion was also detected in 1 case (1%). Conclusions', ' A series of potentially targetable gene alterations were detected in Japanese advanced SqLC patients, indicating that our nationwide screening project is able to contribute to the development of novel effective targeted therapies against advanced SqLC. This project is now ongoing with a total of 600 SqLC patients for inclusion. We will present updated data in the 2016 ASCO Annual Meeting.']",
        "Doc_id":"ASCO_164744-176",
        "Doc_title":" Development of a nationwide genomic screening network for squamous cell lung cancer in Japan (LC-SCRUM-Japan).",
        "_version_":1606188991008210944},
      {
        "Meeting_name":" Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications.",
        "Background":"['Background', '    Amplification of cMET has been described as mechanism underlying resistance to EGFR-targeted therapy in EGFR-mutated NSCLC. Nevertheless, few is known about cMET amplification beside the EGFR-resistance setting. This study was performed in order to characterize patients with low-level, intermediate-level and high-level cMET amplification focusing on frequency, co-occuring driver mutations and clinical outcome.  Methods', '    Within a regional molecular screening network cMET amplification status was analyzed by fluorescence in-situ hybridization (FISH) in 588 patients with NSCLC regardless of histology. Next-generation parallel sequencing (NGS) using 102 amplicons and 14 genes was performed in all analyzed samples. Clinical parameters (age, sex, UICC tumor stage, smoking status and medical and therapeutical history) of all patients were assessed.  Results', '    171 patients (29.1%) with cMET amplification were identified, whereof 17 (9.9%) had high-level amplification. cMET amplifications co-occured in 98 patients (57.3%) with a large spectrum of other driver mutations (EGFR, KRAS, HER2, STK11, NRAS, BRAF) or amplifications (FGFR1) in both adenocarcinoma (60.2%) and squamous cell carcinoma (21.1%). 9 patients of the high-level-amplified patients did not have an additional driver mutation, while the remaining 8 patients had mutations within EGFR, KRAS, PIK3CA, BRAF and STK11. cMET amplification was associated with a history of smoking and detected in all UICC tumor stages.  Conclusions', '    Our data suggest a high prevalence of cMET amplification in NSCLC patients with many oncogenic driver mutations. Most patients with an additional mutations had KRAS mutations. These data show that screening for MET-amplified patients in order to identify patients for  MET-targeted treatment should not be performed on the basis of sequencing results.']",
        "Doc_id":"ASCO_149488-156",
        "Doc_title":" Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications.",
        "_version_":1606189021305765889},
      {
        "Meeting_name":" FGFR1 and SOX2 amplification in squamous cell carcinoma (SCC) of the lung.",
        "Background":"['SRY-related HMG-box (SOX2) gene is a key transcription factor that coordinates development, differentiation and self-renewal of normal non-alveolar epithelium of the airway. SOX2 amplification has been reported in lung squamous cell carcinoma (SCC). Fibroblast growth factor receptor 1 (FGFR1) is a receptor tyrosine kinase that, upon activation, promotes cell proliferation, survival and apoptotic resistance through PLC/PKC, RAS/MAPK and PI3K-AKT pathways, respectively. FGFR1 is also amplified in 15-25% of lung SCC and pre-clinical data with targeted inhibitors showed a growth dependency on FGFR1 amplification either in vitro and in vivo. A clinical trial with BIBF1120 (which also inhibits FGFR1), will be developed in the Netherlands and Spain in second line SCC of the lung with FGFR1 amplified by FISH. Genetic heterogeneity in solid tumors is a major research area and therefore its assessment in SCC of the lung is of great relevance.We have examined FGFR1 and SOX2 gene copy number (GCN) in 76 lung SCC by multiplex ligation-dependent probe amplification (MLPA). Analysis of mutations in DDR2, PIK3CA, BRAF, EGFR, KRAS, and TP53 is ongoing.Genomic DNA (gDNA) was isolated from enriched tumor cells by laser captured microdisection from formalin-fixed paraffin embedded (FFPE) tumor tissue sections. 50-100 ng of gDNA was analyzed in each of the three independent replicates per tumor sample. Two independent probe sets were used for each gene analyzed. For inter-patient GCN value comparisons, the tumor results from each patient was normalized against the GCN values derived from FFPE peripheral blood leukocytes control. We also used MLPA technique to study intra-tumor heterogeneity (TH) by analyzing FGFR1 and SOX2 in different tumor areas. In particular, in 4 cases FGFR1 and SOX2 were co-amplified. Also, TH was examined in serial tumor biopsies and/or resections obtained at different points of disease progression in two patients.Of the 76 patients evaluable for FGFR1 and SOX2 GCN, FGFR1 high amplification was detected in 13/76 (17.10%) and low amplification in 7/76 (9.21%). SOX2 presented high amplification in 38/63 (60.32%) and low amplification in 9/63 (14.28%). Interestingly, 46.15% of the FGFR1-amplified tumors were also co-amplified for SOX2. An important degree of TH was found in 2 of the 4 tumors analyzed. GCN changes in FGFR1, SOX2, PIK3CA, PDGFRa, KDR, EGFR and MET over 10 years follow-up will be presented for one surgically resected SCC lung cancer patient. Frequencies of FGFR1 and SOX2 gene amplifications detected are in agreement with previously published data. Survival according to FGFR1 and SOX2 status will also be presented. FGFR1 and SOX2 co-amplification, together with the TH, warrants further research and could represent a novel therapeutic target.']",
        "Doc_id":"AACR_2013-53",
        "Doc_title":" FGFR1 and SOX2 amplification in squamous cell carcinoma (SCC) of the lung.",
        "_version_":1606189035944935424},
      {
        "Meeting_name":" Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC).",
        "Background":"['Background', '  D is an ATP competitive pan-aurora kinases inhibitor with activity also against FGFRs, VEGFR, Ret, TrkA, Scr, and Abl.  Methods', '  Eligible pts had NSCLC progressing for advanced/metastatic disease after 1 prior chemotherapy line (CT). Primary endpoint was progression-free survival at 4 months (PFS-4) evaluated in a Simon two-stage design. Number of successes required for not rejecting the alternative hypothesis (40% PFS-4) was 4/19 evaluable pts while the number of successes required to reject at the end of stage 2 the null hypothesis (20% PFS-4) was 11/36 ( 1-sided = 0.1). D was administered at 500 mg/m as 24 hr IV infusion q2w. The expression of Aurora A/B, TPX-2, MDR, Scr, Survivin by IHC and the amplification of FGFR1 by FISH on tumor biopsies of consenting pts were evaluated.  Results', '  3 out of 19 evaluable pts were PFS-4 at the end of the 1st stage, thus precluding passage to the 2nd stage. Interestingly, in pts with squamous (SCC) (n=7), median PFS and OS were 6.4 and 10.6 mos respectively (vs. 2.2 and 7.6 mos, in non-SCC pts), suggesting a possible specific effect in this subtype. Additional pts with SCC were therefore treated under a protocol amendment. At the end of this 2nd stage, 5/31 evaluable SCC pts (80% CI', ' 0.08-0.28) were PFS-4 indicating that the predefined threshold required to conclude for activity would not have been reached. Overall 56 pts, all histology NSCLC, were treated', ' median age 62 yrs (39-79), 64% male, 70% SCC, 36% with >1 prior CT. Best response was a PR in 1 pt and SD in 20 pts; median PFS and OS were 2.1 and 8.3 mos respectively. The most frequent drug-related AEs (any Grade, 20%) were', '  uncomplicated and short lasting neutropenia (94%), nausea (39%), fatigue (37%), asthenia (30%), anorexia and diarrhea (29%), alopecia (23%). Histological analyses by IHC and FISH is still ongoing', ' results will be presented. Conclusions', '  Limited evidence of activity was observed, insufficient to meet the predefined threshold to call efficacy in NSCLC when D was administered as monotherapy at this dose/schedule. D confirmed to have a manageable safety profile. Clinical trial information', ' 2006-003772-35.']",
        "Doc_id":"ASCO_114379-132",
        "Doc_title":" Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC).",
        "_version_":1606189036243779585},
      {
        "Meeting_name":" Prognostic impact of FGFR1 amplification in patients with early-stage resected squamous cell carcinomas of the lung (SQCLC).",
        "Background":"['Background', '    The spectrum and frequency of oncogenes in squamous cell lung cancers (SQCLCs) has recently been defined. Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in ~20% of SQCLCs; clinical trials of FGFR1 inhibitors for advanced SQCLCs are ongoing. The frequency, clinicopathologic features, and prognosis of FGFR1 amplification in early-stage, resected SQCLCs have been reported but with discrepant results (Kim et al, J Clin Oncol 2012, Heist et al, J Thorac Oncol 2012).  Methods', '    A cohort of histopathologically-defined and clinically-annotated resected SQCLCs was tested for FGFR1 amplification by FISH (Zytovision Dual Color Probe). Amplification was defined by FGFR1 copy number  2.2x CEP8 control copy number and was assessed by two evaluators (MW, LW) who were blinded to clinical results. Disease-free survival (DFS) was defined as date of resection until relapse, recurrence, or death, whichever occurred first. We assessed association between FGFR1status and clinical features (Fishers exact test) and DFS (long-rank test). Multivariate DFS analysis was performed using Cox regression analysis.  Results', '    63 resected SQCLCs were evaluated. FGFR1 amplification was detected in 16 (24%). The median age of the cohort was 70 years (range 48-88). 15 (24%) currently smoked, 47 (75%) former, 1 (1%) never. 7 (11%) received neo-adjuvant therapy. 35 (56%) were stage I, 15 (24%) were stage II, and 13 (20%) were stage IIIA. There was no association between FGFR1 amplification and age (p>0.99), sex (p>0.99), smoking status (p=0.32), or stage of disease (p=0.18). 1-year and median DFS in FGFR1-amplified vs non-amplified cases were 86% vs 71% (p=0.022) and not reached vs 2.3 yrs (95% CI 1.1-3.4 yrs), respectively. Multivariate analysis (FGFR1 status, sex, and stage) found FGFR1amplification significantly associated with improved DFS (HR 3.2, 95% CI 1.1-9.4).     Conclusions', '    In this cohort of resected SQCLCs FGFR1 amplification was associated with improved outcomes. There was no association between FGFR1 status and sex, age, smoking status, or stage. FGFR1 amplification is common in SQCLCs.']",
        "Doc_id":"ASCO_115698-132",
        "Doc_title":" Prognostic impact of FGFR1 amplification in patients with early-stage resected squamous cell carcinomas of the lung (SQCLC).",
        "_version_":1606189012340441089},
      {
        "Meeting_name":" Molecular profiling in African American NSCLC patients to identify novel potential driver mutations",
        "Background":"['African Americans continue to have poorer 5 year survival after a lung cancer diagnosis than whites for reasons that remain to be fully characterized. This disparity remains even with advances in treatments targeting specific driver mutations that have improved outcomes for some patients. Although the relative frequency of these genetic alterations varies in subsets of individuals defined by sex, histologic subtype, smoking history and race, little is known about the occurrence of these mutations in African Americans. In this study, we characterize the spectrum of known driver mutations in 200 African American NSCLC patients and seek to identify novel somatic mutations in this population. Initially, the population was screened using the Sequenom LungCarta panel of 216 mutations in 24 genes known to contain alterations associated with lung cancer, RET and ROS1 fusion gene expression, and amplification of FGFR1. Whole-exome sequencing is being performed on tumors from those patients with no known somatic mutations. Paired normal and tumor DNA/RNA samples are being genotyped to distinguish germline from somatic mutations in both the screening and sequencing phases. Initial screening has been completed on 130 patients, with the remaining 70 underway. The mean age of the patients enrolled is 61.7 years, 58.5% are female, and 8.5% are never smokers. In profiling the first 130 African American patients, we find that only 28% of patients (N = 36) carry a known somatic mutation that is not present in the germline, far lower than the 41% reported in white patients in our previous studies. Of the identified mutations, approximately 23.8% are KRAS and 23.8% are PT53 alterations. The next most frequent somatic alterations are in EGFR (16.7%). The remaining alterations occurred in only 1 or 2 tumors and include EPHA3, ERBB2, FGFR1, MET, NOTCH1, NRAS, NTRK2, PIK3CA, PTEN, RET and STK11. Five percent of patients have tumors with two driver mutations. Half of the tumors carrying 2 driver mutations had concurrent alterations in KRAS and TP53. Patients with known genetic alterations were more likely to be female than patients with no known genetic alterations (p = 0.42), but did not differ in age, smoking status, pack-years, family history of lung cancer, history of COPD, stage at diagnosis or histology. Mutations in EGFR were responsible for the differences by sex. Exome sequencing is complete for the first 48 of the 92 patients with no known somatic mutations. Sequences are being aligned using Novoalign and GATK will be used for variant calling; results will be available soon. Genetic profiling of NSCLC in African Americans has the potential to both identify novel mutations, expanding the list of potential targets for tailored treatments, and aid clinical decision making in African American patients leading to improvements in outcomes.']",
        "Doc_id":"AACR_2016-5227",
        "Doc_title":" Molecular profiling in African American NSCLC patients to identify novel potential driver mutations",
        "_version_":1606188979986628608},
      {
        "Meeting_name":" Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology.",
        "Background":"['Background', '  The FGFR1 gene is located in the chromosomal region 8p12 and encodes a transmembrane receptor tyrosine kinase. Amplification of FGFR1 has been reported in lung cancer, predominantly in SCC (in up to ~ 20%) and has been considered a potential target for treatment with anti-FGFR1 agents. Different methods and cutoff levels to determine FGFR1 amplification have been reported but as yet no consensus has been reached on standard method. The aim of this study is to assess FGFR1 amplification determined by FISH analysis in a set of samples from 101SCC pts and to explore their clinical features.  Methods', '  Tumor samples from 101SCC pts diagnosed at our institution from August 2007 to August 2011 were screened for FGFR1 amplification by FISH using the ZytoLight SPEC FGFR1/CEN8 probe. FGFR1 was considered FISH positive with a ratio > 2.2 and FISH FGFR1 was polysomic with 3 or more signals in 30% of tumor cells, any other result was considered as negative. For exploratory analyses FGFR1 amplification was considered positive if a median of 6 or more gene copies were identified and FISH were polysomic with more than 2 gene copies but less than 6.  Results', '  Pts characteristics', ' median age 76 yrs (range 45-80), 91% male, 33% current smokers, 67% former smokers, stage', ' 8% IA/ 15% IB/ 11% IIA/ 11% IIB/ 24% IIIA,  12% IIIB/ 19% IV. With a median follow up of 48 months, the median overall survival was 18 months. FISH FGFR1 was positive (ratio > 2.2) in 7 (6.9%) pts', ' 6 were male, 4 former smokers. FISH FGFR1 was  considered negative but polysomic (3 or more signals in 30% of tumor cells) in 43/94 (45%) pts. If we use for FISH positivity a cutoff of 6 or more copies only 3 patients were considered as positive for FGFR1 amplification (2 were also FISH positive by ratio>2.2). All those 5 patients considered FISH negative by gen copy number (but positive by ratio) were polysomic.  Conclusions', '  In our experience FGFR1 amplification detected by FISH isrelatively uncommon in SCC, although a relevant proportion of FGFR1 FISH negative tumors had polysomy. Standarization of methods to determine FGFR1 amplification and the potential clinical significance of the presence of FGFR1 polysomy are needed.']",
        "Doc_id":"ASCO_96185-114",
        "Doc_title":" Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology.",
        "_version_":1606189027942203392},
      {
        "Meeting_name":" Clinical features of squamous cell lung cancer with targetable gene alterations in a nationwide genomic screening network in Japan (LC-SCRUM-Japan).",
        "Background":"['Background', ' Molecular-targeted therapies for precision medicine in squamous cell lung cancer (SqLC) have not yet been established. To identify precise patients for targeted therapies and to reveal their clinical characteristics, we have operated clinical sequencing of advanced SqLCs in our nationwide genomic screening project in Japan (LC-SCRUM-Japan) since March 2015. Methods', ' As of December 2016, 190 institutions across Japan were participating and 263 advanced SqLC patients had been enrolled in this project. Submitted tumor samples were subjected to a next-generation sequencing system, Oncomine Comprehensive Assay, enabling the simultaneous analysis of 143 cancer-related genes. Results', ' The median age of the 263 patients was 74 years (range, 27-87 years). Two hundred thirty (87%) were male and most patients (97%) were smokers. Among 211 available samples, potentially targetable gene alterations were detected in 58 (27%). Based on these gene alterations, the patients were subdivided into 4 groups, consisting of 25 (12%) with genetic alterations of FGFR family (FGFR type; 23 FGFR1 amplifications, 1 FGFR2 amplification and 1 FGFR3 fusion), 20 (9%) with genetic alterations of the PI3K pathway (PI3K type; 10 PIK3CA mutations, 8 PTEN mutations and 2 AKT mutations), 15 (7%) with other oncogene alterations (KRAS/EGFR/ALK type; 10 KRAS mutations, 3 EGFR mutations and 2 ALK fusions) and others. Comparative analyses of clinical characteristics between the 4 types showed that brain metastases were significantly more frequent in the FGFR type than the others (24% vs. 5%, p = 0.0007), and females (40% vs. 11%, p = 0.0009) and never-smokers (21% vs. 3%, p = 0.0004) were significantly frequent in the KRAS/EGFR/ALK type compared to the others. The prognostic significance of these genetic alterations has not yet been evaluated because of short follow-up time (median, 8.5 months). Conclusions', ' A series of potentially targetable gene alterations have been identified in SqLC patients. The SqLC patients had distinct clinical features according to the molecular subtypes, and genotype-directed therapeutic strategy should be developed for the individual subtypes.']",
        "Doc_id":"ASCO_189125-199",
        "Doc_title":" Clinical features of squamous cell lung cancer with targetable gene alterations in a nationwide genomic screening network in Japan (LC-SCRUM-Japan).",
        "_version_":1606189008689299456},
      {
        "Meeting_name":" In vivo response and molecular characterization of a Caucasian NSCLC squamous cell carcinoma PDX sensitive to FGFR inhibitors",
        "Background":"['BACKGROUND', 'The fibroblast growth factor receptor (FGFR) family are reported to be involved in key cellular processes such as proliferation, differentiation, migration & survival with the deregulation of signalling through genetic modification or amplification being observed in cancer. FGFR1 has been reported to be amplified in squamous cell non-small cell lung cancer (NSCLC) as well as other indications (e.g. breast) and there are several FGFR inhibitors currently in clinical trial. It is therefore essential to develop relevant in vivo models for the development and characterisation of new FGFR agents and/or combination strategies which may prolong benefit and delay the emergence of resistance.METHODS', 'Patient derived xenograft (PDX) models were maintained subcutaneously in vivo in serial passage and their growth monitored by calliper measurements three times weekly; mice were recruited to treatment groups when the mean tumour volume was approximately 200mm3. Response to treatment was evaluated by tumour growth inhibition in response to FGFR inhibitors such as AZD4547 and chemotherapy. Resistance to both chemotherapy (Paclitaxel/Carboplatin) and AZD4547 in the squamous cell carcinoma (SCC) PDX model, LU6429, was generated in vivo through repeated dosing and the resulting models characterised for their treatment response. Molecular characterisation was carried out by RNA sequencing.RESULTS', ' A number of novel PDX models have been developed which harbour FGFR amplification and mutations including LU6429, a Caucasian NSCLC SCC PDX model which has modest FGFR1 and FGFR2 amplification and responds to FGFR inhibitors. LU6429 PDX tumours (SCC confirmed by IHC) exhibited reproducible sensitivity to AZD4547 (p<0.001) which was maintained in continuous serial passage and following cryogenic storage. FGFR expression and mutational analysis was assessed in nave tumours, tumours following continuous AZD4547 treatment and in the acquired chemo-resistance setting. Other models show differential response to FGFR inhibitors.CONCLUSIONS', ' Pre-clinical models such as LU6429, a novel patient-derived NSCLC SCC xenograft model with moderate FGFR amplification which showed significant sensitivity to the FGFR inhibitor AZD4547, are invaluable in assessing novel agents targeting the FGFR pathway and in the development of new combination strategies which may prevent or overcome resistance.']",
        "Doc_id":"AACR_2015-769",
        "Doc_title":" In vivo response and molecular characterization of a Caucasian NSCLC squamous cell carcinoma PDX sensitive to FGFR inhibitors",
        "_version_":1606189036873973761},
      {
        "Meeting_name":" Identifying driver mutations in squamous cell lung cancer (SCC)",
        "Background":"['Background', '  Targeting oncogenic drivers has transformed the care of lung adenocarcinoma. However, there is no approved targeted therapy for lung SCC. LCGI aims to identify potential targets in lung SCC.  Methods', '  The LCGI study is being carried out in patients with surgically resected lung SCC. We used the platform of Sequenoms MassArray to perform genotyping for 548 somatic hotspot mutations in 49 genes including genes in the MAPK and PI3K pathways. We also evaluated FGFR1 amplification by fluorescence in situ hybridization (FISH) and MET protein expression by immunohistochemistry (IHC).  Results', '  Lung SCCs from 201 patients have been tested by Sequenom MassArray to date. Lung SCCs from 150 patients have been evaluated for MET protein expression and 89 for FGFR1 amplification. 134 (66.7%) patients were male. The median age of the cohort was 68. The majority of patients were either current (32.8%) or former (64.2%) smokers at the time of diagnosis. 104 (57.1%) were stage I, 68 (33.8%) were stage II, 29 (14.5%) were stage III SCCs. At least one aberrant, potentially targetable oncogene was identified in the SCC of 81 (40.3%) patients (see Table). The presence of PIK3CA or KRAS mutations, or FGFR1 amplification did not have a statistically significant impact on median overall survival or recurrence-free survival. However, the presence of two or more aberrations in driver oncogenes in a tumor (patients, n = 19) was associated with a worse median overall survival compared to patients with either a single driver aberration (p = 0.04) or no aberrations (p < .001).  Conclusions', '  40.3% of lung SCC patients have an aberrant, potentially targetable driver oncogene in their tumor. The presence of two or more aberrant oncogenes is a poor prognostic factor. These findings can be used to guide clinical trials in lung SCC.   Frequency of driver mutations in LCGI compared to The Cancer Genome Atlas (TCGA) study.MutationLCGI (n = 201)TCGA (n = 178)FGFR1 amp (n = 89)12.4%16.8%PIK3CA12.4%10.1%KRAS6.5%0.6%PTPN114%1.7%STK111.9%1.7%MYC1.9%0.0%NRAS1.5%0.0%BRAF1.5%3.9%HRAS 1.5%1.7%CTNNB11.5%1.7%FBXW71.5%3.4%MET Overexpression (n = 150)1.3%NAEGFR0.9%2.8%AKT10.5%0.6%CDK40.5%0.0%GNA11 0.5%0.6%MAP2K10.5%0.6%DDR20%1.1%']",
        "Doc_id":"ASCO_147270-156",
        "Doc_title":" Identifying driver mutations in squamous cell lung cancer (SCC)",
        "_version_":1606189016663719936},
      {
        "Meeting_name":" Activation of FGFR signaling as a mechanism of acquired resistance to erlotinib in EGFR-mutant lung cancer associated with an EMT.",
        "Background":"['Treatment of NSCLC patients harboring activating EGFR mutations with EGFR TKIs results in anti-tumor responses to therapy, however patients ultimately progress on therapy due to the acquisition of drug resistance. Known mechanisms of resistance include secondary mutations in the EGFR gene (EGFRT790M) or MET gene amplification, however the underlying mechanism of resistance remains to be elucidated in 40-45% of cases. Previous studies provide evidence for an epithelial-to-mesenchymal transition (EMT) in a subset of cases that is not associated with the known mechanisms of resistance. In this study, we identify 2 models of acquired resistance to erlotinib that are associated with an EMT phenotype and a dependence on autocrine FGF-FGFR signaling for resistance. Evidence for FGFR pathway activation in the erlotinib-resistant cell population included an increase in FGF2, FGFR1 and phospho-FRS2. Inhibition of FGFR signaling using a small molecule kinase inhibitor or FGFR1-Fc neutralization of FGFR1 ligands re-sensitized resistant cells to erlotinib. Re-sensitization was accompanied by an inhibition of downstream signaling. In contrast, inhibition of AXL, a kinase that has recently been identified as an EMT-associated driver of erlotinib resistance in some pre-clinical models, failed to re-sensitize erlotinib-resistant cells. Our findings are consistent with autocrine FGFR pathway activation, as FGF ligand neutralization in the absence of an exogenous source of ligand can re-sensitize cells to erlotinib. Finally, FGFR pathway inhibition suppressed the development of resistance to erlotinib in sensitive parental cells. These data indicate that FGFR activation could potentially serve as a mechanism of acquired resistance to erlotinib in cases associated with an EMT and suggest that combined inhibition of EGFR and FGFR signaling could be beneficial in treating such cases.']",
        "Doc_id":"AACR_2013-4463",
        "Doc_title":" Activation of FGFR signaling as a mechanism of acquired resistance to erlotinib in EGFR-mutant lung cancer associated with an EMT.",
        "_version_":1606189023694422016},
      {
        "Meeting_name":" FGFR3 as a therapeutic target in squamous cell lung carcinoma",
        "Background":"['Squamous cell lung carcinoma (lung SCC) is the second most common subtype of non-small cell lung cancer with, 40,000 new cases diagnosed every year in the United States. Unlike lung adenocarcinoma, few targetable genomic events are known drivers of lung SCC, and therefore, therapeutic options are limited for patients with this disease. As part of The Cancer Genome Atlas (TCGA) project, we have analyzed the entire coding sequence of 196 lung SCCs for mutated genes which may be amenable to targeted therapeutics. In the 108 patient samples analyzed to date, we have observed mutations in the Fibroblast Growth Factor Receptor 3 (FGFR3) kinase gene in six cases at four sites, or 3% of samples. The observed FGFR3 mutations are present in both the extracellular domain and the kinase domain of the protein, an observation that is consistent with activating mutations in FGFR3 that are known to drive bladder cancer, and in fact, two of the observed mutations are at sites previously observed in bladder cancer. We therefore hypothesized that these mutations are oncogenic and may be driving transformation in a subset of lung SCC patients. Expression of mutated FGFR3 in NIH-3T3 cells led to anchorage-independent colony formation, which was inhibited by treatment with a pan-FGFR inhibitor. A known mechanism of FGFR3 activation is the constitutive dimerization of receptors with mutated extracellular domains via intermolecular disulfide bond formation, and we have observed this phenomenon in our ECD mutants as well. These data suggest that mutations in the FGFR3 gene are sufficient to transform cells. This finding, along with recently published data suggesting that FGFR1 amplification is also able to drive lung SCC development, demonstrates that the FGFR family may be a promising therapeutic target in lung SCC.']",
        "Doc_id":"AACR_2012-2",
        "Doc_title":" FGFR3 as a therapeutic target in squamous cell lung carcinoma",
        "_version_":1606188987376992256},
      {
        "Meeting_name":" Multimutational profiling of rebiopsy samples from NSCLC developing acquired resistance to EGFR-TKI in Japanese patients.",
        "Background":"['Background', '  The majority of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations eventually acquire resistance to EGFR tyrosine kinase inhibitors (TKI). There are little data about genetic alterations in rebiopsy samples of NSCLC developing acquired resistance to EGFR-TKI in Asian patients.  Methods', \"  We retrospectively reviewed the medical records of patients with NSCLC harboring EGFR mutations, who had undergone rebiopsy after acquired resistance to EGFR-TKI. We analyzed 30 practicable samples using our tumor genotyping panel to assess 23 hot-spot sites of genetic alterations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), gene copy number of EGFR, MET, PIK3CA, FGFR1 and FGFR2, and ALK, ROS1 and RET fusions using pyrosequensing plus capillary electrophoresis, quantitative PCR, and reverse transcription PCR, respectively.  In addition, 23 samples were analyzed by commercially available EGFR mutation tests (Cycleave PCR or Scorpion Amplification Refractory Mutation System). Acquired resistance was defined according to Jackman's criteria.  Results\", '  A total of 43 patients had undergone rebiopsy and analysis of resistance mechanisms. Thirty rebiopsy samples were analyzed using our tumor genotyping panel, and 13 rebiopsy samples were analyzed for EGFR mutations only by commercial clinical laboratories. Anatomic sites of rebiopsy were 28 thoracic lesions, 10 central nervous system lesions, and 5 other lesions. Eleven patients (26%) had second-site EGFR T790M mutations, and 4 patients had no EGFR activating mutations in rebiopsy samples. No patients had small cell histologic transformation. In samples analyzed using our tumor genotyping panel, MET gene copy number gain was seen in 3 of 30 (10%). In addition, we detected PIK3CA mutation (E542K), PIK3CA gene copy number gain, BRAF mutation (G466V), and KRASmutation (G12D), in one sample each. Genetic alterations were identified in 36% of central nerve system samples, and 53% of other samples.  Conclusions', '  Althoughfrequency of T790M mutation was lower than earlier reports for western patients, that of MET gene copy number gain was comparable to previous reports.']",
        "Doc_id":"ASCO_131062-144",
        "Doc_title":" Multimutational profiling of rebiopsy samples from NSCLC developing acquired resistance to EGFR-TKI in Japanese patients.",
        "_version_":1606188986697515008},
      {
        "Meeting_name":" Phase II study of dovitinib in patients (Pts) progressing on anti-vascular endothelial growth factor (VEGF) therapy.",
        "Background":"['Background', '  Prior work identified the fibroblast growth factor (FGF) pathway as a mediator of resistance to anti-VEGF therapy. We tested dovitinib, an oral inhibitor of both FGFRs and VEGFRs in pts progressing on anti-VEGF treatment.  Methods', '  Pts with measurable advanced colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) with progression despite treatment with an anti-VEGF agent within 56 days, good performance status (PS) and adequate organ function were eligible. A pre-treatment tumor biopsy was followed by treatment with dovitinib 500 mg on a 5 day on / 2 day off schedule for 28-day cycles. The primary endpoint of response (RECIST 1.1) was evaluated every 2 cycles. Secondary endpoints included toxicity and the disease control rate at 8 weeks. Intratumor mRNA expression was analyzed using a Next Generation Sequencing based expression array and circulating angiogenic factors analyzed by a multiplex bead-based assays and ELISAs.  Results', '  Ten pts (9 CRC, 1 NSCLC) treated previously with bevacizumab (8) or ziv-aflibercept (2) enrolled. The study closed with termination of dovitinib development. No responses were observed in 7 evaluable pts; 3 withdrew consent during cycle 1. The best response was stable disease in 1 patient. Common toxicities included gastrointestinal, metabolic, and biochemical derangements. All pts experienced at least 1 grade 3 or higher treatment-related adverse event, most commonly fatigue, elevated GGT, and lymphopenia. Expression of multiple angiogenic mediators was common in tumors progressing on anti-VEGF therapy including high levels of FGFR1 and VEGFA. Dovitinib modulated circulating VEGF pathway components; however, no hyperphosphatemia was observed and plasma FGF2 increased continuously.  Conclusions', '  We found no evidence for the activity of dovitinib in pts with CRC progressing on anti-VEGF therapy and could not confirm potent FGFR inhibition. Toxicities were significant. In tumors progressing despite anti-VEGF therapy, a multitude of pro-angiogenic mediators are expressed, including members of the FGF pathway. Clinical trial information', ' NCT01676714']",
        "Doc_id":"ASCO_158961-173",
        "Doc_title":" Phase II study of dovitinib in patients (Pts) progressing on anti-vascular endothelial growth factor (VEGF) therapy.",
        "_version_":1606188970810540032},
      {
        "Meeting_name":" Patterns of metastasis and survival in patients with PI3K pathway-driven stage IV squamous cell lung cancers (SQCLC).",
        "Background":"['Background', '  The majority of actionable drivers in SQCLCs occur in the PI3K (30%) and FGFR1 (20%) pathways.  The biologic behaviors and natural histories of these oncogenic subtypes are not well characterized.  Methods', '  As of October 2011, all patients with SQCLCs at MSK have undergone prospective, multiplex testing of their FFPE tumors for FGFR1 amplification (FISH), PIK3CA mutations (Sequenom), PTEN loss (IHC), and PTEN mutations (exon sequencing), among others.  Patient characteristics, outcomes, and metastatic sites were identified.  Survival probabilities were estimated using the Kaplan-Meier method.  Group comparisons were performed with log-rank tests and Cox proportional hazards methods.   Results', '  68 stage IV SQCLC patients were analyzed.  39 had tissue sufficient for next-gen sequencing.  Genotypes were', ' FGFR1 amplified (16%); PTEN loss (24%), PIK3CA mutant (7%), PTEN mutant (13%).  Events were non-overlapping save for 2 cases with PTENnonsense mutations and PTEN loss.  The sole significant clinical difference (KPS, age, sex, lines of tx) was sex (women in PI3K group 52% vs. in others 23%, p=0.02).  Metastatic patterns vs. other are shown in the Table. Median OS for PI3K vs. other', ' 10mo (95%CI', '6.5-14.3) vs. 14mo (95%CI', '9.6-36.7), p=0.02.  Median OS for FGFR1 vs. others', ' 19mo (95%CI', '9-NR) vs. 10mo (95%CI', '6.5-14.3), p=0.3.  Multivariate analysis for OS', ' PI3K vs. other, HR death=2.3 (95%CI', '1.1-4.8, p=0.03); Age 65, HR=1.3 (95%CI', '0.6-2.9, p=0.6); KPS70, HR=0.5 (95%CI', '0.2-1.7, p=0.3); Male sex, HR=0.7 (95%CI', '0.3-1.4, p=0.3).    Conclusions', '  Patients with stage IV PI3K-aberrant SQCLCs have poorer survival compared to other patients with SQCLCs.  Brain metastases occurred exclusively in patients with PI3K-aberrant tumors.  These data suggest that PI3K pathway activation confers a distinct biology, and that targeting this in SQCLC patients with brain metastases may be an effective therapeutic strategy.']",
        "Doc_id":"ASCO_115102-132",
        "Doc_title":" Patterns of metastasis and survival in patients with PI3K pathway-driven stage IV squamous cell lung cancers (SQCLC).",
        "_version_":1606189008541450240},
      {
        "Meeting_name":" S49076, a kinase inhibitor of AXL, MET and FGFR with strong, selective preclinical activity against tumor cells with acquired resistance to EGFR inhibitors not carrying the T790M mutation",
        "Background":"['Background', ' Aberrant activity of MET, FGFR1 and AXL has been associated with development of resistance to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) patients. S49076 is a potent ATP-competitive tyrosine kinase inhibitor (TKI) of MET, AXL/MER, FGFR1/2/3 currently in phase I clinical trials.Methods', \" We obtained six resistant lines by treating EGFR-mutated, TKI-sensitive PC9 cells with increasing concentrations of gefitinib (GR1-5) or erlotinib (ER). The six resistant cell lines conserved the exon 19 deletion but the T790M resistance mutation only emerged in two (GR1, GR4), which remained sensitive to AZD9291, a third generation EGFR TKI. Six new AZD9291-resistant cell lines were derived from GR1 and GR4 by exposure to increasing concentrations of the inhibitor. Three of the AZD9291 resistant cell lines lost the exon 19 and T790M mutations, one conserved only the sensitizing mutation and two kept both mutations but with the T790M dropping to very low allelic fractions (1% and 0.03%). All resistant cell lines were characterized for AXL, MET, MER, FGFR1 and FGFR2 expression by Q-RT-PCR, immunohistochemistry and Western blotting. The effects of S49076 on the parental and resistant cell lines were analyzed by MTT, colony formation, basal membrane invasion and migration assays. Western blotting of key signal transduction proteins was used to gain insight in the drug's mechanism of action.Results\", ' AXL overexpression was the most common event related to gefitinib/erlotinib resistance in the panel of cell lines, with T790M mutation, FGFR1 or BCL-2 overexpression and MET activation being less frequent events. Regarding AZD9291 resistance, AXL upregulation was again widespread, with loss of EGFR mutations as the second most frequent event. In proliferation assays, S49076 showed strong antitumor activity against all PC9-derived cell lines with acquired resistance to EGFR TKIs (erlotinib, gefitinib or AZD9291) and not carrying the T790M mutation, with IC50 of 0.2-1.2 M and less than 10% surviving cells at 1 M of drug in most cases. In contrast, S49076 was less active against the parental PC9 cells and the T790M positive resistant lines, with more than 50% of surviving cells at 50 M of drug. S49076 also inhibited the anchorage-independent growth and migration of the resistant cell lines. A correlation was found between mRNA and protein levels of AXL and sensitivity to S49076. Also, PARP cleavage and moderate but reproducible inhibition of AKT phosphorylation by S49076 were observed exclusively in the non-T790M resistant cell lines.Conclusions', ' S49076 shows strong activity in preclinical assays against EGFR mutated cell lines resistant to EGFR TKIs not harboring EGFR T790M mutation and overexpressing AXL. A clinical trial of S49076 in non-T790M patients progressing to EGFR TKI and overexpressing AXL or MET has been initiated.']",
        "Doc_id":"AACR_2016-336",
        "Doc_title":" S49076, a kinase inhibitor of AXL, MET and FGFR with strong, selective preclinical activity against tumor cells with acquired resistance to EGFR inhibitors not carrying the T790M mutation",
        "_version_":1606189014486876160},
      {
        "Meeting_name":" Multiplexed mutational profiling of Japanese lung adenocarcinoma patients for personalized cancer therapy.",
        "Background":"['Background', ' Integration of genotype-based stratification into the lung cancer clinic is essential to implement the personalized medicine for patients with lung adenocarcinoma. Thus we have developed a multiplexed tumor genotyping panel for detecting somatic mutations relevant to molecular targeted therapies for lung cancer. The mutation profile data are communicated to clinicians to assign patients to appropriate therapy and/or clinical trials.Methods', ' Multiplexed tumor genotyping panel was developed to assess 23 mutations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), 5 genes amplifications (EGFR, MET, PIK3CA, FGFR1 and FGFR2), and 5 fusion genes (EML4-ALK, CD74-ROS1, SLC34A2-ROS1, KIF5B-RET and CCDC6-RET) using pyrosequencing plus capillary electrophoresis, qRT-PCR, and multiplex RT-PCR, respectively. A written informed consent was obtained upfront from all patients enrolled into this study. Surgically resected tissues, tumor biopsies, pleural effusions and/or pericardial effusions from 280 patients were collected between July 2011 and July 2012 and used for tumor genotyping.Results', ' Somatic mutations were detected in 52.9% (148/280) of all patients. The most common mutation detected in this study was EGFR mutation (35.4%, 99) followed by KRAS mutation (10.4%, 29). EGFR L858R (52.5%) and KRAS G12C (44.8%) was the most frequent among EGFR and KRAS mutations, respectively. Other detected mutations were PIK3CA mutation (2.5%), PIK3CA amplification (2.5%), EGFR amplification (2.5%), MET amplification (2.1%), EML4-ALK fusion gene (1.4%), BRAF mutation (1.1%), NRAS mutation (1.1%), HER2 mutation (1.1%), MEK1 mutation (0.7%), AKT1 mutation (0.7%), KIF5B-RET fusion gene (0.4%), CD74-ROS1 fusion gene (0.4%) and FGFR1 amplification (0.4%). EGFR tyrosine kinase inhibitor (EGFR-TKI) was administered to 71.9% (41/57) of previously untreated patients who harbor EGFR activating mutations. Among those treated with EGFR-TKIs, simultaneous mutations in other genes with EGFR mutations were detected in 21.9% (9/41). Response rate of EGFR-TKIs in patients with simultaneous mutations (44.4%) was lower than that in patients with EGFR mutation alone (68.8%), suggesting that additional mutations may play some role in evading oncogenic signaling blockade. EGFR mutations were detected less frequently in smokers than in never-smokers (25.1% vs 60.5%, p<0.0001). Meanwhile, KRAS mutations were detected more frequently in smokers than in never-smokers (13.6% vs 2.5%, p=0.0043), which is consistent with previous reports. The majority of patients with never-smoking history harbored targetable somatic mutations compared to those with smoking history (71.6% vs 45.2%, p<0.0001).Conclusions', ' We have established the multiplexed tumor genotyping panel and this should be incorporated into lung cancer clinical practice to facilitate personalized cancer medicine.']",
        "Doc_id":"AACR_2013-37",
        "Doc_title":" Multiplexed mutational profiling of Japanese lung adenocarcinoma patients for personalized cancer therapy.",
        "_version_":1606188971989139456},
      {
        "Meeting_name":" Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin",
        "Background":"['Squamous cell carcinoma (SCC) is a common subtype of lung cancer and is strongly associated with smoking. In contrast to adenocarcinomas of the lung, SCCs do not significantly harbor epidermal growth factor (EGFR) mutations or ALK, ROS1 or RET translocations, which are therapeutically tractable. SCC of the lung and SCC of the head and neck region and esophagus not only share risk factors, morphologic features and mechanisms of tumorigenesis but also frequent fibroblast growth factor receptor 1 (FGFR1) gene alterations. In addition, we found that FGFR2 and FGFR3 expression were also altered in patient derived models of SCC of various origins. FGFRs may thus represent viable therapeutic targets for the treatment of SCC.BAY 1163877, an orally available and potent inhibitor of FGFR1, FGFR2 and FGFR3, inhibited SCC cell proliferation as well as downstream FGFR signaling in vitro. When applied in vivo, BAY 1163877 was able to reduce growth of a FGFR1-overexpressing lung SCC xenograft model, a FGFR1-overexpressing esophageal SCC xenograft model, and a FGFR3-overexpressing head and neck SCC xenograft model, achieving reductions in tumor growth by 67 to 92% as compared to the vehicle control. BAY 1163877 was very well tolerated in all models performed.These data suggest that selective inhibition of FGFR1 to 3 with BAY 1163877 might have therapeutic potential for the treatment of SCC malignancies. A phase I clinical trial (NCT01976741) to determine the safety, tolerability and recommended Phase 2 dose in advanced cancer patients is ongoing.']",
        "Doc_id":"AACR_2015-772",
        "Doc_title":" Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin",
        "_version_":1606189016049254401},
      {
        "Meeting_name":" Expression profiling of FGF-receptor pathway genes in squamous NSCLC tissue by Nanostring.",
        "Background":"['FGFR1 amplifications have recently been identified in 22% of squamous non-small cell lung cancers (sqNSCLC) (Weiss et al., Sci Transl Med., 2(62), 2010) and in pre-clinical models this amplification confers sensitivity to FGFR inhibitor induced cell growth arrest and death (Zhang et al., Clin. Can. Res., In press). Ongoing clinical trials of FGFR inhibitors are selecting patients based on FGFR1 amplifications, as determined by FISH. The development of additional biomarker assays to evaluate the expression of FGFRs, FGF ligands and other potential modulators of response to support analysis of clinical tissues is warranted.We validated the Nanostring platform to allow gene expression (mRNA) analysis of 194 genes, including FGFRs and FGF ligands, from one 5m section of formalin fixed paraffin embedded clinical tumor tissue. Intra- and inter-assay variability was low, as was variability between adjacent sections from the same tumor sample. Further validation of a subset of these genes by RT-PCR revealed a good correlation between platforms. A panel of 50 sqNSCLC tumors were analysed for FGFR1 gene amplification by FISH and for gene expression by Nanostring. FGFR1 amplfied tumours were enriched for high FGFR1 mRNA expression (p<0.02) compared to non-amplified samples, although a subset of non-amplified tumours also demonstrated increased FGFR1 mRNA expression. Immunohistochemical analysis, employing an FGFR1 specific antibody, revealed a correlation between FGFR1 mRNA levels and protein expression in these tumors. Nanostring analysis of additional genes on the 8p12 region, revealed that several of these, for example PPAPDC1B, ASH2L, TACC1 and in particular the FGFR1 neighbouring gene WHSC1L1 are highly expressed in FGFR1 amplified tumors (p<0.0001 for WHSC1L1). In contrast, expression of LETM2, located between WHSCL1 and FGFR1, was not significantly increased in amplified tumors.An FGF ligand expression profile was generated for each tumor, showing that a-FGF, b-FGF and FGF7 were the most abundantly expressed ligands in the sqNSCLC samples, with increased b-FGF expression detected in high FGFR1 expressing tumours. The expression of a panel of potential mediators of resistance to FGFR inhibitor therapy such as c-MET, EGFR and IGF1R were also profiled across the samples, revealing differential expression of these factors across each of the tumors and an inverse correlation between FGFR1 expression and ERBB3 expression.Taken together, these data validate the utility of the Nanostring platform for expression analysis of FGFR pathway genes using mRNA isolated from FFPE tumor samples and this platform can be used to assess the level of expression of potential modulators of clinical outcome.']",
        "Doc_id":"AACR_2013-2407",
        "Doc_title":" Expression profiling of FGF-receptor pathway genes in squamous NSCLC tissue by Nanostring.",
        "_version_":1606189025794719744},
      {
        "Meeting_name":" A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC).",
        "Background":"['Background', '   Lucitanib, a potent, oral inhibitor of the tyrosine kinase activity of Fibroblast Growth Factor Receptors 1/2 (FGFR1/2), Vascular Endothelial Growth Factor Receptors 1-3 (VEGFR1-3) and Platelet-Derived Growth Factor Receptors A/B (PDGFRA/B), is being developed for the treatment of lung cancer and breast cancer. FGFR1-amplification is a hallmark genomic alteration in sqNSCLC, observed at a frequency of 10-20%. As such, inhibition of the FGF-axis represents a promising potential target for therapy of sqNSCLC.     Methods', \"   The current study evaluates daily oral lucitanib monotherapy in patients (pts) with FGFR1-amplified sqNSCLC. This is an international, multicenter, open-label, single-arm study. The primary endpoint is objective response rate (ORR; RECIST1.1) with secondary endpoints of response duration, clinical benefit rate, progression-free survival, and safety evaluation.  Exploratory objectives include volumetric assessment of tumor growth kinetics, serial circulating tumor DNA measurement, and identification of additional biomarkers of lucitanib activity including determination of FGFR1 or FGF ligand RNA or protein expression using in-situ hybridization or immunohistochemistry. A Simon's minimax two-stage design will be used to provide 80% power to test the hypothesis H0\", ' p  10% versus H1', ' p  25%, with a type I error at 5% (one sided). A minimum of 22 and maximum 40 pts will be enrolled.  Key inclusion criteria include', ' pts aged  18 years with stage IV sqNSCLC and tumor FGFR1-amplified, tumors that are not invading or abutting a major vessel and/or tumors that are not cavitary.  FGFR1 amplification will be assessed centrally by FISH but local FGFR1 testing is sufficient for enrollment. Pts should have measurable disease and have had at least one previous treatment for advanced disease.   This study will begin enrolling pts in the United States and Europe in early 2014 at a network of centers skilled in the identification of pts with relatively uncommon tumor characteristics. Clinical trial information', ' 2013-003874-29.']",
        "Doc_id":"ASCO_132036-144",
        "Doc_title":" A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC).",
        "_version_":1606188984354996224},
      {
        "Meeting_name":" Combining the pan-FGFR inhibitor AZD4547 with radiation in lung and head and neck squamous cell carcinoma.",
        "Background":"['The fibroblast growth factor receptors (FGFR1, FGR2, FRG3, FGR4) are frequently altered or overexpressed in both lung and head and neck squamous cell carcinomas (SCC). Amplification of FGFR1 has been reported to be as high as 22% in lung SCC and 17% in head and neck SCC (HNSCC). FGFRs have been identified as a potential therapeutic target in lung and head and neck cancers. In addition, FGFRs activate multiple pathways involved in the radiation response including RAS/RAF/MAPK, PI3K/AKT and STAT. AZD4547 is a potent and selective tyrosine kinase inhibitor of the FGFR family and is currently being investigated in clinical trials. Since a substantial portion of lung cancer and HNSCC patients are treated with radiotherapy, we examined the anti-tumor effects of AZD4547 in combination with radiation in both lung and head and neck cancer model systems. FGFR protein and RNA expression and cell proliferation with AZD4547 were evaluated in 8 lung and 8 head and neck cancer cell lines. Clonogenic survival assays were performed on 4 lung and 4 head and neck cancer cell lines and xenograft experiments were performed on one HNSCC cell line. These cell lines demonstrated varying levels of FGFR1, 2 and 3 protein and RNA expression. The half maximal inhibitory concentration (IC50) of AZD4547 in these cell lines ranged from 0.05 to 128 uM. Sensitivity to AZD4547 did not correlate directly with protein or RNA expression. In vitro clonogenic survival assays showed limited effects of combining AZD4547 with radiation. However, significant tumor growth delay was observed with the combination of radiation and AZD4547 compared to radiation or drug alone in the SCC1483 FGFR2 expressing HNSCC xenograft model. These findings suggest that AZD4547 can augment the response of radiation in an in vivo model system. Further studies are underway to test these findings in additional cell lines including FGFR dependent amplified cancer cell lines.']",
        "Doc_id":"AACR_2017-1094",
        "Doc_title":" Combining the pan-FGFR inhibitor AZD4547 with radiation in lung and head and neck squamous cell carcinoma.",
        "_version_":1606189003184275456},
      {
        "Meeting_name":" A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies.",
        "Background":"['Background', ' XL228 is a protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, ABL and SRC family kinases. It is being evaluated in a phase 1 trial in patients (pts) with advanced malignancies. Methods', ' XL228 is administered as weekly 1-hour IV infusions. Cohorts of pts with refractory solid tumors or lymphoma are evaluated for determination of the maximum tolerated dose, pharmacokinetics, and pharmacodynamic effects using FDG-PET, signal pathway analysis in tumor and normal tissue biopsies, and plasma marker analysis. MTD expansion cohorts will include pts with multiple myeloma and colorectal cancer. Results', ' Thirty-six pts have been treated at doses ranging from 0.45 to 8.0mg/kg. The maximum administered dose was defined as 8.0mg/kg as a result of the dose limiting toxicities of Grade (Gr) 4 neutropenia, and Gr 3 neutropenia requiring dose skipping. XL228 is generally well tolerated; one serious adverse event of drug-related Gr 3 vomiting has been observed. Common drug-related adverse events include Gr 1 nausea, fatigue, decreased appetite, and flushing, and Grade 1-2 hyperglycemia (fasting) lasting up to 4 hours post- infusion. XL228 exposure was approximately dose-proportional; the mean terminal half-life (t1/2, z) ranged from 27 to 54 hours. Low accumulation was observed after weekly administration. Protein phosphorylation measurements in skin, hair, and blood samples demonstrate inhibition of IGF1R, SRC and FGFR1 signaling by XL228, including reductions in hair follicle phospho-IGF1R and phospho-FAK1 of 39% and 42%, respectively, in a pt dosed at 5.4mg/kg. Evidence of clinical activity includes one non-small cell lung cancer pt with an unconfirmed partial response (confirmation pending) and 9 additional pts (of 30 evaluable) with stable disease (SD) lasting >3 months, including a small cell lung cancer pt on study for 13.3+ months after failing carboplatin/etoposide. For pts with SD, the median time on study is currently 5.9 months (range 3.3+ to 13.3+). Conclusions', ' XL228 is generally well tolerated and has shown encouraging preliminary clinical and pharmacodynamic activity.']",
        "Doc_id":"ASCO_35000-65",
        "Doc_title":" A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies.",
        "_version_":1606188996014112768},
      {
        "Meeting_name":" Use of tumor mRNA expression for patient selection in a phase I study of the pan-fibroblast growth factor receptor inhibitor BAY 1163877.",
        "Background":"['BAY 1163877 is a potent and selective, oral, small molecule pan-FGFR inhibitor with anti-tumor activity in a wide range of cancer types. In vivo profiling in xenograft models identified tumor FGFR mRNA levels as a predictor of drug efficacy. Anti-tumor efficacy was largely independent of the tumor type surveyed or the FGFR isoform being overexpressed. Preclinical models included a patient-derived squamous head and neck cancer (HNSCC) xenograft (PDx) model overexpressing FGFR3 mRNA, a bladder cancer PDx model overexpressing FGFR2 mRNA, and a squamous esophageal cancer PDx model overexpressing FGFR1 mRNA. Against this background, clinical proof-of-concept was assessed by enrolling patients into the stratified expansion cohort of a Phase 1 study of BAY 1163877 (NCT01976741) based on tumor FGFR1-3 mRNA levels. FGFR1-3 mRNA was quantified in archival or newly obtained FFPE tumor biopsies by RNA in situ hybridization (RNAscope, ACD) and digital transcript counting (NanoString). In total, biopsies from > 500 patients were studied for FGFR1-3 mRNA expression levels. Based on preclinical xenograft experiments showing that low to moderate FGFR1-3 mRNA overexpression was not sufficient for a robust drug response, only patients with an RNAscope score of 3 or 4 (range 0-4) or a normalized Nanostring signal of 800 counts were eligible for enrollment. By applying these stringent criteria, FGFR1-3 mRNA positivity was on average observed with a 2- to 3-fold higher prevalence than published data for genetic aberrations of FGFRs in the respective tumor types (including amplifications, translocations, mutations). We further identified FGFR mRNA(+) tumor types in which genetic FGFR aberrations have not been previously reported. FGFR1-3 mRNA positivity ranged from 10% in lung adenocarcinoma to 45% in squamous non-small cell lung cancer (sqNSCLC) and 54% in HNSCC. As of August 2016, 57 FGFR mRNA(+) patients were enrolled and treated with BAY 1163877. Six patients experienced a partial remission (PR) by RECIST v1.1 criteria; including an FGFR3 mRNA(+) HNSCC patient without FGFR3 amplification or translocation, an FGFR1 mRNA(+) adenoid cystic carcinoma patient, and an FGFR1 mRNA(+) sqNSCLC patient (both without FGFR1 gene amplification), as well as an FGFR3 mRNA(+) bladder cancer patient without FGFR3 amplification, mutation or translocation. These results suggest that high FGFR1-3 mRNA expression identifies patients sensitive to FGFR inhibition. This population includes patients with and without genetic aberrations of FGFR1-3 encoding genes. In summary, an mRNA expression-based selection approach may identify a broader patient population with potential benefit from BAY 1163877, including tumor types not previously associated with altered FGFR signaling.']",
        "Doc_id":"AACR_2017-3738",
        "Doc_title":" Use of tumor mRNA expression for patient selection in a phase I study of the pan-fibroblast growth factor receptor inhibitor BAY 1163877.",
        "_version_":1606189000239874049},
      {
        "Meeting_name":" A Mouse-Human co-clinical trial with patient-derived xenograft (PDX) models demonstrates a predictive signature for dovitinib (TKI258), an FGFR and VEGFR inhibitor,in lung squamous cell carcinomalung cancer (LSCC)",
        "Background":"['Background', ' We conducted a co-clinical trial with PDX models in conjunction with a phase II clinical trial with dovitinib in patients with fibroblast growth factor receptor 1 (FGFR1) amplified LSCC in order to identify a predictive biomarker for dovitinib, a FGFR inhibitor.Methods', ' PDX models were established using tumor samples obtained from LSCC patients enrolled in the trial. We conducted an in vivo efficacy test with dovitinib in PDX models and comprehensive molecular profiling by whole exome sequencing (WES), array comparative genomic hybridization (aCGH), and microarray-based gene expression.Results', ' The histological and genomic characteristics of xenograft tumors (F2) resembled case-matched original tumors (F0). Dovitinib treatment resulted in tumor shrinkage in PDXL01, but not in PDXL02-04, which corresponded to responses in LSCC patients enrolled in the clinical trial. The patient, from whom PDXL01 was derived, showed a partial response to dovitinib with progression-free survival of 6 months, whereas the patient, from whom PDXL04 was derived had rapid disease progression within 2 months of treatment. Mutation profiles of F0 and F2 were largely concordant with each other in at least 70% of somatic mutations. The genome-wide copy number alterations were also largely concordant between F0 and F2, suggesting that PDX tumors can successfully represent the genomic features of the tumors from LSCC patients. Notably, mutation in FGFR 1-3 genes was not observed. FGFR1 amplification largely due to arm-level 8p gain was consistently observed, regardless of sensitivity to dovitinib. This finding suggests that FGFR1 amplification may not be a predictor for dovitinib sensitivity. Finally, we compared gene expression between a responder and non-responders. In a Heatmap analysis of the top 50 significantly up- and down-regulated genes, FGFR gene signature including FGF3 and FGF19 was significantly up-regulated in the responder. Gene set enrichment analysis (GSEA) identified that gene sets, such as FGFR ligand binding and activation and SHC-mediated cascade pathway, were significantly enriched in the responder, highlighting FGFR pathway activation as a key molecular determinant for sensitivity to dovitinib. To identify predictive gene signatures from independent datasets, we further performed GSEA in dovitinib-sensitive lung cancer cell lines compared to resistant ones as available in the CCLE (Cancer Cell Line Encyclopedia) database. Among the four functional modules (FGFR signaling, Immune, Cell cycle, and RNA) that we identified, the FGFR signaling module performed well in the prediction of dovitinib sensitivity of PDXL01-04Conclusions', ' FGFR gene expression signatures are predictors for response to dovitinib in LSCC.']",
        "Doc_id":"AACR_2016-5194",
        "Doc_title":" A Mouse-Human co-clinical trial with patient-derived xenograft (PDX) models demonstrates a predictive signature for dovitinib (TKI258), an FGFR and VEGFR inhibitor,in lung squamous cell carcinomalung cancer (LSCC)",
        "_version_":1606188981096022016},
      {
        "Meeting_name":" Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.",
        "Background":"['Background', '    AZD4547 is a selective inhibitor of FGFR 1, 2, and 3, with activity in patient-derived explant models with FGFR gene amplification. Study 1C1 assessed safety and clinical activity of AZD4547 (80 mg bid continuous dosing), in patients with advanced solid tumors, prospectively selected for amplification of FGFR 1 or 2. FGFR gene amplification status was determined using fluorescent in situ hybridization (FISH) analysis of archival tumor tissue.  Methods', '    Analysis of FFPE diagnostic tumor samples included FGFR expression by IHC, expression analysis of ~200 pathway related genes by Nanostring and targeted Next Generation Sequencing (NGS) of a 287 gene panel at Foundation Medicine.  Results', '    Of 21 patients dosed with AZD4547, seven had high FGFR amplification (ratio FGFR', 'Centromeric probe  3.0) and three of these, a squamous NSCLC, breast and bladder cancer patients, had target lesion shrinkage or prolonged (24 weeks) disease stabilization. NGS analysis of tumor from a partial response squamous NSCLC patient, confirmed high FGFR1 amplification together with amplification of 11q13 genes FGF3/4/19 and CCND1. A breast cancer patient, with 25% reduction in target lesions, was highly FGFR1 amplified by NGS and expressed FGFR1 protein. Four patients with high FGFR gene amplification by FISH had little sign of efficacy. Of these, one patient was not confirmed FGFR amplified by NGS analysis, likely due to tumor heterogeneity. The other three patient tumors had an additional Receptor Tyrosine Kinase (RTK) amplification (IGF1R, HER2 or EGFR), with accompanying high expression. Two out of three bladder cancer patients experienced prolonged disease stabilization, both with marked FGFR1 and FGFR3 expression, one with high FGFR1amplification while an FGFR3 ligand binding domain mutation was found in tumor from the other.  Conclusions', '    In this AZD4547 Phase I study, evidence of FGFR pathway expression was observed in tumor samples from advanced cancer patients with signs of efficacy. Co-amplification of RTKs may confer resistance to AZD4547.  FGFR1/3 expression, amplification and mutation are potential selection markers for bladder cancer patients. Clinical trial information', ' NCT00979134.']",
        "Doc_id":"ASCO_130762-144",
        "Doc_title":" Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.",
        "_version_":1606188994777841664},
      {
        "Meeting_name":" Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC)",
        "Background":"['Background', ' LungMAP is a National Clinical Trials Network umbrella trial for previously-treated SqNSCLC. S1400D is a phase II biomarker-driven therapeutic sub-study evaluating the FGFR inhibitor AZD4547 in patients (pts) with FGFR positive chemo-refractory SqNSCLC. Methods', ' Eligible pts had tumor FGFR alteration and/or mutation by next generation sequencing (Foundation Medicine), measurable disease, Zubrod PS 0-2, progression after 1 line of systemic therapy, and adequate end organ function. Receipt of prior immunotherapy was allowed. Eligible pts received AZD4547 80 mg bid orally. Primary endpoint was overall response rate (ORR) by RECIST; secondary endpoints included progression-free survival (PFS) and duration of response (DoR). Originally designed as a randomized trial of AZD4547 versus docetaxel, it was redesigned to be a single arm AZD4547 trial with the emergence of immunotherapy as standard 2ndline therapy. Forty pts were required to rule out an ORR of < = 15% if the true ORR was > 35% (90% power, alpha 0.05). Results', ' 93 pts (13% of pts screened on S1400) were assigned to S1400D; 43 were enrolled with 28 receiving AZD4547. Pt characteristics', ' median age 66.3 y (49-88), female (n = 8, 29%), & Caucasian (n = 25; 89%). Biomarker profile', ' FGFR1 amplification (n = 38; 86%); FGFR3 S249C (n = 4; 9%); FGFR3 amplification (n = 3; 7%); and FGFR3 fusion (n = 2; 5%). Nine pts (26%) had more than one biomarker alteration. The study was closed at interim analysis for futility in October 2016. Treatment related Grade 3 AEs were seen in 5 pts (dyspnea, fatigue, hyponatremia, lung infection & retinopathy); 1 pt had Grade 4 sepsis. There were no Grade 5 AEs. Median follow up among alive pts was 4.3 months (mos). Of 25 response evaluable pts, one with FGFR3 S249C had unconfirmed PR (4%, 95% CI 1-20%) with DoR of 1.5 mos. Median PFS was 2.7 mos (95% CI 1.4 - 4.3 mos). Conclusions', ' This is the first Phase II trial to evaluate AZD4547 as a targeted approach in pts with previously treated FGFR-altered SqNSCLC. AZD4547 had an acceptable safety profile but minimal activity in this biomarker-enriched cohort. Evaluation of other targeted agents in LUNG-MAP is currently ongoing. Clinical trial information', ' NCT02965378']",
        "Doc_id":"ASCO_191100-199",
        "Doc_title":" Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC)",
        "_version_":1606189019018821632},
      {
        "Meeting_name":" Classification of somatic variants in solid tumors detected by next-generation sequencing (NGS) and the need for clinical guidelines.",
        "Background":"['Background', '    NGS approaches to clinical mutation testing reveal previously uncharacterized, or poorly characterized, somatic variants. A major challenge in reporting is categorization of these variants in the absence of formal guidelines. The process is subjective and the potential for variation between molecular pathologists is significant.  Methods', '   To better characterize variation between molecular pathologists we retrospectively reviewed 95 clinical cases sequenced with the Ion Ampliseq Cancer Hotspot Panel v2 at ARUP Laboratories. We focused on variants that were reclassified upon re-review by three molecular pathologists.  Results', '   Ninety eight mutations and 31 variants of unknown significance (VUS) were reported in 72 total tumors. There were seven reclassifications (5% of total classifications) in seven different tumors (3 urothelial carcinomas, 1 bladder adenocarcinoma, 1 melanoma, 1 lung carcinoma, and 1 unknown). Most of these were point mutations and involved FGFR1 (x1), FGFR3 (x1), CTNNB1 (x1), RB1 (x1) and PIK3CA (x3). Six of seven were reclassified from mutation to VUS based upon insufficient evidence of oncogenicity.  Conclusions', '   Five of the reclassifications involved actionable genes (FGFR1, FGFR3, and PIK3CA). The original classification of these as mutation was primarily based on in vitro data. A mutation classification implies there is sufficient evidence for an oncogenic change that may be amenable to targeted therapy. In vitro biochemical and cell biologic assays are artificial systems which may not fully recapitulate in vivo tumor behavior. This study emphasizes the subjective nature of variant classification and the need for the development of weighted criteria devised by a multidisciplinary panel of experts. Until then, it is of utmost importance that molecular pathologists develop systematic methods to determine the quality of available data. We propose a simple checklist to optimize the way variants are classified. We suggest that medical oncologists critically scrutinize the classification of variants as they appear in clinical reports.']",
        "Doc_id":"ASCO_132577-144",
        "Doc_title":" Classification of somatic variants in solid tumors detected by next-generation sequencing (NGS) and the need for clinical guidelines.",
        "_version_":1606189016521113600},
      {
        "Meeting_name":" MET amplification (amp) as a resistance mechanism to osimertinib.",
        "Background":"['Background', ' Osimertinib (osi) is an EGFR T790M inhibitor. Mechanisms (mech) of acquired resistance (AR) are under study. We report a cohort of osi-AR pts with extensive pre/post-osi tissue and plasma. Methods', ' We analyzed 23 pts with AR to osi. Tumor biopsies (bx) underwent NGS (SNaPshot, MGH) and FISH for EGFR, MET amp (target', 'CEP7 > 2.2.) Plasma underwent ctDNA NGS (Guardant360). Results', ' Of the 23 osi-treated EGFR-mutants (13 with EGFR del19, 10 L858R), 2 had de novo T790M, 21 acquired T790M. 13 had prior 3rd gen EGFR TKIs before osi - rociletinib(11), ASP8273(1), EGF816(1). Median time on osi was 12 mo (range 2-25), med total time on 3rd-gen EGFR TKIs was 18 mo. Bx types were tissue (16), plasma (18), and both (11, med interval 31d). All pts retained their founder EGFR mutation, but 15/23 (65%) lost T790M post-osi, suggesting AR arose from a T790wt subclone (Table). Common AR mech were MET amp (7/23; 30%) and EGFR C797S (5/23; 22%). 1 pt each had SCLC transformation, PIK3CA E545K/PIK3CA amp and FGFR1 D60N/FGFR1 amp. 2 pts had 2 distinct post-osi tissue bx showing heterogeneity. Pt 8 had plasma and a lung nodule with C797S/T790M while a mediastinal LN was wt at both loci. Pt 22 had MET-amp in pleural fluid but no MET amp on lung bx. Plasma identified AR mech not seen in tissue in 2/11 pts with both bx types. Among 7 pts with MET amp, 3 received combo EGFR/ MET TKI; all 3 had a RECIST PR. Conclusions', ' In this osi-resistant cohort, we commonly saw MET amp (30%) and C797S (22%). MET amp seems more common post-osi than after 1st-line TKIs, and 3/3 pts responded to EGFR+MET TKIs. AR heterogeneity was seen in 2 pts with matched tissue/plasma and 2 with >1 tissue bx, underscoring the complementary roles of plasma and tissue. PtTissue Result (T790M Status)Plasma Result (T790M)1METa (-)METa (-)2XU (-)3XU (-)4METa/EGFRa (g)X5EGFRa (-)U (-)6U (-)U (-)7XU (+)8C797S (+)*C797S (+)9U (+)X10XPIK3CA E545K/a (-)11METa/EGFRa (-)U (-)12XC797S (+)13U (-)X14U (-)U (-)15U (-)FGFR1 D60N/a (-)16METa (-)METa/EGFRa (-)17U (-)U (-)18SCLC (-)EGFRa (-)19U (-)C797S/METa/EGFRa (+)20METa/EGFRa (-)X21XC797S/EGFRa (+)22METa (-)*X23XC797S (+)*Different AR mech in concurrent bx; U- unknown, no mech identified; X- testing not done; T790M', ' (+) positive; (-) not detected; (g) germline; a- amplified']",
        "Doc_id":"ASCO_191211-199",
        "Doc_title":" MET amplification (amp) as a resistance mechanism to osimertinib.",
        "_version_":1606189018555351041},
      {
        "Meeting_name":" Identification of driver gene alterations in Chinese female patients with squamous cell carcinomas of the lung.",
        "Background":"['Background', '  Smoking remains the leading risk factor of NSCLC. Activating mutations in EGFR gene have been reported more frequently in never smokers than smokers with NSCLC. Female pts with squamous cell carcinomas of the lung (SQCLC) differ from males in that most females are life-long never/light smokers. However, molecular abnormalities in female pts with SQCLC have not been well-characterized.  Methods', '  We retrospectively screened 38 female and 40 male pts with SQCLC in China from 2009 to 2012 to determine the prevalence of alterations in EGFR, KRAS, ALK, PI3K, PTEN and FGFR1. Mutational analysis of EGFR, PIK3CA, KRAS and PTEN was performed using PCR-based DNA sequencing. FGFR1 amplification and ALKrearrangements were detected by FISH. A Cox regression model was used to assess the association between genomic mutation status and clinical features as well as OS.  Results', '  10.3% (8/78) pts were detected with EGFR mutation, 6.4% (5/78) with KRAS mutation, 7.7% (6/78) with PI3K mutation and 6.4% (5/78) with FGFR1 abnormality. No one harbored PTEN or ALK alteration. PI3K mutation were less common (P=0.026) in females compared to males.  Most of the pts (84.6%, 66/78) were stage IV at their first diagnosis and the median age was 57 year-old. There were significantly more male pts with a history of smoking than females (90% vs. 5.3%; P<0.001). Median survival time of the whole cohort was 14.1 months. There was no statistical difference in OS based on gender. The median OS was 15.0 months in females and 13.6 months in males. Multivariate Cox regression analysis indicated that no variable was the independent risk factor for OS.  Conclusions', '  We demonstrated thatdespite for the significantly low percent of smoking history, targetable alterations in Chinese female pts with SQCLC were similar with those in males. Furthermore, we report for the first time that female pts with SQCLC might be a distinct disease entity with a particularly lower frequency of PI3K mutation. However, the lower frequency of PI3K mutation in Chinese female pts seems to have no influence on their OS. Due to the small sample size of the study, our data need to be confirmed in future studies.']",
        "Doc_id":"ASCO_130503-144",
        "Doc_title":" Identification of driver gene alterations in Chinese female patients with squamous cell carcinomas of the lung.",
        "_version_":1606189012825931776},
      {
        "Meeting_name":" Molecular evaluation of primary tumor (PT) and synchronous liver metastasis in colorectal cancer (srLmCRC) patients after cetuximab-based chemotherapy.",
        "Background":"['Background', '   Molecular heterogeneity among PT and LmCRC is not yet defined. Next Generation Sequencing (NGS) in clinical practice could increase the change of identifying multiple molecular driver alterations calling for therapy. This study evaluates mutations in PT and sLmCRC exon2 KRAS wt patients who underwent chemotherapy (CT) containing cetuximab.  Methods', '    Genomic analysis was conducted in 7 sLmCRC pts', ' before CT on a PT biopsy, after CT on a PT surgical specimen and all srLmCRC. A total of 54 lesions were examined. DNA libraries were generated using the Ion AmpliSeq Colon and Lung Cancer Panel including 22 mutated genes (KRAS, EGFR, BRAF, PIK3CA, AKT1, ERBB2, PTEN, NRAS, STK11, MAP2K1, ALK, DDR2, CTNNB1, MET, TP53, SMAD4, FBXW7, FGFR3, NOTCH1, ERBB4 , FGFR1, FGFR2) and sequenced on a Ion PGM system Results', '    A partial response was achieved in all pts, with a median PFS of 11 months (4-15). Molecular analysis of genes correlated with target therapy is shown in the following table (K=KRAS; N=NRAS; P=PIK3AC; M=MET; m= -; wt= + ). Pt 1 showed heterogeneity in PT before and after CT with KRASm clonal selection and related expression of the mucinous pattern; in srLmCRC', ' 5/9 KRASm exon2, 1/9 PIK3CAm exon20, 2/9 KRASm exon2 and PIK3CA exon20. In pt 7 NRASm exon2 was identified in PT before and after CT; differences in srLmCRC', ' 3/5 no mutation, 1/5 NRASm exon2, 1/5 PIK3CAm exon20. The other cases showed rare mutations', ' SMAD4 (pt 2), TP53 (pts 2,5,6,7), FBXW7 (pt1).  Conclusions', '    Our preliminary data suggest a potential role for NGS in the evaluation of biological drug resistance affecting future sequential treatments strategy']",
        "Doc_id":"ASCO_133879-144",
        "Doc_title":" Molecular evaluation of primary tumor (PT) and synchronous liver metastasis in colorectal cancer (srLmCRC) patients after cetuximab-based chemotherapy.",
        "_version_":1606189035268603904},
      {
        "Meeting_name":" Nonclinical activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib in FGFR3 translocated tumor models",
        "Background":"['Lucitanib (S 80881, E-3810, CO-3810) is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR-). A Phase 1/2 clinical study (Soria et al., 2014, Ann. Oncol. 25(11)', '2244-51) showed compelling activity of lucitanib in solid tumors and, in particular, a 50% (6 of 12 patients) RECIST partial response rate in breast cancer patients with FGF-aberrant (FGFR1 and/or FGF3/4/19 gene amplified) tumors. On-going clinical studies are further defining the activity of lucitanib in breast (NCT02053636;  NCT02202746) and lung cancer (NCT02109016). FGFR gene translocations (fusions; e.g. FGFR3-TACC3) resulting in constitutively active FGFR signaling and tumor proliferation are observed in a wide variety of cancers (Stransky et al., 2014; Nat. Comm. (5)', '5006), and inhibition of FGFR signaling in FGFR translocated tumors with lucitanib may be a potential new therapeutic strategy. We evaluated the nonclinical activity of lucitanib in FGFR3 translocated models with the hypothesis that the combined blockade of FGFR and VEGFR signaling would be more effective than targeting each receptor tyrosine kinase independently. The in vitro activity of lucitanib was first evaluated in a panel of bladder carcinoma cell lines (n = 8) with and without FGFR3 translocation. Lucitanib preferentially inhibited the growth of cell lines with FGFR3 translocations in 2D and 3D cell culture, with GI50 values of 80-120 nM in a 72-hour cell viability assay, coincident with a reduction in phosphorylated FGFR3 with an IC50 of 60 nM. Minimal activity was observed in five wild-type FGFR3 cell lines (GI50 > 5 M) with the exception of the JMSU1 bladder cell line that is reported to be dependent on FGFR1 signaling for proliferation (Tomlinson et al., 2009, Cancer Res. 69(11)', '4613-20). The anti-tumor activity of lucitanib dosed orally at 20 mg/kg/day was evaluated in three bladder carcinoma cell-line derived xenografts with FGFR3 translocation (RT112/84, RT4 and SW780) and a patient-derived xenograft (PDX) model of glioblastoma (BN2289; Crown Bioscience) harboring a FGFR3-TACC3 fusion. Administration of lucitanib resulted in significant (p<0.0001) tumor growth inhibition and, in some cases, tumor regression. The anti-tumor activity of lucitanib in these xenograft models was greater than that observed with either sunitinib (VEGFR/PDGFR inhibitor; 40 mg/kg/day) or BGJ398 (FGFR1-4 inhibitor; 20 mg/kg/day). Together, these results provide a strong nonclinical rationale for further exploration of lucitanib in tumors with FGFR translocations in clinical studies.']",
        "Doc_id":"AACR_2015-784",
        "Doc_title":" Nonclinical activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib in FGFR3 translocated tumor models",
        "_version_":1606188980806615041},
      {
        "Meeting_name":" JNJ-42756493 is an inhibitor of FGFR-1, 2, 3 and 4 with nanomolar affinity for targeted therapy",
        "Background":"['The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance. Alterations in FGFR family members including focal amplification of FGF receptor 1 (FGFR1), mutations in FGFR 2, 3 and 4, translocations involving FGFR 2 and FGFR3, as well as amplification or transcriptional upregulation of various ligand family members have been associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in subsets of various disease settings. A number of agents targeting the FGF signaling axis including small-molecule FGFR targeted agents, with diverse kinase inhibitory and pharmacological profiles, are currently in clinical development.JNJ-42756493 (first disclosure of the structure) has a pharmacological profile that is differentiated from other agents in this class currently under investigation. JNJ-42756493 displays single digit nanomolar FGFR (1, 2, 3 4) tyrosine kinase inhibitory activity. JNJ-42756493 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in engineered cell lines and tumor cell lines dependent upon deregulated FGFR expression. JNJ-42756493 demonstrated highly specific tumor inhibitory effects in FGFR1-4 dependent cell lines, in vitro cell lines based xenografts and direct patient derived xenografts, with no discernible activity in models that were not dependent on FGFR signaling. JNJ-42756493 showed favorable drug like properties and displayed a high distribution to lung, liver and kidney tissue. JNJ-42756493 was well tolerated at efficacious doses and resulted in potent dose-dependent antitumor activity accompanied by pharmacodynamic modulation of tumor FGFR and downstream pathway components.Data presented here highlights JNJ-42756493 as a novel, highly potent and selective small-molecule inhibitor of all four known active FGFR kinase family members with potent antitumor activity against FGFR-dependent tumor models. These data, together with emerging observations from our ongoing Phase 1 clinical trial, position JNJ-42756493 as a differentiated FGFR 1, 2, 3 and 4 kinase inhibitor and support its continued clinical development in lung cancer and other malignancies associated with aberrant FGFR signaling.']",
        "Doc_id":"AACR_2014-1738",
        "Doc_title":" JNJ-42756493 is an inhibitor of FGFR-1, 2, 3 and 4 with nanomolar affinity for targeted therapy",
        "_version_":1606189022591320064},
      {
        "Meeting_name":" Stromal expression of long Pentraxin-3 impairs tumor growth and metastasis",
        "Background":"['Long Pentraxin-3 (PTX3) is a soluble pattern recognition receptor expressed by endothelial and immune cells in inflammatory contexts. We have previously demonstrated that PTX3 binds to different members of the FGF family, thus inhibiting their biological activity. The FGF/FGFR system strongly contributes to cancer progression by inducing tumor growth and neovascularization. To date, recombinant PTX3 protein or PTX3-overexpressing tumor cell lines have been exploited to assess the antitumor effects of this natural FGF trap. Here we generated C57BL/6 transgenic mice expressing human (h)PTX3 under the control of the endothelial specific Tie2/Tek transcription regulatory sequences. These animals were used to investigate the impact of PTX3 overexpression by the host stroma on tumor growth, vascularization and metastasis.Transgenic Tie2-hPTX3 mice were generated by cloning the hPTX3 cDNA into the late-generation, self-inactivating lentiviral vector Tie2p/e to obtain the Tie2-hPTX3 lentiviral transfer vectors that were injected into fertilized oocytes. Expression of the transgene was confirmed by RT-PCR and western blot analyses of different organs from Tie2-hPTX3 mice that showed increased levels of circulating PTX3 (80-180 ng/ml) when compared to wild type (wt) animals (<1.8 ng/ml). Also, histological analysis confirmed the perivascular accumulation of hPTX3 in transgenic animals. To assess the anti-angiogenic activity of endothelium-derived hPTX3, we performed ex vivo aorta ring and in vivo matrigel plug assays. Both assays revealed a significant inhibition of FGF2-driven angiogenesis in Tie2-hPTX3 mice that maintained their responsiveness to VEGF-A, thus confirming the specificity of the effect. Next, different syngeneic FGF-dependent tumor cell lines, including TRAMP-C2 prostate carcinoma, B16-F10 melanoma and Lewis Lung carcinoma cells, were subcutaneously injected in Tie2-hPTX3 mice. Notably, the growth of all tumor grafts was significantly reduced in Tie2-hPTX3 mice when compared to wt animals. Also, histological analysis of TRAMP-C2 tumors grown in Tie2-hPTX3 mice showed a strong perivascular expression of hPTX3 and a significant reduction of FGFR1 phosphorylation. This was paralleled by a significant decrease of tumor vascularity and tumor cell proliferation whereas no difference in tumor growth was observed for TRAMP-C2 grafts expressing a constitutively activated form of FGFR1. Finally, B16-F10 melanoma and M5076 ovarian sarcoma cells showed a dramatic decrease of their capacity to form experimental metastases in the lung and liver, respectively, after intravenous injection in Tie2-hPTX3 mice.PTX3 is a natural FGF ligand trap. Our findings demonstrate for the first time that the production of PTX3 by the host stroma may exert a dramatic impact on tumor growth, vascularization and metastasis with potential exploitation for the therapy of FGF-dependent tumors.']",
        "Doc_id":"AACR_2014-178",
        "Doc_title":" Stromal expression of long Pentraxin-3 impairs tumor growth and metastasis",
        "_version_":1606189004179374080},
      {
        "Meeting_name":" Practical implications of single-gene versus NGS testing in advanced NSCLC.",
        "Background":"['Background', ' Genetic testing to guide 1st-line treatment is recommended for advanced non-small cell lung cancer (aNSCLC), but is complicated by small biopsy specimens available to test increasing numbers of biomarkers. This study compared commercially-available genetic tests for aNSCLC and the investigational use Oncomine Dx Target Test next generation sequencing (NGS) assay. Methods', ' This retrospective analysis used data from a large commercial lab, which offered clinical single-gene tests (EGFR therascreen, ALK Vysis, BRAF cobas, laboratory developed tests [LDT] for ROS1, BRAF, KRAS, MET, RET, and FGFR1); and NGS LDT (Illumina NextSeq 500). The lab also conducted investigational use of Oncomine Dx Target Test assay (Ion Torrent PGM Dx) on archival tissue. Clinical test orders received September 2015  October 2016 were included. Sample rejection, test initiation, success rates, slide consumption, testing time, and turnaround time (TAT) were assessed. Results', ' Clinically, 3,857 single-gene and 219 NGS LDT tests were ordered on 1,479 samples for 1,436 patients. A total of 169 Oncomine Dx Target Tests were conducted. Conclusions', ' Investigational use of Oncomine Dx Target Test at this laboratory showed higher rates of test initiation and successful completion while using less tissue compared to either single-gene testing for 4 biomarkers or NGS LDT. This early experience suggests Oncomine Dx Target Test may enable therapy selection with multiple biomarker testing on small tissue samples for more aNSCLC patients compared to current methods. Single-gene Tests per Sample (N*)NGS LDT (N*)Oncomine Dx Target Test (N*)1234% sample rejection0  15.4 71.4 (206)0 (169)% sufficient tissue to initiate tests91.0 (1,404)91.1 (1,116)90.0 (701)65.6 (282)28.6 (206)100 (169)Total slides used to initiate tests2.4 (241)4.4 (360)5.8 (411)9.1 (75)13.5 (40)1.0 (169)% successfully generate results, when initiated96.9 (1,278)92.8 (1,017)83.4 (631)84.9 (185)30.5 (59)87.0 (169)Testing time (days)3.2  6.5 10.9 (11)4.6 (141)TAT (days)6.9 (262)9.2 (394)10.4 (361)11.3 (73)16.5 (12)N/A* Samples available per evaluation;  Tests not initiated due to tumor quantity;  Range per test across test types;  Successfully completed tests']",
        "Doc_id":"ASCO_187208-199",
        "Doc_title":" Practical implications of single-gene versus NGS testing in advanced NSCLC.",
        "_version_":1606188974911520768},
      {
        "Meeting_name":" Molecular profiling of neuroendocrine tumors (NETs)",
        "Background":"['Background', '  The rarity of NETs can limit clinical trial accrual to develop new therapies. Given fewer approved treatments, a better understanding of underlying biology is critical to development of and assignment of patients (pts) to clinical trials.  Methods', ' Pts with NETs (excluding small/large cell lung cancer) of all grades at FCCC were enrolled onto a prospective IRB approved protocol that utilized an NGS platform to detect somatic mutations (SM) in 50 cancer-related genes (Cancer Code) on archived tissue from primary or metastatic sites. Genes tested included ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO,SRC, STK11, TP53 and VHL. Review of pathology specimens for grade and Ki -67 was also performed.  Results', '  Thirty-nine pts (median age 59 y, males 46%) were enrolled from October 2013 to July 2014. Gene profiling results are available on thirty-five pts. Ki-67 score was reviewed for 31/35 tumors. 6 (20%) pts had high grade (HG) tumors (Ki-67 > 20%) and 25 (80%) had low/intermediate grade (LIG) tumors (Ki-67 20%). Thirteen (37%) pts were found to have SMs and 22 (63%) did not, with 4 (12%) pts tumors having >1 SMs (2 HG and 2 LIG tumors). Incidence of SM was 41% (12/29) in Caucasians, 16% (1/6) in other races, 46% (6/13) in smokers and 30% (6/20) in non-smokers. Incidence of SM was 24% (6/25) in LIG NETs and 84% (5/6) in the HG NETs. Among HG tumors, 66% (4/6) harbored TP53 gene mutation and 33% (2/6) were BRAF mutation positive.  Conclusions', ' Tumor-specific mutations are seen in a minority of low grade NETs but are common in high grade tumors. Interestingly, no mutations were identified in pts with unknown primary.  Analysis of clinical outcomes based on treatment received is ongoing to assess for possible prognostic/therapeutic implications of these mutations.   Mutations according to primary site.Primary siten (total)n (with mutations)Type of mutationStomach/bowel164BRAF, PIK3CA, TP53, KRAS, CTNNB1Pancreas115KRAS (2), RB1, ATM, TP53Unknown40Other22TP53, KRAS']",
        "Doc_id":"ASCO_139139-158",
        "Doc_title":" Molecular profiling of neuroendocrine tumors (NETs)",
        "_version_":1606189000943468544},
      {
        "Meeting_name":" Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.",
        "Background":"['Background', '  JNJ-42756493 is an orally bioavailable FGFR 1, 2, 3 and 4 inhibitor with nanomolar antitumor activity in cell lines and in vivo models with FGFR pathway aberration.  Methods', '    This first in human study consists of 3 parts', ' dose escalation part 1to determine the recommended phase 2 dose (RP2D), dose confirmation part 2 with focus on pharmacodynamic effects, and dose expansion part 3 to evaluate the antitumor activity in selected solid tumors with FGFR gene amplification, mutation or translocation at the RP2D. Biomarkers include tumor tissue genomic profiling, skin/tumor biopsies and soluble serum markers. Toxicity is graded with CTCAE-4 and antitumor activity is assessed using RECIST 1.1.  Results', '    As of 27 January 2014, 37 patients have been treated at 6 dose levels (0.5, 2, 4, 6, 9 and 12 mg daily continuously) in part 1. Most common ( 20% of patients) adverse events (AEs) were hyperphosphatemia (60%), asthenia (46%), dry mouth (30%), constipation (27%), abdominal pain (22%), stomatitis (22%), and vomiting (22%); all were  Grade 2 in toxicity. Ten (27%) patients had  Grade 3 AEs, and one dose limiting toxicity of Grade 3 AST/ALT elevation was noted at 12 mg dose. Daily 9 mg continuous dosing was declared the RP2D. Seven (19%) patients had serious AEs, including 1 death, but none were drug-related. Six (16%) patients had dose reductions due to drug-related hyperphosphatemia at 9 and 12 mg. Pharmacokinetics were linear, dose proportional and predictable with a half-life of 50 to 60 hours. Exposure dependent increases in phosphate blood levels were observed at doses up to 9 mg, thereafter reaching a plateau. Also a trend was seen for increase in FGF23 and decrease in PTH. Out of 8 patients enrolled to date with FGFR pathway aberration, we observed 1 partial response in a bladder cancer patient with FGFR3-TACC3 translocation and 1 near complete response in an urothelial cancer of renal pelvis harboring FGFR2 truncation at the RP2D. Four patients (2 lung cancer, 1 chondrosarcoma and 1 breast cancer patients with FGFR1 amplification) had stable disease.  Conclusions', '    JNJ-42756493 has favorable pharmaceutical properties, with manageable side effects at the RP2D and evidence of antitumor activity. Clinical trial information', ' NCT01703481.']",
        "Doc_id":"ASCO_126428-144",
        "Doc_title":" Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.",
        "_version_":1606189037519896576},
      {
        "Meeting_name":" Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.",
        "Background":"['Background', '  ARQ 087 is a novel, orally bioavailable, ATP-competitive inhibitor of multiple kinases, including FGFR1-3. It has potent in vitro and in vivo inhibitory effects on a variety of human tumor cell lines and xenograft models dependent on FGFR signaling.   Methods', '  This first-in-human 2-step study was initiated in pts with advanced solid tumors. Step 1', ' dose escalation/food-effect to characterize PK, safety, maximum tolerated and recommended Phase 2 Dose (RP2D; unselected for FGFR aberration). Step 2', ' expansion cohort to to assess safety and clinical activity of ARQ 087 in selected tumor types, including FGFR gene amplification, translocation and mutation. Assessments included tumor molecular status, response by RECIST v.1.1 every 8 weeks (wks), plasma concentrations of FGF19, 21, 23, fasting glucose and phosphate.   Results', '  61pts were treated (dose range 25-425mg QOD or QD) in Step 1; the majority were female (61%), mean age 64 yrs (34 -78). The RP2D was defined as 300 mg QD continuous dosing. Dose-limiting toxicities included increased liver enzymes (reversible Grade (G) 3 AST increase). Common drug-related adverse events (AEs; mostly G  2) were fatigue (53%), elevated LFTs (45%), nausea (45%), vomiting (20%) and diarrhea (20%). Only 2 pts (3%) experienced G1 drug-related hyperphosphatemia. Drug t1/2 was 2-11 days, PK was unaffected by food. FGF 19/21/23 concentrations post-treatment were increased 1.5-6 fold.   Ten pts in Step 1 had confirmed stable disease (SD)  16 wks (adrenocortical [2], endometrial, ovarian, NSCLC, choroidal melanoma, carcinoid, sarcoma [3]). A squamous NSCLC pt with Src amplification had SD (24% tumor reduction) for 32 wks. One adrenocortical carcinoma pt with FGFR1 amplification remains on study > 22 months. Two ongoing pts with intrahepatic cholangiocarcinoma with FGFR2 fusions demonstrated a partial response and SD > 24 wks with 26% decrease in target lesions, respectively.   Conclusions', '  ARQ 087 has manageable, mostly G  2 AEs. It has demonstrated preliminary antitumor activity in pts with FGFR-pathway aberrations. Further evaluation of ARQ 087 in pre-defined tumor types is ongoing. Clinical trial information', ' NCT01752920']",
        "Doc_id":"ASCO_149025-156",
        "Doc_title":" Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.",
        "_version_":1606188981934882816},
      {
        "Meeting_name":" A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.",
        "Background":"['Background', '   Lucitanib is a potent, oral inhibitor of the tyrosine kinase activity of FGFR1/2, VEGFR1-3 and PDGFRA/B.  These well-described signaling pathways are essential for tumor growth, survival, migration, and angiogenesis.  Further, several tumor types, including carcinoma of the breast, demonstrate amplification of FGF-related genes.  Currently, there are no approved drugs for patients (pts) with molecularly defined FGF-aberrant (FGFR1 or FGF3/4/19 amplified) tumors.  Methods', '  The first in human 3-part study is evaluating oral lucitanib monotherapy. Part 1 employed a 3+3 ascending cohort design in pts with advanced solid tumors to establish a recommended dose for further study. Parts 2 and 3 evaluated safety and efficacy of lucitanib in pts with FGF aberrant or angiogenesis sensitive tumors using continuous (part 2) or intermittent schedules (part 3) of administration.  Results', '  109 (part 1 n=17; part 2 n=59; part 3 n=33) pts were treated. Median age was 55 yrs [range 34-80]; 59 female; 105 stage IV; 29 breast cancer, 16 colon, 13 thyroid and 51 other tumor. Doses from 5 mg to 30 mg were evaluated with dose limiting toxicities (DLTs) dominated by VEGF-inhibition related toxicity at the 30 mg dose level. The most common adverse events (all grades, all cohorts, continuous and intermittent dosing schedules) were hypertension (86%), asthenia (73%) and proteinuria (69%).  Exposure increased with dose and a t1/2 of 25-40 hours, deemed suitable for once daily administration. Clinical activity was observed at all doses tested with durable RECIST PRs in a variety of tumor types. In evaluable FGF-aberrant breast cancer pts, 50% (6 of 12) achieved RECIST PR with a median PFS of 9.4 months for all treated patients. Additionally, 1 of 3 pts with advanced squamous NSCLC experienced SD for 8 months with lucitanib therapy.  Conclusions', '   Lucitanib demonstrated promising clinical activity and a tolerable side-effect profile in pts with advanced solid tumors, including those with FGF pathway aberrations. A phase 2 program in FGF aberrant breast and squamous NSCLC is underway in US and Europe. Clinical trial information', ' NCT01283945.']",
        "Doc_id":"ASCO_132100-144",
        "Doc_title":" A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.",
        "_version_":1606188984012111873},
      {
        "Meeting_name":" Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.",
        "Background":"['Background', ' In pts with EGFR+ NSCLC, genotyping of plasma cell-free DNA (cfDNA) has become a routine option for non-invasive detection of EGFRT790M. We hypothesized that serial NGS of cfDNA would allow early detection of co-existent resistance mutations during osimertinib treatment. Methods', ' Serial plasma samples were collected from pts with advanced EGFR+ NSCLC and T790M+ acquired resistance treated with osimertinib. Up to 4 specimens were analyzed, blinded to tumor genotype', ' baseline, initial 2 follow-ups, and progression. Plasma NGS was performed using enhanced tagged amplicon sequencing of hotspots and coding regions from 36 genes. Diagnostic accuracy was compared to tumor genotype (including NGS when available) and droplet digital PCR (ddPCR) of cfDNA. Results', ' 94 specimens from 26 pts underwent plasma NGS. Studying 26 baseline specimens, plasma NGS was more sensitive than ddPCR for known EGFR driver mutations (100% vs 88.5%). In 8 pts with pretreatment tumor NGS, 5 of 6 TP53 mutations were detected; one plasma positive/tissue negative result was seen across 36 genes, a PIK3CA mutation (0.6% AF) which was confirmed using ddPCR (99.6% specificity). Quantitative concordance of AF compared to ddPCR was high (R = 0.94). 21 pts had detectable EGFR driver mutations at resistance. Among 6 pts with maintained T790M, 4 acquired C797S and 2 of these additionally acquired low level KRAS mutations (G13D, Q61K). Among 15 pts with loss of T790M, 7 had competing non-EGFR alterations identified', ' MET amp, PIK3CA E545K, BRAF V600E (n = 2), HER2 amp, KRAS G12S, and FGFR1 amp. Resistance mutations detected at AF > 0.3% were confirmed with ddPCR. In 3 pts, a competing resistance mutation (1 KRAS, 2 BRAF) could be detected in plasma NGS pretreatment and reemerged as putative drivers at time of resistance. Conclusions', ' In this retrospective blinded validation, tagged amplicon-based plasma NGS was more sensitive than ddPCR with high specificity and quantitative concordance. In a subset of cases, serial plasma NGS can detect emergence of competing resistance mutations, creating an opportunity for the study of osimertinib-based targeted therapy combinations.']",
        "Doc_id":"ASCO_187023-199",
        "Doc_title":" Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.",
        "_version_":1606189040012361729},
      {
        "Meeting_name":" Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM).",
        "Background":"['Background', ' FGF ligand-dependent signaling plays an important role in cancer development and promotion through secretion of FGF ligands or amplification of FGF receptors (FGFRs). MPM, a disease with significant unmet needs, overexpresses FGF2 ligand, which binds FGFR1 and promotes tumor cell growth. FP-1039/GSK3052230 is a soluble fusion protein consisting of the extracellular domain of human FGFR1c linked to the Fc portion of human IgG1, and acts as a ligand trap for FGFs. Methods', ' This multi-arm, open-label phase 1b study evaluated GSK3052230 (IV weekly) in combination with 1st-line paclitaxel+carboplatin (Arm A) or > 2nd-line docetaxel (Arm B) in FGFR1 gene-amplified metastatic squamous NSCLC and with 1st-line pemetrexed+cisplatin in untreated, unresectable MPM (Arm C). Each arm involved dose escalation until MTD/MFD followed by a cohort expansion phase. Endpoints include safety, response rates, PFS, duration of response, and translational measures. Preliminary data from Arms A and B have been presented previously. Herein, only preliminary results from Arm C are reported. Results', ' As of 10 Dec 2015, 24 patients (pts) were dosed in Arm C at 10, 15 and 20 mg/kg doses of GSK3052230. Three DLTs were observed at 20 mg/kg GSK3052230', ' Gr 5 bowel perforation/ischemia, Gr 3 elevated creatinine levels and Gr 3 infusion reaction. There were no DLTs at 15 mg/kg GSK3052230, and therefore MTD was declared at this dose. Most common adverse events (AEs; all grades) were', ' nausea (54%) decreased appetite (50%), fatigue (46%), and infusion reaction (33%). Preliminary objective response rate (ORR) is 57%, with disease control rate (DCR) of 100% (n = 14 evaluable pts, 10 and 15 mg/kg GSK3052230, confirmed/unconfirmed per mRECIST 1.1). The majority of patients are still on trial (duration on trial > 7.2 months); PFS data will be presented. Conclusions', ' The MTD of GSK3052230 in combination with pemetrexed+cisplatin in MPM is 15 mg/kg and the most frequent AEs are nausea and decreased appetite. Toxicities associated with small-molecule FGFR inhibitors (i.e hyperphosphatemia and retinal, nail, and skin changes) were not observed. The preliminary efficacy data are encouraging. Study sponsored by GSK. Clinical trial information', ' NCT01868022']",
        "Doc_id":"ASCO_170158-176",
        "Doc_title":" Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM).",
        "_version_":1606189016102731776},
      {
        "Meeting_name":" The discovery of AZD4547",
        "Background":"['There is increasing evidence that FGFR signaling plays an important role within human cancer, with members of FGFR family acting as driving oncogenes in a significant number of human tumors. Deregulation of FGFR-signaling has been documented within clinical samples of breast multiple myeloma, bladder, endometrial, gastric, squamous NSCLC and prostate cancers. This dysregulation most frequently occurs through gene amplification, or through genetically altered forms of FGFR proteins. This increasing body of evidence implicating FGFR signaling in cancer has provided rationale for the identification and testing of selective inhibitors of FGFR signaling in the clinic. In this presentation, we describe the progress of our FGFR tyrosine kinase inhibitor programme and report the discovery of N-(5-pyrazolyl)benzamide FGFR inhibitors. Early compounds in this series suffered from poor in vivo pharmacokinetic (PK) properties. The key site of metabolism was identified to be at a basic N-methyl group. This group was shown to be located in the solvent channel of the ATP binding site on binding to FGFR1, and modification could be made without causing major changes to intrinsic binding affinity. However, the first compounds identified with low metabolic clearance also showed a significant reduction in oral bioavailability, due to apparent low permeability and increased efflux potential. The characterization of these PK issues and the discovery of compounds which overcame them, through modulation of pKa, lipophilicity and masking of the polar groups, will be described. Leading compounds showed significant anti-tumor activity in xenograft tumors grown in mice. Detailed characterization of these compounds led to the identification of AZD4547, a potent and selective FGFR tyrosine kinase inhibitor currently in Phase I clinical studies.']",
        "Doc_id":"AACR_2012-3912",
        "Doc_title":" The discovery of AZD4547",
        "_version_":1606188996821516289}]
  }}
